A small dose of toxicology : role of mitochondrial dysfunction in hepatic and skeletal muscle toxicity by Kaufmann, Priska M.
 
 
 
 
 
 
A Small Dose of Toxicology: 
Role of Mitochondrial Dysfunction in Hepatic 
and Skeletal Muscle Toxicity 
 
 
 
 
 
 
Inauguraldissertation 
 
 
 
 
Zur  
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät  
der Universität Basel 
 
 
 
 
 
 
von 
Priska M. Kaufmann 
aus Wikon (LU) 
 
 
 
 
 
Basel, 2005 
 
 
  2 
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag der Herren: 
 
 
 
 
Prof. Dr. Dr. Stephan Krähenbühl 
 
Prof. Dr. Jürgen Drewe 
 
 
 
 
 
Basel, den 11.01.2005 
 
 
 
 
 
 Prof. H.-J. Wirz 
 Dekan 
 
 
  3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine Eltern  
 
 
 
  4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To know that we know what we know,  
and to know that we do not know what we do not know, 
 that is true knowledge. 
 
 
Nikolaus Kopernikus (1473-1543) 
 
 
  5 
Table of contents 
1. Acknowledgments/Danksagung................................................................................................. 8 
2. Summary .................................................................................................................................... 9 
3. Zusammenfassung................................................................................................................... 11 
4. Abbreviations............................................................................................................................ 13 
5. Introduction............................................................................................................................... 15 
5.1. Toxicology..................................................................................................................... 15 
5.1.1. Background....................................................................................................... 15 
5.1.2. Toxicology today ............................................................................................... 16 
5.1.3. Principles of toxicology...................................................................................... 16 
5.2. Mitochondria ................................................................................................................. 17 
5.2.1. Origin................................................................................................................. 17 
5.2.2. Introduction ....................................................................................................... 18 
5.2.3. Mitochondrial Dysfunction & Mitochondrial Cytopathies ................................... 19 
5.3. Drug Toxicity................................................................................................................. 20 
5.3.1. From the Status Quo to the “Magic Bullet”........................................................ 20 
5.3.2. Development of drug toxicity............................................................................. 21 
5.3.3. Mechanisms of drug toxicity.............................................................................. 22 
5.3.4. Mitochondrial permeability transition (MPT)...................................................... 23 
5.3.5. Cell Death ......................................................................................................... 24 
5.4. References ................................................................................................................... 28 
6. Aims of the thesis ..................................................................................................................... 31 
7. Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with 
trimethylhydraziniumpropionate ............................................................................................... 32 
7.1. Summary ...................................................................................................................... 33 
7.2. Introduction................................................................................................................... 33 
7.3. Materials and Methods ................................................................................................. 35 
7.3.1. Induction of carnitine deficiency in vivo palmitate metabolism.......................... 35 
7.3.2. Isolation of rat liver mitochondria ...................................................................... 35 
7.3.3. Oxidative metabolism of intact mitochondria..................................................... 35 
7.3.4. In vitro mitochondrial β-oxidation and formation of ketone bodies .................... 36 
7.3.5. Activities of the enzyme complexes of the respiratory chain............................. 36 
7.3.6. Determination of CoA and carnitine .................................................................. 36 
7.3.7. Lipid determinations in liver............................................................................... 37 
7.3.8. Determination of plasma lipids .......................................................................... 37 
7.3.9. Cytochemical localization of catalase in liver sections...................................... 38 
7.3.10. SDS-PAGE and immunoblotting ....................................................................... 38 
7.3.11. Determination of acyl-CoA oxidase activity....................................................... 38 
7.3.12. Statistics............................................................................................................ 38 
7.4. Results.......................................................................................................................... 39 
7.5. Discussion .................................................................................................................... 48 
7.6. References ................................................................................................................... 51 
8. Mechanisms of benzarone and benzbromarone induced hepatic toxicity................................ 55 
8.1. Abstract......................................................................................................................... 56 
8.2. Introduction................................................................................................................... 56 
8.3. Materials and Methods ................................................................................................. 58 
8.3.1. Reagents........................................................................................................... 58 
8.3.2. Cell lines............................................................................................................ 58 
8.3.3. Animals ............................................................................................................. 58 
8.3.4. Isolation of rat liver mitochondria ...................................................................... 58 
8.3.5. Isolation of rat hepatocytes ............................................................................... 58 
8.3.6. Mitochondrial membrane potential .................................................................... 59 
  6 
8.3.7. Oxygen uptake .................................................................................................. 59 
8.3.8. Mitochondrial β-oxidation and formation of ketone bodies................................ 59 
8.3.9. Activities of mitochondrial β-oxidation enzymes................................................ 60 
8.3.10. Reactive oxygen species (ROS) ....................................................................... 60 
8.3.11. Mitochondrial swelling ....................................................................................... 60 
8.3.12. Hepatocellular ATP content .............................................................................. 60 
8.3.13. Apoptosis and necrosis ..................................................................................... 61 
8.3.14. Mitochondrial release of cytochrome c.............................................................. 61 
8.3.15. Statistical methods ............................................................................................ 61 
8.4. Results.......................................................................................................................... 61 
8.4.1. Mitochondrial membrane potential .................................................................... 61 
8.4.2. Oxidative metabolism of mitochondria .............................................................. 62 
8.4.3. Mitochondrial β-oxidation and formation of ketone bodies................................ 64 
8.4.4. Production of ROS ............................................................................................ 66 
8.4.5. Mitochondrial swelling ....................................................................................... 66 
8.4.6. Apoptosis and necrosis ..................................................................................... 67 
8.5. Discussion .................................................................................................................... 71 
8.6. References ................................................................................................................... 72 
9. Mitochondrial Toxicity of Statins............................................................................................... 76 
9.1. Summary ...................................................................................................................... 77 
9.2. Introduction................................................................................................................... 77 
9.3. Materials and Methods ................................................................................................. 79 
9.3.1. Materials............................................................................................................ 79 
9.3.2. Animals ............................................................................................................. 79 
9.3.3. Cells .................................................................................................................. 79 
9.3.4. Preparation of simvastatin acid ......................................................................... 80 
9.3.5. Isolation of rat skeletal muscle mitochondria .................................................... 80 
9.3.6. In vitro cytotoxicity assays................................................................................. 80 
9.3.7. Mitochondrial membrane potential (∆Ψm) ......................................................... 80 
9.3.8. Oxygen consumption ........................................................................................ 81 
9.3.9. Activity of NADH-oxidase .................................................................................. 81 
9.3.10. In vitro mitochondrial β-oxidation ...................................................................... 81 
9.3.11. Activities of mitochondrial β-oxidation enzymes................................................ 82 
9.3.12. Determination of mitochondrial swelling............................................................ 82 
9.3.13. Cytochrome c immunocytochemistry ................................................................ 82 
9.3.14. Determination of apoptosis ............................................................................... 83 
9.3.15. Statistical analysis............................................................................................. 83 
9.4. Results.......................................................................................................................... 83 
9.4.1. In vitro cytotoxicity assays................................................................................. 83 
9.4.2. Mitochondrial membrane potential .................................................................... 84 
9.4.3. Oxygen consumption ........................................................................................ 85 
9.4.4. Activities of mitochondrial NADH-oxidase......................................................... 88 
9.4.5. Beta-oxidation ................................................................................................... 90 
9.4.6. Mitochondrial swelling ....................................................................................... 92 
9.4.7. Cytochrome c release ....................................................................................... 93 
9.4.8. Determination of apoptosis ............................................................................... 93 
9.5. Discussion .................................................................................................................... 96 
9.6. References ................................................................................................................... 98 
10. Mechanisms of venoocclusive disease for the combination of cyclophosphamide and 
roxithromycin .......................................................................................................................... 102 
10.1. Abstract ........................................................................................................... 103 
10.2. Introduction ..................................................................................................... 103 
10.3. Materials and Methods.................................................................................... 105 
10.3.1. Materials.......................................................................................................... 105 
10.3.2. Cell lines and cell culture conditions ............................................................... 105 
10.3.3. Solutions and incubations ............................................................................... 105 
  7 
10.3.4. LDH leakage assay ......................................................................................... 105 
10.3.5. P-glycoprotein ................................................................................................. 105 
10.3.6. In vitro microsomal assay................................................................................ 106 
10.3.7. Quantification of cyclophosphamide metabolites ............................................ 106 
10.3.8. Determination of apoptosis ............................................................................. 106 
10.3.9. Cytochrome c immunocytochemistry .............................................................. 107 
10.3.10. Mitochondrial membrane potential ........................................................... 107 
10.3.11. Statistical analysis .................................................................................... 107 
10.4. Results ............................................................................................................ 107 
10.4.1. In vitro cytotoxicity........................................................................................... 107 
10.4.2. P-glycoprotein ................................................................................................. 108 
10.4.3. In vitro microsomal metabolism....................................................................... 110 
10.4.4. Mechanism of cell death ................................................................................. 112 
10.4.5. Mechanism of apoptosis ................................................................................. 113 
10.5. Discussion....................................................................................................... 114 
10.6. References...................................................................................................... 116 
11. Discussion.............................................................................................................................. 119 
11.1. Conclusions and Outlook ................................................................................ 119 
11.2. References...................................................................................................... 122 
12. Cirrculum Vitae....................................................................................................................... 123 
13. Publication Record ................................................................................................................. 125 
Abstracts..................................................................................................................... 125 
Papers ........................................................................................................................ 125 
14. Appendix: Supporting Literature............................................................................................. 127 
14.1. Myocardial function and energy metabolism in carnitine deficient rats ........... 127 
14.1.1. Summary......................................................................................................... 128 
14.1.2. Introduction ..................................................................................................... 128 
14.1.3. Materials and methods.................................................................................... 129 
14.1.4. Measurement of carnitine palmitoyl transferase, citrate synthase, and 
cytochrome c oxidase ................................................................................................. 131 
14.1.5. Results ............................................................................................................ 132 
14.1.6. Discussion....................................................................................................... 137 
14.1.7. References...................................................................................................... 138 
14.2. Contractile function and metabolic characterisation of rodent skeletal muscle in the 
presence and absence of carnitine deficiency............................................................ 141 
14.2.1. Summary......................................................................................................... 142 
14.2.2. Introduction ..................................................................................................... 142 
14.2.3. Methods .......................................................................................................... 144 
14.2.4. Results ............................................................................................................ 146 
14.2.5. Discussion....................................................................................................... 152 
14.2.6. References...................................................................................................... 155 
14.3. Veno-occlusive disease associated with immuosuppressive cylophosphamide and 
roxithromycin .............................................................................................................. 159 
14.3.1. Summary......................................................................................................... 160 
14.3.2. Introduction ..................................................................................................... 160 
14.3.3. Case report ..................................................................................................... 160 
14.3.4. Discussion....................................................................................................... 161 
14.3.5. References...................................................................................................... 162 
Acknowledgments  
  8 
1. Acknowledgments/Danksagung 
What can I possibly say in acknowledgment of the people to whom I owe so much. Even a 
most gifted author is telling you that it is a very hard job to put thoughts in words, you might can 
imagine how difficult it is for me to express how much I am indebted to so many of you and how much 
I am thanking you.  
Molière, this famous French author who already kept my mind busy during the Matura once 
said: People don’t die from a disease they die from the medicine. Ok, it is a quote of the 17th century 
and fortunately not quite true nowadays, unfortunately it is not entirely wrong either. I would like to 
thank Stephan for giving me the opportunity, the challenge, the impetus, the chance and the 
confidence to carry out studies in this field in his lab. In his lab where he is head, guiding and leading 
the group, providing ideas and pulling the team together… Not to mention all the fundraising work and 
more which has been constantly done in the background to keep the way clear for us. A special thank 
to Jürgen, for being part of my committee and for the support and joy having given me. On this 
occasion I also would like to express my appreciation to Hans Leuenberger for being chairman.  
Im Grunde und erster Linie sind es immer die Verbindungen mit Menschen, die dem Leben 
und der Arbeit ihren Wert geben. Und so ist es mir ein Verlangen, ein Bedürfnis und ein Vergnügen, 
mich bei den Menschen an und auf meinem Weg zu bedanken. Ich möchte mich bei allen ehemaligen 
und gegenwärtigen 410-ern, 411-ern, Ex-Rosettis, Neo-MGH-lern und ZLF-lern bedanken, die in den 
letzten 4 Jahren Freude, Überraschung, Nervenkitzel, Frustration, Erstaunen, Ärger, Spass, Euphorie, 
Melancholie, Entdeckungen, Misserfolg und Erfolg geteilt sowie Hilfe und Unterstützung geschenkt 
haben. Speziellen Dank gebührt Liliane für ihre unglaubliche Gabe zu wissen was wo ist und wer was 
braucht um mit einem Lächeln durchs Labor zu gehen…. Michi für seine schier unerschöpfliche 
Geduld, Hilfe, Beratung, Rückhalt, Beruhigung, Unterstützung, Beistand, Trost und Unterhaltung…. 
Markus für seinen Humor…. Der Coffeegang für die Pausen... 
Natürlich und glücklicherweise gab und gibt es ein Leben ausserhalb des Labors. Ich möchte 
die Chance ergreifen, mich bei Sara & Simon, Tanja & Lukas, Corinna, Cordula, Brigitte, Dominique & 
Sascha, Barbara, Andrea und Sabrina zu bedanken für ihre Freundschaft, die fröhlichen Momente, die 
wir teilten und die Zeit, welche wir verbrachten. Obwohl nicht direkt beteiligt tragt ihr unwissentlich 
einen grossen Anteil am Zustandekommen dieser Diss. Ein grosses Cheers auch an Centurion und 
seine Truppe in der Hard-Apotheke dafür dass ihr mich in Eurem Kreise behalten habt. 
Змейчо, твояа съм и ти си мой.... I am not a machine but i still live my dream; when I look at 
you I.... schön und einzigartig, dass Du Träume und Leben mit mir teilst!! Obwohl es nicht die 
Naturwissenschaft ist welche uns verbindet, so ist es doch die Naturwissenschaft die uns indirekt 
verbunden hat. Ganz einfach: Мерси, благодаря и много целувки!!! Auf die Zukunft Змейчо! 
Zwei Dinge sollten Kinder von ihren Eltern bekommen: Wurzeln und Flügel. Ich bin in der 
glücklichsten aller Lagen. Meine Eltern haben mir beides mit auf den Weg gegeben. Mit meinen Eltern 
möchte ich auch meine beiden Brüder Markus und Stephan hier nennen.... Es ist ganz einfach: Ohne 
Euch wär ich nicht hierher gelangt und was ich Euch verdanke passt in keine Danksagung und auf 
kein Papier!! 
 
 
Summary  
  9 
2. Summary 
Research over the last decade has extended the prevailing view of mitochondrial function well 
beyond its critical bioenergetic role in supplying ATP. Recently, it has been recognized that 
mitochondria play a critical role in cell regulatory and signaling events, in the responses of cells to drug 
effects, genetic stresses and cell death. Based on this, four studies were conducted in order to gain 
more insight into several aspects of mitochondrial toxicity of drugs, consequences of mitochondrial 
dysfunction and role of mitochondria in cell death induction.  
Project 1 (Chapter 7) aimed to investigate the mechanisms leading to liver steatosis in rats 
treated with trimethylhydraziniumpropionate, an inhibitor of butyrobetaine hydroxylase. Rats were 
treated with trimethylhydraziniumpropionate for three or six weeks and were studied after 24h of 
starvation. Beside the mechanisms leading to liver steatosis, we also investigated adaptive changes 
secondary to a decrease in the hepatic carnitine pool and to impaired in vivo mitochondrial β-
oxidation. Our studies demonstrate that hepatic carnitine deficiency is the most important cause for 
liver steatosis in trimethylhydraziniumpropionate-treated rats and suggest that reduced mitochondrial 
fatty acid oxidation may be partially compensated by increased peroxisomal fatty acid metabolism due 
to proliferation of peroxisomes.  
Project 2 (Chapter 8) describes a study about hepatic toxicity of benzarone and 
benzbromarone having its source in clinical findings. Both drugs have similar structural features like 
amiodarone, a well-known mitochondrial toxin. Liver toxicity of benzarone and benzbromarone and of 
the two analogues benzofuran and 2-butylbenzofuran was therefore investigated using freshly isolated 
rat hepatocytes or freshly isolated rat liver mitochondria. In particular, we were interested in 
mitochondrial mechanisms leading to cell damage or even death. We also investigated the structure-
toxicity relationship by including the molecular analogues benzofuran and 2-butylbenzofuran along 
with amiodarone, benzarone and benzbromarone in our studies. We could show that benzarone, 
benzbromarone as well as amiodarone are toxic to liver cells and liver mitochondria. The side chain at 
position 2 enhances the toxic potential to some extent but does not fully explain it. Bromide atoms in 
the p-hydroxybenzene moiety are not essential for the toxicity of these compounds but clearly 
enhance the toxic potential. The benzofuran structure alone was not responsible for the toxic effects. 
Hepatic injury associated with the ingestion of these drugs can be explained by mitochondrial damage 
with subsequent induction of cell death.  
Myotoxicity, rhabdomyolysis in particular, is a rare but severe adverse drug reaction of statins. 
The aim of project 3 (Chapter 9) was to evaluate the mitochondrial toxicity of five different statins and 
to assess their role in cell death induction in skeletal muscle cells. Lipophilic statins reduced cell 
viability and impaired mitochondrial functions, such as β-oxidation and respiratory chain, which are 
essential for cell survival. As a consequence, the mitochondrial membrane potential dissipated, the 
mitochondrial permeability transition pore opened and apoptosis inducing factors were released. 
Mitochondrial dysfunction and the subsequent release of mitochondrial proteins are tightly linked to 
the process of programmed cell death, also called apoptosis. Consistently, induction of apoptosis 
could be convincingly demonstrated, since lipophilic statins did cause DNA fragmentation and an 
increase in annexin V stained cells. Myotoxicity, a known side effect after treatment with statins, in 
particular rhabdomyolysis in response to lipophilic statin treatment can be explained at least in part by 
mitochondrial toxicity and the subsequent induction of apoptosis of myocytes.  
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Project 4 (Chapter 10) was dealing with a putative drug-drug interaction. The aim of the study 
was to investigate the mechanisms by which venoocclusive disease was provoked in a patient, who 
was treated with immunodepressive doses of cyclophosphamide and roxithromycin. We therefore 
determined first the effect of roxithromycin on the metabolism of cyclophosphamide in vitro. 
Furthermore, by the use of cultured human umbilical endothelial cells, we could confirm the toxicity of 
the cyclophosphamide/roxithromycin combination and were able to investigate the underlying 
mechanisms of cell death induction. Roxithromycin causes an overall inhibition of hepatocyte 
cyclophosphamide metabolism and inhibition of P-glycoprotein, leading to an accumulation of 
cyclophosphamide in hepatocytes and possibly also endothelial cells. Apoptosis is the principle 
mechanism of toxicity of cyclophosphamide in endothelial cells, most probably associated with 
activation of the mitochondrial pathway of initiation of apoptosis. 
Zusammenfassung  
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3. Zusammenfassung 
Die Forschung des letzten Jahrzehntes zeigte, dass Mitochondrien weit mehr sind als die 
Kraftwerke der Zelle. Ihnen kommt eine entscheidende und ausschlaggebende Rolle bei der 
Zellregulation und Signalauslösung respektive -weiterleitung im Zusammenhang mit 
Arzneimittelnoxen, genetischen Stressfaktoren oder Zelltod zu. Basierend auf den Erkenntnissen 
dieses neueren Forschungsgebiets wurden vier Studien durchgeführt, mit dem gemeinsamen Ziel 
mehr über unterschiedliche Aspekte der mitochondrialen Toxizität von Arzneistoffen, 
Folgeerscheinungen der mitochondrialen Dysfunktion und die Rolle der Mitochondrien in der 
Zelltodinduktion zu erfahren.  
Das erste Projekt (Kapitel 7) war darauf gerichtet herauszufinden, welche Mechanismen der 
Auslösung einer Lebersteatose in Ratten nach Behandlung mit Trimethylhydraziniumpropionat zu 
Grunde liegen. Es handelt sich dabei um einen Inhibitor der Butyrobetainhydroylase. Abgesehen vom 
Mechanismus der zur Lebersteatose führt, wurden ausserdem sekundär induzierte, adaptive 
Veränderungen untersucht, welche als Folge des reduzierten Carnitinpools und der verringerten in 
vivo β-Oxidation auftraten. Es konnte gezeigt werden, dass die hepatische Carnitindefizienz die 
Hauptursache für die Lebersteatose in mit Trimethylhydraziniumpropionat behandelten Ratten ist. Die 
Einschränkung der mitochondrialen Fettsäureoxidation wird möglicherweise teilweise durch 
verstärkten peroxisomalen Fettsäuremetabolismus in Folge peroxisomaler Proliferation kompensiert.  
Das zweite Projekt (Kapitel 8) handelt von der hepatischen Toxizität von Benzaron und 
Benzbromaron. Die Arbeit ging aus klinischen Fallberichten über Leberschädigung nach Behandlung 
mit Benzaron oder Benzbromaron hervor. Beide Arzneimittel weisen auffällige strukturelle 
Ähnlichkeiten mit Amiodaron auf, welches seit längerem als mitochondriales Toxin bekannt ist. 
Deshalb wurde die Lebertoxizität der zwei Arzneistoffe Benzaron und Benzbromaron, sowie der 
beiden Strukturanaloga Benzofuran und 2-Butylbenzofuran untersucht. Als Modell dienten frisch 
isolierte Hepatozyten sowie frisch isolierte Lebermitochondrien. Insbesondere fokussierten wir auf die 
mitochondrialen Mechanismen welche zur Zellschädigung oder sogar Zelltod führen. Des Weiteren 
wollten wir einen Beitrag zur Aufklärung der Beziehung zwischen Struktur und Toxizität leisten. Es 
konnte gezeigt werden, dass Benzaron, Benzbromaron und Amiodaron toxisch sind für ganze 
Leberzellen wie auch für isolierte Mitochondrien. Die Seitenkette an Position 2 erhöht das toxische 
Potential in bestimmten Ausmassen, vermag es jedoch nicht vollständig zu erklären. Die Bromatome 
wiederum sind nicht essentiell für die Toxizität verstärken diese aber deutlich. Das Benzofurangerüst 
alleine ist nicht verantwortlich für die toxischen Wirkungen. Die Leberschädigung im Zusammenhang 
mit der Einnahme von Benzaron oder Benzbromaron kann durch die Auslösung eines mitochondrialen 
Schadens mit nachfolgender Induktion des Zelltodes erklärt werden.  
Muskuläre Toxizität, insbesondere Rhabdomyolyse, sind seltene aber schwerwiegende 
unerwünschte Wirkungen von Statinen. Das Ziel des dritten Projektes (Kapitel 9) war es, die 
mitochondriale Toxizität fünf verschiedener Statine auf die Skelettmuskulatur zu bestimmen und deren 
Rolle in der Zelltodinduktion zu untersuchen. Lipophile Statine reduzierten die Überlebensrate von 
Rattenmyoblasten und verschlechterten die mitochondrialen Funktionen wie jene der β-Oxidation und 
der Atmungskette, welche essentiell sind für das Überleben einer Zelle. In Folge davon verschwand 
das mitochondriale Membranpotential, eine Pore in der mitochondrialen Membran öffnete sich und 
Apoptose induzierende Faktoren wurden ins Zytoplasma freigesetzt. Die mitochondriale Dysfunktion 
mit der anschliessenden Freisetzung mitochondrialer Proteine sind eng mit dem so genannten 
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programmierten Zelltod (Apoptose) gekoppelt. Folgerichtig konnte überzeugend gezeigt werden, dass 
die lipophilen Statine zu Fragmentierung der DNA und zur Zunahme Annexin V-gefärbter Zellen 
führte. Muskuläre Toxizität und insbesondere Rhabdomyolyse ist ein bekanntes Problem unter 
Statintherapien, welche mindestens teilweise durch mitochondriale Toxizität und darauf folgende 
Apoptoseauslösung erklärt werden kann.  
Das vierte Projekt (Kapitel 10) beschäftigt sich mit einer vermuteten Arzneimittelinteraktion. Bei 
einer Patientin trat unter Therapie mit immunosuppressiven Cyclophosphamiddosen und 
Roxithromycin das Krankheitsbild „veno-occlusive disease“ auf. Das Ziel der Arbeit war es der dieser 
Komplikation zu Grunde liegende Mechanismus zu erforschen. In einem ersten Schritt wurde der 
Effekt von Roxithromycin auf den Cyclophosphamidmetabolismus in vitro bestimmt. Ausserdem 
konnte mittels einer kultivierter humaner umbilikalen Endothelzelllinie die Toxizität der 
Cyclophosphamid/Roxithromycin-Kombination bestätigt werden und ermöglichte uns dadurch den 
Toxizitätsmechanismus zu erforschen. Roxithromycin bewirkt eine umfassende Hemmung des 
hepatischen Cylcophosphamidmetabolismus wie auch des P-Glykoproteins. Vermutlich kommt es zu 
einer Akkumulation von Cyclophosphamid in Hepatozyten und in Endothelzellen. Apoptose ist der 
Haupttoxizitätsmechanismus in Endothelzellen, vermutlich via Aktivierung des mitochondrialen Wegs 
der Apoptoseauslösung.  
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4. Abbreviations 
AC Acrolein 
ADP Adenosine diphosphate 
ADR Adverse drug reaction 
Ami Amiodarone 
AOX Acyl-CoA oxidase 
Ato Atorvastatin 
ATP Adenosine triphosphate 
B Benzarone 
BB Benzbromarone 
BF Benzofuran 
BBF 2-Butlybenzofuran 
CA Chloroacetaldehyde 
Cer Cerivastatin 
Cn Carnitine 
Conj Conjugation 
CoA Coenzyme A 
CPA Cyclophosphamide 
CPT Carnitine palmitoyltransferase 
Cy A Cyclosporin A 
CYP Cytochrome P450 
DAB Diaminobenzidine 
DMEM Dublecco’s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
ECV 304 Human umbilical vein endothelial cell  
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasm(at)ic reticulum 
Ery Erythromycin 
FACS Fluorescence activated cell sorting 
Fas Fas ligand 
Flu Fluvastatin 
FSC Forward scatter 
FU Fluorescence unit 
HEPES N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HDL High densitiy lipoprotein 
HMG-CoA Hydroxymethylglutaryl coenzyme A 
HPLC High performance liquid chromatography 
Imm Inner mitochondrial membrane 
Ip intraperitoneal 
Lca Long-chain acylcarnitine 
JC-1 5,5’,6,6’-Tetrachloro-
1,1’,3,3’.tetraethylbenzimidazolylcarbocyanide iodide 
LDH Lactate dehydrogenase 
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LDL Low density lipoprotein 
L6 Rat skeletal muscle myoblasts 
MPT Mitochondrial permeability transition 
MOPS  3-[N-morpholino]propanesulfonic acid 
MPP+ 1-Methyl-4-phenylpyridinium  
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MSM Mannitol sucrose mops 
MTX Methotrexate 
NADH β-Nicotinamide adenine dinucleotide 
NADPH β-Nicotinamide adenine dinucleotide phosphate 
n.d. Not determined 
Neo Neomycin plasmid; negative control to Fas ligand plasmid 
Omm Outer mitochondrial membrane 
P338/MDR murine monocytic leukaemia cell line  
PBS Phosphate buffered saline pH 7.4 
P-gp P-glycoprotein 
PPAR peroxisome proliferator-activated receptor 
PPI Propidium iodide 
Prav Pravastatin 
ψm Mitochondrial membrane potential 
R 123 Rhodamine 123 
RCR Respiratory control ratio 
ROS Reactive oxygen species 
ROX Roxithromycin 
Sca Short-chain acylcarinitine 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
Sim Simvastatin 
Tris Tris(hydroxymethyl)-aminomethan 
TPP+ Tetraphenylphosphonium bromide 
VLDL Very low density lipoprotein 
VOD Veno-occlusive disease 
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5. Introduction 
5.1. Toxicology 
5.1.1. Background 
Toxicology! What an exciting word with interesting connotations. It initially evoked thoughts of 
poisons, poisoners, intrigue, cloak-and-dagger, villains, victims and perpetrator as well as plants and 
chemicals as instruments of ill. But what does to word conjure up today? Polluted water, air laden with 
noxious gases, foods contaminated with pesticides or antibiotics, soil loaded with heavy metals and 
people suffering from undesired effects of modern therapeutic agents (1) 
Toxicology is a young science. However, its origins are very old. The earliest cultures having 
developed knowledge of drugs and poisons were the Egyptians (The Ebers Papyrus), the Chinese 
(Pen Ts’ao) and the Hindus (Rig-Veda). Knowledge on poisonous substances was recognized in 
essentially all over recorded history and was passed down. In Roman and Greek times, poisons, 
generally of plant origin, were used for murder and suicide, considered to be the „easier alternative“. 
Of Cleopatra it is bequeathed that in 30 B.C. she chose „to fall on her asp rather than to fall on her 
sword“, many years after she poisoned her younger brother in order to claim the throne. Poisoning for 
nefarious purposes has remained a problem ever since, and much of the earlier impetus to the 
development of toxicology was primarily forensic. 
Philippus Theophrastus Aureolus Bombastus von Hohenheim (Paracelsus 1492? – 1541) 
determined that specific chemicals were actually responsible for the toxicity of a plant or animal 
poison, as opposed to the Greek concept of a mixture or blend. He also documented that the body's 
response to those chemicals depended on the dose received. His studies revealed that small doses of 
a substance might be harmless or beneficial whereas larger doses could be toxic. This is now known 
as the dose-response relationship, a major concept of toxicology. Paracelsus is often quoted for his 
statement: "All substances are poisons; there is none which is not a poison. The right dose 
differentiates a poison and a remedy." 
Another motive for the development of toxicology has been the careful description of adverse 
reactions to medicinal products that began to appear in the eighteenth century. Thus, William 
Withering described digitalis toxicity in 1785, and in 1790, Hahnemann carried out toxicological studies 
on himself and his healthy friends with therapeutic agents of his time.  
In World War I a variety of poisonous chemicals were used in the battlefields of Northern 
France. This was the stimulus for much work on mechanisms of toxicity as well as medical 
countermeasures to poisoning. In fact, war played as great a part in the development of toxicology as 
of many other sciences. Major extensive and rapid developments in the scientific basis and practice of 
toxicology have been obvious since the 1950s (2). 
The essence of toxicology in our today’s understanding is that it is an integrative discipline that 
combines the elements of biology, chemistry, mathematics, physics and medicine. Toxicological 
research is driven by the need to understand and assess the human and ecological risks of exposure 
to chemicals and other toxicants as well as by interest in using toxic agents to elucidate basic 
biological and pathobiological processes. The level of research activity in this field nowadays is high 
and the rate of change of knowledge very rapid.  
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5.1.2. Toxicology today  
5.1.2.1. Categories of toxicology 
As a consequence of the markedly expanded scope of toxicology, the number of differing 
subdisciplines, which have emerged have increased considerably. Classifications are necessary and 
useful to organize information and concepts. They are neither rigid nor discrete but overlapping and 
broad instead.  
Roughly, the main activities in toxicology fall into three main categories: descriptive, 
mechanistic and regulatory. Although each has distinctive characteristics, each contributes to the 
other, and all are vitally important to chemical risk assessment. A mechanistic toxicologist is 
concerned with identifying and understanding the cellular, biochemical and molecular mechanisms by 
which chemicals exert toxic effects. A descriptive toxicologist is concerned directly with toxicity testing, 
which provides information for safety evaluation and regulatory requirements. A regulatory toxicologist 
has the responsibility for deciding on the basis of data provided by descriptive and mechanistic 
toxicology, whether a drug or another chemical poses a sufficiently low risk to be marketed for a stated 
purpose. In addition to the above categories, there are other specialized areas of toxicology, such as 
forensic, clinical, environmental, and occupational toxicology (3)  
 
5.1.2.2. Aims of toxicology: Risk Assessment 
Due to the large scope of toxicology nowadays, one finds more than one definition on 
toxicology in the literature. While a clinician would focus on the clinical safety of drugs, an 
environmental toxicologist emphasizes the toxicity of compounds on flora and fauna, whereas a 
regulatory toxicologist aims at estimation of risk and of the contribution to the risk/benefit ratio for its 
intended use. A term that has become very important for toxicologist independent of the individual field 
is the so-called “risk assessment”. Risk assessment or safety assessment, respectively, consists of 
four components: (I) identify hazard, (II) characterize hazard, (III) describe exposure, and (IV) present 
risk. In this context it is important to point out, that hazard describes the potential for a damaging effect 
whereas the risk includes the likelihood that a hazard would occur. In case of drug development these 
data are contributing to the go or no-go decision in drug development. However, in the interpretation of 
safety data, risk-benefit considerations need to be applied. The therapeutic benefit has to be analyzed 
in view of the indication. The degree of adverse drug reaction, which is acceptable, is different for an 
anti-cancer therapy compared to treatment of hypertension.  
 
5.1.3. Principles of toxicology 
As Paracelsus proposed centuries ago, the dose differentiates whether a substance will be a 
remedy or a poison. A xenobiotic in small amounts may be non-toxic and even beneficial but when the 
dose is increased, toxic and lethal effects may result. 
With the exception of adverse drug reaction on the basis of immunological or idiosyncratic 
processes, the dose-response relationship is a fundamental and essential concept in toxicology. It 
correlates exposures and the spectrum of induced effects. Generally: the higher the dose, the more 
severe the response. The dose-response relationship is based on observed data from experimental 
animal, human clinical, or cell studies. 
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Knowledge of the dose-response relationship: 
o establishes causality that the chemical has in fact induced the observed effects 
o establishes the lowest dose where an induced effect occurs - the threshold effect 
o determines the rate at which injury builds up - the slope for the dose response. 
 
Within a population, the majority of responses to a toxicant are similar; however, a wide 
variance of responses may be encountered, some individuals are susceptible and others resistant. 
The dose-response curve normally takes the form of a sigmoid curve (see Figure 1, Panel A). Small 
doses are not toxic. The point at which toxicity first appears is known as the threshold dose level. 
From that point, the curve increases with higher dose levels. Knowledge of the shape and slope of the 
dose-response curve is extremely important in predicting the toxicity of a substance at specific dose 
level (see Figure 1, Panel B). 
 
Figure 1: dose-response curve: 
Panel A: The dose-response relationship normally describes a sigmoid curve with the threshold level 
indicating the dose at which first signs of toxicity appear. 
Panel B: The shape and the slope of the curve are essential parameters in order to predict the toxic 
potential of a xenobiotic. Compound I has a lower threshold level whereas compound II has a higher 
slope value indicating a small dose range from first signs to maximal manifestation of toxicity.  
 
5.2. Mitochondria 
5.2.1. Origin 
About 2 billion years ago, cell destined to be the ancestors of all eukaryontic cells entered into 
a partnership with an ancestor of today’s purple bacteria. This collaboration promised benefits to both 
parties: it allowed them to exploit the energy opportunities inherent in the emerging oxygen 
atmosphere, which was toxic to most forms of life. The result was a protoeukariontic cell, and the 
endosymbiotic bacteria were to become mitochondria. For very many years, the mitochondria were 
considered to be the powerhouse of the cell and appreciated for their essential role in energy supply. 
But in the 1990s a flurry of publications highlightened a new task, that of an organellar cerebus, the 
gatekeeper of cell death. It was natural to wonder whether the life-supporting functions of mitochondria 
were somehow linked to a death-promoting activity.  
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5.2.2. Introduction 
Mitochondria derive from bacterial origin and have two membranes: a circular outer membrane 
limiting the intermembrane space, and an inner membrane with inner folds (the mitochondrial cristae), 
which limits the mitochondrial matrix. Enzymes involved in β-oxidation of fatty acids or TCA cycle are 
in the matrix, together with the mitochondrial DNA (mtDNA), whereas the enzymes of the respiratory 
chain are sitting in the inner mitochondrial membrane. Cytochrome c, engaged in the electron 
transport of the respiratory chain, is located in the mitochondrial intermembrane space (Figure 2). 
 
 
 
 
Figure 2: Structure of mitochondria: 
Mitochondria are organelles with two well-defined compartments: the matrix, surrounded by the inner 
mitochondrial membrane, and the intermembrane space, surrounded by the outer mitochondrial 
membrane. The inner membrane is folded into numerous cristae, which greatly increases the surface. It 
contains the complexes of the electron transport chain, the ATP synthase and the adenine nucleotide 
transporter. To function properly, the inner membrane is almost impermeable in physiological conditions.  
 
At the contact sites between inner and outer mitochondria a large conductance channel is 
located, known as the mitochondrial permeability transition (mpt) pore. The structure and composition 
remain only partially defined, but its constituents include both inner membrane proteins (such as 
adenine nucleotide translocator) and outer membrane proteins, such as porin (voltage-dependent 
anion channel), which operate most likely in concert, creating a channel through which molecules < 
1500 Da pass.  
Mitochondria produce most of the cell energy by the oxidation of various fuels and the 
oxidative phosphorylation. The β-oxidation of fatty acyl-coenzyme A derivatives and oxidation of 
acetyl-CoA by the TCA cycle are associated with the conversion of NAD+ and FAD into NADH and 
FADH2. These reduced cofactors are then reoxidized by the respiratory chain. Most electrons migrate 
along the respiratory chain up to cytochrome c oxidase, where they safely combine with protons and 
oxygen to form water. This transport of electrons along the respiratory chain is associated with the 
extrusions of protons from the matrix into the intermembrane space. This creates a high 
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electrochemical potential across the inner mitochondrial membrane, whose potential energy is used to 
synthesize ATP.  
MtDNA is extremely sensitive to oxidative damage owing to its proximity to the inner 
membrane with the electron transport chain, the absence of protective histones and incomplete repair 
mechanisms (4). 
 
5.2.3. Mitochondrial Dysfunction & Mitochondrial Cytopathies 
Mitochondrial dysfunction describes the conditions in which the proper function of mitochondria 
is impaired resulting in inadequate energy production, independent of its actual trigger. These 
dysfunctions can be drug induced, due to pathogenic conditions such as cholestasis (5) as well as of 
acquired or inherited origin. The latter are also termed mitochondrial cytopathies. Mitochondrial 
dysfunctions include inhibition of the respiratory chain, uncoupling of oxidative phosphorylation or 
inhibition of fatty acid oxidation.  
The association between mitochondrial abnormalities and disease has been known for about 
forty years, with the description of a patient with hypermetabolism and a skeletal muscle biopsy 
demonstration large numbers of abnormal mitochondria (6-8) 
Mitochondrial cytopathies are inherited or acquired disorders. They can be caused by 
inheritable genetic mutations, acquired somatic mutations, or the aging process itself. The two most 
common inheritance patterns are Mendelian and Maternal. Mitochondrial cytopathies actually include 
more than 40 different identified diseases that have different genetic features. The disorders range in 
severity from minimal symptoms to death. The result is often muscle weakness, fatigue and problems 
with the heart, eyes and various other systems. Some mitochondrial cytopathies include Leber 
hereditary optic neuropathy (LHON), myoclonus epilepsy with ragged-red fibers (MERRF), 
mitochondrial encephalomyopathy, lactic acidosis and stroke-like syndrome (MELAS), Leigh 
syndrome and Kearn-Sayre syndrome (KSS) (9). 
That mitochondria represent a target for drug toxicity is not surprising, bearing in mind their 
central role in energy generation and metabolic function. Principle mechanisms of drug induced 
mitochondrial toxicities are: (a) inhibition of the electron transport chain, (b) uncoupling of oxidative 
phosphorylation, (c) inhibition of fatty acid metabolism, (d) oxidation of mtDNA or (e) inhibition of 
mitochondrial DNA synthesis. The list of toxins known to cause mitochondrial injury nowadays is 
increasingly long, including drugs like valproate, salicylate (10-13), diclofenac (14), naproxen (15) 
benzbromarone (see chapter 8), bupivacaine (16), buprenorphine (17), amiodarone (18), zidovudine 
(19), extracts from kava kava, bacterial toxins like cereulide (20) or aflatoxin (21). Mitochondrial 
dysfunction with subsequent possible induction of organ failure is well described for many drugs. 
However, the question arises, why only a certain population taking a specific toxic compound develops 
side effects and what in particular makes them vulnerable. Further investigations are needed to cast 
more light on this matter. With regards to mitochondria, some factors are known to increase the risk of 
developing unwanted effects. Reduced mitochondrial metabolism represents a risk factor for induction 
of toxicity. This reduction might be due to inborn deficiencies in mitochondrial metabolism or due to co-
administration of drugs known to inhibit mitochondrial functions.  
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5.3. Drug Toxicity 
5.3.1. From the Status Quo to the “Magic Bullet” 
In the early 1900s, the German scientist Paul Ehrlich described an ideal drug as a „magic 
bullet“; such a drug would be targeted precisely at a disease site and would not harm healthy tissues. 
Although many new drugs are targeted more accurately than their predecessors, none of them, as of 
yet, hit the target precisely. Most drugs produce several effects, but usually only one effect, namely 
the therapeutic effect, is desired for the treatment of a disorder. The other actions of a drug may be 
regarded as adverse effects, whether they are intrinsically harmful or not.  
Not surprisingly, adverse drug reactions (ADR) are common. Most ADRs are relatively mild, 
and many disappear when the drug is stopped or the dose is reduced. Some gradually subside as the 
body adjusts to the drug. Other ADRs are more serious and last longer. Up to 5% of hospital 
admissions in the United States are estimated to be for treatment of adverse drug reactions (22-24). 
Each time a person is hospitalized, the risk of having at least one adverse drug reaction is 10 to 30% 
(25-27). The risk is directly correlated to the amount of different drugs a person is treated with and to 
the age of the patient (23, 28). 
Many ADRs represent an exaggeration of the drug’s effects (type A or augmented reaction). 
This type is usually predictable and in many cases avoidable. It may occur if the dosage of a drug is 
too high, if another drug reduces the metabolism of the first drug (see next paragraph) or if the 
elimination of a drug is impaired. The reaction is related to the exposure. Around 70 to 80% of total 
adverse drug reactions account for type A reactions. Some adverse drug reactions result from 
mechanisms that may not be fully understood (type B or bizarre reactions). This type of reaction is 
largely unpredictable, normally dose-independent and tends to be potentially severe or even life 
threatening. Type B reaction, also called idiosyncratic drug reactions, can be due to intolerance, 
allergy or pseudoallergy (24).  
ADRs can be caused if an organism is exposed to one xenobiotic at one time. Medical 
treatment, however, consist often of multiple exposures. Xenobiotics administered or received 
simultaneously may act independently of each other. However, in many cases, the presence of one 
chemical may drastically affect the response to another chemical. The toxicity of a combination of 
chemicals may be less or it may be more than would be predicted from the known effects of each 
individual chemical. The effect that one chemical has on the toxic effect of another chemical is known 
as an interaction. 
As mentioned before, some ADRs are unpredictable. Related to this, the issue of idiosyncratic 
drug reactions should be raised. There are host-related factors that will contribute to determining 
whether a xenobiotic will induce an ADR or not. These host factors are only partially known but may 
include both genetic and acquired factors. Such a host (patient)-specific mixture of characteristics is 
called “idiosyncrasy”. The term implies that the reactions are based on specific combinations of 
factors, that is characteristic for an individual and which predisposes the individual to succumb to overt 
manifestation of toxicity. Idiosyncratic drug reactions involve many different mechanisms. Immune-
mediated toxicity is one of them. Abnormalities in biochemical pathways leading to metabolic 
idiosyncrasy have also been defined, which refers back, at least in part, to the topic of mitochondrial 
dysfunction and cytopathies (29)  
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5.3.2. Development of drug toxicity 
Chemicals may adversely affect the function and/or structure of living organisms. The 
characterization of these harmful or toxic effects is essential. It is also valuable to understand the 
mechanisms responsible for the manifestation of toxicity – that is, how a toxicant enters an organism, 
how it interacts with target molecules, and how the organism deals with this insult. Elucidation of the 
mechanisms of toxicity has led to a better understanding of fundamental physiologic and biochemical 
processes. Consequently there are various pathways that may lead to toxicity (see figure 3). A 
common course is when a toxicant delivered to its target reacts with it, and the resultant cellular 
dysfunction manifests itself in toxicity. An example of this route of toxicity is that taken by the puffer 
fish poison tetrodotoxin. After ingestion (step 1) it reacts with its target (step 2b), resulting in blockade 
of Na+ channels, inhibition of the activity of motoneurons (step 3) and ultimatively skeletal muscle 
paralysis. No repair mechanisms can prevent the onset of such toxicity.  
 
 
 
Figure 3: Potential stages in the development of toxicity after chemical exposure (30) 
 
Sometimes a xenobiotic does not react with a specific target molecule but rather adversely 
influences the biological environment, causing molecular, organellar, cellular or organ dysfunction 
leading to deleterious effects. For example, 2.4-dinitrophenol, after entering the mitochondrial matrix 
(step 1), collapses the proton gradient across the inner mitochondrial membrane by its mere presence 
(step 2b), causing mitochondrial dysfunction (step 3), which is manifested in toxic effects such as 
seizures or hyperthermia.  
The most complex path of toxicity involves more steps. First the toxicant is delivered to its 
target(s) (step 1), after which the ultimate toxicant interacts with endogenous target molecules (step 
2a), triggering perturbations in cell function and/or structure (step 3), which initiate repair mechanisms 
at the molecular, cellular, and/or tissue levels (step 4). When the perturbations induced exceed repair 
capacity or when repair becomes malfunctional, toxicity occurs (30).  
As a result of the huge number of potential toxicants and the multitude of biological structures 
and processes that can be impaired, there is a tremendous number of possible toxic effects. 
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Considering the focus of the succeeding chapters, emphasis was put on basic toxic mechanisms of 
particular importance for this thesis.  
 
5.3.3. Mechanisms of drug toxicity 
Toxic damage to cells can cause individual cell death and if sufficient cells are lost, the result 
can be tissue or organ failure, ultimately leading to death of the organism. Apparent adverse drug 
reactions, cell damage or tissue damage have an underlying mechanism on the molecular, 
biochemical or cellular level. Toxicity occurs due to specific changes within the cell. These events lead 
to impairment of internal cellular maintenance, which can be considered as a comprehensive basic 
concept of drug toxicity. It is interesting to note, that in all disorders, mitochondria play a key role.  
There are three critical biochemical mechanisms how chemicals may initiate cell damage , 
namely ATP depletion, sustained rise in intracellular Ca2+ and overproduction of reactive oxygen 
species (ROS).  
 
5.3.3.1. Biochemical changes 
5.3.3.1.1. ATP depletion 
ATP plays a central role in cellular maintenance. Chemical energy is released by hydrolysis of 
ATP to ADP or AMP. The ADP is rephosphorylated in the mitochondria by ATP synthase. Coupled to 
oxidation of hydrogen to water, this process is termed oxidative phosphorylation.  
Oxidative phosphorylation requires (a) the delivery of hydrogen in the form of NADH to the 
initial electron transport complex: (b) delivery of oxygen to the terminal electron complex,: (c) delivery 
of ADP and inorganic phosphate to ATP synthase; (d) flux of electrons along the electron transport 
chain; and (e) return of protons across the inner mitochondrial membrane into the matrix down the 
electrochemical gradient to drive ATP synthase. Chemicals can impede these processes, interfering 
with mitochondrial ATP synthesis. Impairing agents can interfere at different stages, like inhibitors of 
hydrogen delivery to the electron transport chain (i.e. inhibition of β-oxidation), inhibitors of the 
electron transport chain (i.e. rotenone, cyanide, amiodarone, antimycin), inhibitors of oxygen delivery 
to the electron transport chain, inhibitors of ADP phosphorylation (i.e. oligomycin, uncouplers), or 
chemicals causing mitochondrial DNA damage and impaired transcription of key mitochondrial 
proteins. Impairment of oxidative phosphorylation is detrimental to cells because failure of ADP 
rephosphorlylation results in accumulation of ADP and its breakdown products as well as depletion of 
ATP. These changes cause a cascade of aftereffects, which may be devastating and disastrous in 
such a tightly and subtly regulated system like a cell.  
 
5.3.3.1.2. Sustained rise of intracellular Ca2+  
Intracellular Ca2+ levels are highly regulated. The 10’000-fold difference between extracellular 
and cytosolic Ca2+ concentration is maintained by the impermeability of the plasma membrane to Ca2+ 
and by transport mechanisms that remove Ca2+ from the cytoplasm. Ca2+ is actively pumped from the 
cytosol across the plasma membrane and is sequestered in the endoplasmatic reticulum and 
mitochondria. Because they are equipped with a low-affinity transporter, the mitochondria play a 
significant and essential role in Ca2+ sequestration when the cytoplasmatic Ca2+ levels rise into the 
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micromolecular range. Toxicants induce elevation of cytoplasmatic Ca2+ by promoting Ca2+ influx or 
inhibiting Ca2+ efflux from the cytoplasm. Toxicants also increase cytosolic Ca2+ inducing its leakage 
from mitochondria. Sustained elevation of intracellular Ca2+ is harmful because it can result in (a) 
depletion of energy reserves, (b) dysfunction of microfilaments, (c) activation of hydrolytic enzymes, 
and (d) generation of ROS.  
 
5.3.3.1.3. Overproduction of reactive oxygen species (ROS) 
There are a number of xenobiotics that can directly generate ROS, such as transition metals. 
However, mitochondria are the major source of ROS in a cell. Overproduction can be secondary to 
inhibition of the mitochondrial electron transport chain, due to leakage of reduced molecular oxygen 
from complex III. Similarly complex I also provides superoxide anions (31). For example, mitochondria 
form O2--anions, which in turn are converted into H2O2 and the potent reactive species hydroxyl radical 
(OH). As already mentioned in the chapter before, oxidative stress causes a sustained elevation of 
cellular Ca2+ with all its consequences. The alteration of mitochondrial Ca2+ concentration has been 
suggested to be an important event in the induction of oxidative stress. ROS have been shown to 
mediate cell death in a number of systems (32).  
 
5.3.4. Mitochondrial permeability transition (MPT) 
The before mentioned biochemical changes such as mitochondrial Ca2+ uptake, generation of 
ROS, depletion of ATP as well as decreased mitochondrial membrane potential (ψm) are all 
considered as causative factors for an abrupt increase in the mitochondrial inner membrane 
permeability, believed to be caused by opening of a proteinaceous pore („megachannel“) that spans 
both mitochondrial membranes (33, 34). As this pore is permeable to solutes of size < 1500 Da, its 
opening permits free influx of protons into the mitochondrial matrix, causing a rapid dissipation of the 
ψm and impairment of ATP generation, osmotic driven influx of water, resulting in mitochondrial 
swelling as well as release of molecules located in the mitochondrial intermembrane space (i.e. 
cytochrome c) (35). The principle is shown in Figure 4. It has to be emphasized that up to now, the 
precise composition and function of this pore is controversial and the model presented here is broadly 
accepted but still hypothetical.  
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Figure 4: The mitochondrial permeability transition: A speculative model showing some of the 
components of the permeability transition pore (36). In the open configuration, water and solutes enter 
the matrix, causing matrix swelling and outer membrane disruption, leading to release of cytochrome c 
and other proteins (imm = inner mitochondrial membrane, omm = outer mitochondrial membrane). 
 
The significance of cytochrome c release is twofold. (a) As cytochrome c is the penultimate link 
in the electron transport chain, its loss will impair ATP generation and increase formation of ROS, and 
thus potentially drive the cell toward cell death. (b) Simultaneously, the released cytochrome c (and 
other proteins set free from the intermembrane space) represents a signal or an initial link in the chain 
of events directing the cell to the apoptotic pathway. Upon binding, together with ATP, to an adapter 
protein (Apaf-1), cytochrome c can induce proteolytic cleavage of the Apaf-1-bound latent procaspace-
9 to active caspase-9 and thereby execute apoptosis.  
Such mitochondria might be incapable of synthesizing ATP. If so, then even glycolysis may 
become compromised by the insufficient ATP supply. A complete bioenergetic catastrophe ensues in 
the cell if the metabolic disorder evoked by the toxic agent is so extensive that most or all 
mitochondria in a cell undergo MPT, causing depletion of ATP on the cellular level, which in the end 
causes a complete failure of maintenance of cellular structure and function possibly culminating in cell 
death.  
 
5.3.5. Cell Death 
5.3.5.1. Mechanisms of Cell Death 
Toxic cell death can occur via two processes, which are fundamentally different in their nature 
and biological significance (37). These are termed necrosis and apoptosis. “Apoptosis” comes from 
the ancient Greek meaning “falling off petals from a flower” or “falling off leaves from a tree”. The 
name refers to the morphological feature of formation of apoptotic bodies from a cell (38).  
Necrosis or „accidental“ cell death was the classic model and was thought to be the universal 
mode of cell death until apoptosis was identified in 1972 as a separate mode of cell death. Necrotic 
cell death is the typical consequence of severe acute cellular injury, such as occurs in strokes or heart 
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attacks. The cellular events leading up to necrotic cell death are somewhat variable from one cell type 
to another, but certain events occur regularly. One of the earliest changes is the formation of 
protrusions of the plasma membrane, called blebs. Cellular swelling accompanies this formation. 
Irreversible injury occurs when one of these blebs ruptures, leading to failure of the plasma membrane 
permeability barrier, release of intracellular enzymes and metabolites, and collapse of electrical and 
ionic gradients across the plasma membrane.  
Apoptosis, unlike necrosis, is a form of physiological cell death that causes cell deletion without 
inflammation and describes a process of controlled cell deletion and that has an opposite role to 
mitosis in the regulation of cell population. In apoptosis, cells begin a characteristic sequence of 
structural and biochemical changes. These changes include cell shrinkage, alteration of plasma 
membrane lipids, condensation of chromatin, DNA degradation, and shedding of membrane-bound 
cytoplasmatic fragments containing organelles and chromatin. These apoptotic bodies are taken up by 
macrophages. One major pathway for the induction of apoptosis is the receptor-mediated or extrinsic 
pathway. The receptors triggering this pathway are located in the plasma membrane and are activated 
by extracellular ligands. Typical death receptors are Fas (also called CD-95) and tumor-necrosis factor 
receptor (TNF-R). The receptor-induced pathway leads to recruitment of capsase-8 or -10 to the death 
signaling complex without involving mitochondria at this stage. However, mitochondria are engaged 
through the formation of tBid (Bcl-2 protein family) at a later stage, leading to amplification of the 
signal (38). The mitochondrial pathway is activated by a variety of extra- and intracellular stresses, 
including oxidative stress and treatment with cytotoxic drugs. Members of the protein family Bcl-2 
modify and regulate apoptotic pathways by a variety of either pro (Bax, Bak, Bid) and antiapoptotic 
proteins (Bcl-2, Bcl-XL). They up or down-regulate the caspase cascade or act on mitochondria 
directly. The apoptotic signal leads to the release of cytochrome c from the mitochondrial 
intermembrane space into the cytosol, where it binds to the Apoptotic Protease Activation Factor 
(Apaf-1). This triggers the activation of caspases (38).  
 
5.3.5.2. Role of Mitochondria in Cell Death 
It appears that most if not all chemical-induced cell death will involve mitochondria, the 
resulting mitochondrial dysfunction may ultimately trigger either necrosis or apoptosis and that MPT is 
a crucial event in both (see Figure 5). Given the importance of mitochondria for cell life, it comes as no 
surprise that mitochondrial dysfunction and failure leads to cell death (35). The decisive mitochondrial 
events in cell death are MPT and release of cytochrome c, thus caspase activation.  
As already pointed out, there are several common features in the process of apoptosis and 
necrosis. It is of interest to know that toxic agents can cause both apoptosis and necrosis (39, 40). 
Many substances induce apoptosis at low but necrosis at higher doses (40, 41) .In addition, induction 
of cell death by cytotoxic agents may involve similar metabolic disturbances and most importantly 
MPT (33-35). So, regulatory mechanisms underlying apoptosis and necrosis partially on the 
mitochondrial level (42, 43). What determines, then, whether an injured cell undergoes apoptosis or 
necrosis – which may have a significant impact on the surrounding tissue? Recent findings suggest 
that the availability of ATP is critical determining the form of cell death. Lack of ATP depletion favors 
the execution of the apoptotic program, which involves ATP-requiring steps, one of which is formation 
of the complex between Apaf-1, cytochrome c and the procaspase-9 (44). For instance, cells triggered 
Introduction  
  26 
to undergo apoptosis are instead forced to die by necrosis when energy levels are rapidly 
compromised. Thus, the initial death signal is propagated without leading to apoptosis. 
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Figure 5: putative role of mitochondria in cell death induction 
Mitochondrial toxins can inhibit β-oxidation and the respiratory chain, leading to a decrease in 
mitochondrial and cellular ATP levels. Additionally, they can uncouple oxidative phosphorylation, which, 
in particular in combination with the inhibition of the electron transport, increases the generation of 
reactive oxygen species (ROS) leading to permeabilization of the mitochondrial membranes by opening 
of the mitochondrial permeability transition pore. This pore is located in the inner and outer mitochondrial 
membrane (imm and omm, respectively). The osmotically driven influx of water results in an increase in 
mitochondrial volume. Since the inner mitochondrial membrane is highly invaginated and thus 
expandable, an increase in volume can cause a rupture of the outer mitochondrial membrane. Proteins 
from the intermembrane space (i.e. cytochrome c) can be released into the cytoplasm and activate 
apoptotic pathways. If ATP stocks were highly depleted, the same triggers would lead to necrosis 
instead of apoptosis.  
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Aims of the thesis  
6. Aims of the thesis 
This thesis contains four publications on toxicity, covering several aspects of this field. All of 
them have a mutual underlying interest in learning more about mechanisms of toxicity. It needs 
thorough and profound knowledge on what is going wrong, before countermeasures can be tackled in 
order to prevent complications after drug treatment. Even though the aim of the “magic bullet” might 
never be reached it should be approached stepwise towards a more “tailor made” medicine. In order 
to do this, in a first step, several analytical methods and assays need to be established and set up.  
The aim of the first project was to study basic principles of toxicity. The interest in the study of 
an animal model for carnitine deficiency due to treatment with trimethylhydraziniumpropionate (THP) 
was twofold. First, knowledge on the pathogenesis of carnitine deficiency was generated, and 
secondly, general principles of mitochondrial toxicity and its consequences like liver steatosis were 
analyzed and elucidated.  
The second project was looking into induction of hepatic toxicity due therapy with benzarone 
and benzbromarone. The idea to conduct this study derived from case reports about hepatic failure 
after treatment with benzbromarone/benzarone with knowledge on the structural similarity to the well-
known hepatic toxin amiodarone in the back of the head. Besides amiodarone, also benzofuran and 2-
butylbenzofuran were included in the study, in order to gain more insight into chemical structures 
responsible for toxicity.  
The focus of the third project was on mitochondrial toxicity on the muscular level. Statins are 
known to cause rhabdomyolysis dose-dependently in rare cases. The mechanism responsible has not 
been clear yet but mitochondria have been claimed to be responsible, at least in part. The question 
raised by this project was whether mitochondrial toxicity can indeed be blamed for muscular side 
effects of statin therapy. Basic concepts of mitochondrial liver toxicity established in the preceding 
projects were expanded into and adapted for skeletal muscle tissue.  
Last but not least, the fourth project again found its origin in the clinics but dealing with another 
aspect of drug toxicity, namely drug-drug interactions. A patient happened to suffer from veno-
occlusive disease under a low dose, thus immunosuppressive treatment of an anticancer drug shortly 
after having added a macrolide antibiotic to the therapy (see appendix). The aim of the study was to 
clarify whether a drug-drug interaction was responsible for the complication emerged from this therapy 
and if so what the underlying mechanism was.  
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7.1. Summary 
Rats with systemic carnitine deficiency induced by treatment with 
trimethylhydraziniumpropionate (THP) develop liver steatosis. This study aims to investigate the 
mechanisms leading to steatosis in THP-induced carnitine deficiency. Rats were treated with THP (20 
mg/100 g) for 3 or 6 weeks and were studied after starvation for 24 h. Rats treated with THP had 
reduced in vivo palmitate metabolism and developed mixed liver steatosis at both time points. The 
hepatic carnitine pool was reduced in THP-treated rats by 65% to 75% at both time points. Liver 
mitochondria from THP-treated rats had increased oxidative metabolism of various substrates and of 
β-oxidation at 3 weeks, but reduced activities at 6 weeks of THP treatment. Ketogenesis was not 
affected. The hepatic content of CoA was increased by 23% at 3 weeks and by 40% at 6 weeks in 
THP treated rats. The cytosolic content of long-chain acyl-CoAs was increased and the mitochondrial 
content decreased in hepatocytes of THP treated rats, compatible with decreased activity of carnitine 
palmitoyltransferase I in vivo. THP-treated rats showed hepatic peroxisomal proliferation and 
increased plasma VLDL triglyceride and phospholipid concentrations at both time points. A reduction 
in the hepatic carnitine pool is the principle mechanism leading to impaired hepatic fatty acid 
metabolism and liver steatosis in THP-treated rats. Cytosolic accumulation of long-chain acyl-CoAs is 
associated with increased plasma VLDL triglyceride, phospholipid concentrations, and peroxisomal 
proliferation. 
 
7.2. Introduction 
Liver steatosis is a frequent finding in liver biopsies and a frequent cause of asymptomatic 
elevation of transaminases (1). Several risk factors have been identified, among them ingestion of 
certain drugs (2-5), alcohol abuse (6), viral hepatitis (7), diabetes (8), increased body weight (8, 9), 
and intoxications (10). While impaired mitochondrial β-oxidation is considered to be the principle 
cause for microvesicular steatosis (11), the mechanisms leading to macrovesicular steatosis have so 
far not been identified in detail. As shown in Fig. 1, important possibilities leading to this finding include 
a decrease in VLDL export and/or an increase in VLDL formation, which may result from impaired 
mitochondrial fatty acid metabolism or from other causes. 
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Figure 1: Hepatic metabolism of long-chain fatty acids. Palmitate and other long-chain fatty acids are 
activated by palmitoyl-CoA (PCS) on the outer mitochondrial membrane, converted to palmitoylcarnitine 
by carnitine palmitoyltransferase I (CPT I), transported into the mitochondrial matrix and reconverted to 
palmitoyl-CoA by CPT II (see magnification). Palmitoyl-CoA is degraded to acetyl-CoA by the β-oxidation 
cycle. Acetyl-CoA can be converted to ketone bodies (major pathway) or be degraded in the Krebs 
cycle. Palmitoyl-CoA can also be β-oxidized by peroxisomes, which produce medium-chain acyl-CoAs 
that are converted to the corresponding acyl-carnitines and can be metabolized to acetyl-CoA by 
mitochondria. In addition, cytosolic palmitoyl-CoA can also be used for the formation of triglycerides and 
phospholipids, which are both substrates for the formation of VLDL particles. See text for additional 
explanations. CTL, carnitine-acylcarnitine translocase, i.m., inner mitochondrial membrane, o.m., outer 
mitochondrial membrane. 
 
We have recently developed and characterized a rat model with systemic carnitine deficiency 
(12). In this model, carnitine deficiency is induced within 3 weeks by feeding 
trimethylhydraziniumpropionate (THP), which inhibits carnitine biosynthesis and increases renal 
excretion of carnitine. Interestingly, rats treated with THP develop combined micro- and 
macrovesicular liver steatosis within 3 weeks but have no macro- or microscopic accumulation of lipids 
in skeletal muscle or heart (12, 13). Since carnitine is essential for transport of long-chain fatty acids 
into the mitochondrial matrix (14), it can be speculated that at least the microvesicular part of liver 
steatosis in THP-treated rats could be caused by hepatic carnitine deficiency. In support of this 
assumption, both in children with primary systemic carnitine deficiency and in mice with systemic 
carnitine deficiency (JVS mice), microvesicular liver steatosis has been reported (15, 16). However, at 
least the macrovesicular part of liver steatosis in rats treated with THP cannot be explained by an 
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isolated defect in mitochondrial β-oxidation of fatty acids, suggesting additional mechanisms. Since 
the morphology of liver steatosis in THP-treated rats resembles that found in certain types of steatotic 
livers in humans, e.g., certain types of alcohol-induced liver steatosis (17) or steatosis observed during 
administration of amiodarone (18), knowledge about the mechanisms leading to liver steatosis in THP-
treated rats may also be relevant for understanding this disease in humans. We therefore decided to 
study the mechanisms leading to liver steatosis in rats treated with THP for 3 or 6 weeks. Beside the 
mechanisms leading to liver steatosis, we also investigated adaptive changes secondary to a 
decrease in the hepatic carnitine pool and to impaired in vivo mitochondrial β-oxidation. Our studies 
demonstrate that hepatic carnitine deficiency is the most important cause for liver steatosis in THP-
treated rats and suggest that reduced mitochondrial fatty acid oxidation may be partially compensated 
by increased peroxisomal fatty acid metabolism due to proliferation of peroxisomes. 
 
7.3. Materials and Methods 
7.3.1. Induction of carnitine deficiency in vivo palmitate metabolism  
The experiments have been reviewed and accepted by the State Ethics Committee of animal 
research. Carnitine deficiency was induced in male Sprague-Dawley rats by feeding vegetarian food 
poor in carnitine (Kliba Futter 2435, Basel, Switzerland) and THP (20 mg/100 g/day) for 3 or 6 weeks 
(n = 6 rats for each time point) (12). Control rats were kept for the same periods of time with the same 
rat chow ad libitum (n = 12). In order to investigate a potential toxic effect on mitochondrial metabolism 
by THP itself in vivo, rats (n = 3 in each group) were treated with THP (20 mg/100 g/day), with l-
carnitine (50mg/100 g/day), or with the combination of THP and l-carnitine (same dosages) for 3 
weeks. Metabolism of palmitate was determined in vivo after 3 weeks of treatment with THP by 
intraperitoneal injection of [14C]palmitate and determination of exhaled 14CO2 as described previously 
(19). 
 
7.3.2. Isolation of rat liver mitochondria 
Rats were killed by decapitation and mitochondria were isolated from the liver by differential 
centrifugation according to a previously described method (20). This method yields mitochondria of 
high purity with only minor contamination by peroxisomes or lysosomes (21). The mitochondrial 
protein content was determined using the biuret method with bovine serum albumin as a standard 
(22). The content of mitochondrial protein per g liver was determined by correcting for the recovery of 
the mitochondria isolated using the activities of citrate synthase and succinate dehydrogenase as 
described previously (21). 
 
7.3.3. Oxidative metabolism of intact mitochondria 
Oxygen consumption by freshly isolated liver mitochondria was measured in a chamber 
equipped with a Clark-type oxygen electrode (Yellow Springs Instruments, Yellow Springs, OH) at 
30°C as described previously (23). The concentrations of the substrates used were 20 mmol/L for L-
glutamate and succinate, 40 µmol/L for palmitoyl-L-carnitine, 20 µmol/L for palmitoyl-CoA and 80 
µmol/L for palmitate. All incubations with fatty acids contained 5 mmol/L L-malate, incubations with 
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palmitoyl-CoA and palmitate contained in addition 2 mmol/L L-carnitine and incubations with palmitate 
contained in addition 250 µmol/L ATP and 250 µmol/L CoASH. 
 
7.3.4. In vitro mitochondrial β-oxidation and formation of ketone bodies 
The β-oxidation of [1-14C] palmitic acid by liver mitochondria was assessed as described by 
Fréneaux et al. (24) with some modifications described previously (25). This assay measures the 
formation of acid-soluble products from mitochondrial palmitate metabolism, which equals production 
of ketone bodies and citric acid cycle intermediates (24). Ketone body formation was measured using 
freeze-thawed mitochondria according to Chapman et al. (26) with some modifications as described 
previously (25). The reactions were stopped by adding 100 µl of 30% perchloric acid (w/v). After 
having removed the precipitate by centrifugation, the supernatants were analyzed for acetoacetate 
according to Olsen (27).  
 
7.3.5. Activities of the enzyme complexes of the respiratory chain 
Complex I (NADH:decylubiquinone-1 oxidoreductase) was determined spectrophotometrically 
as described by Veitch et al. (28) with some modifications. Briefly, 0.1 mg mitochondria were 
preincubated in 35 mmol/L potassium phosphate buffer pH 7.4, 5 mmol/L magnesium chloride, 2 
mmol/L potassium cyanide, and 60 µmol/l decylubiquinone at 30°C. The reaction was started by the 
addition of 0.13 mmol/L NADH and the decrease of absorption was recorded spectrophotometrically at 
340 nm using rotenone as inhibitor. Complex II (succinate:dichloroindophenol oxidoreductase) was 
determined according to a previously described method (23). This method is based on the reduction of 
dichloroindophenol by complex II using succinate as a substrate. The reaction is followed 
spectrophotometrically at 600 nm in the presence and absence of the inhibitor thenoyltrifluoroacetone. 
Complex III ubiquinol:ferricytochrome c oxidoreductase) was determined spectrophotometrically at 
550 nm by the conversion of ferricytochrome c to ferrocytochrome c using decylubiquinol as substrate 
(29). The reaction velocity was assessed as the difference in absorption with and without antimycin as 
inhibitor. Complex IV (cytochrome c oxidase) activity was measured by following the oxidation of 
ferrocytochrome c at 550 nm as described by Wharton and Tzagaloff (30). 
 
7.3.6. Determination of CoA and carnitine 
Liver samples (about 50 mg/1 mL, prepared without thawing) were homogenized in 3% 
perchloric acid and centrifuged for 5min at 10,000g . Mitochondria (100µL corresponding to about 10 
mg protein) were mixed with 20µL 0.2 mol/L dithiothreitol and precipitated with 1.88 mL3.2% perchloric 
acid. The suspension was vortexed, kept on ice for 5 min, and then centrifuged for 10 min at 10,000g. 
This perchloric acid treatment yields an acid soluble (supernatant) and an acid insoluble fraction 
(pellet). The acid soluble fraction is used to measure free and acetyl-CoA and, after alkaline 
hydrolysis, total acid soluble CoA. The difference between these values represents short chain acyl-
CoA. Long chain CoA is determined in the pellet after alkaline hydrolysis. Total CoA refers to the sum 
of total acid soluble CoA and longchain acyl-CoA. In these fractions, CoASH and acetyl-CoA, total 
acid soluble CoA (supernatant), and long-chain acyl-CoA (pellet) were determined using the CoA 
recycling assay of Allred and Guy (31), with some modifications in the work-up as described before 
(32). Since the CoA recycling assay does not differentiate CoASH and acetyl-CoA, acetyl-CoA was 
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determined specifically using a radioenzymatic assay as described previously (33). For the 
determination of carnitine, liver tissue was worked up as described above for CoA. Plasma was also 
treated with perchloric acid (final concentration 3%) to obtain a supernatant and a pellet. The 
determination of carnitine in these fractions was performed using the radioenzymatic assay described 
by Brass and Hoppel (34). Direct analysis of the supernatant yields free carnitine, and, after alkaline 
hydrolysis, total acid soluble carnitine. The difference between free and total acid soluble carnitine is 
the short-chain acylcarnitine fraction (up to a chain-length of the acyl-group of about 10). Long-chain 
acylcarnitines were determined in the pellet after alkaline hydrolysis. Addition of total acid soluble and 
long-chain acylcarnitine yields total carnitine.  
 
7.3.7. Lipid determinations in liver 
Lipids from rat livers were extracted according to the method described by Bligh and Dyer (35). 
Briefly, about 100 mg of liver tissue were homogenized in 2 ml 20 mmol/L potassium phosphate 
buffer, pH 7.4, and the lipids were extracted by the addition of 5.0 ml chloroform-methanol (1:1, v/v). 
The samples were vortexed and incubated for 60 min under periodical stirring. Then, 2.5 mL 
chloroform and 0.8 mL 0.74% potassium chloride were added and the mixture centrifuged for 5 min at 
500 g . The lower phase was separated and washed with 1.5 mL of a mixture containing 0.74% 
potassium chloride-chloroform-methanol (94:96:6, v/v/v). The organic phase was then evaporated to 
dryness and the lipid extract stored at –20° C until analysis. For lipid determination, liver extracts were 
resuspended in 250µL isopropanol. Total cholesterol, triacylglycerides, and free fatty acids were 
measured using enzymatic methods and reagents from Wako (Neuss, Germany). The measurements 
were calibrated using standards from Roche Diagnostics (Mannheim, Germany). 
 
7.3.8. Determination of plasma lipids 
Total cholesterol (TC), free cholesterol (FC), triacylglycerides (TG), phospholipids (PL), HDL 
cholesterol (HDL-C), and free fatty acids (FFA) were measured using enzymatic methods and 
reagents from Wako (Neuss, Germany). The measurements were performed on a Wako 30R 
automatic analyzer (Wako) and were calibrated using standards from Roche Diagnostics (Mannheim, 
Germany). Esterified cholesterol was calculated as the difference between TC and FC. The 
determination of the lipoprotein fractions was performed by a combined ultracentrifugation-
precipitation method (36, 37). VLDL were removed quantitatively by ultracentrifugation using a TFT 
56.6 rotor (Kontron, Germany) with adapters for 0.8 mL polycarbonate tubes. Five hundred microliters 
of plasma was pipetted into tubes and 0.1 mL of 0.9% sodium chloride solution was layered on top of 
the plasma. After centrifugation (18 h at 30,000 rpm, 10°C), the floating VLDL fraction was aspired 
with a 2 mL syringe until the supernatant was completely clear. The volume was reconstituted to the 
original weight with 0.9% saline. LDL were precipitated in the infranatant using phosphotungstic 
acid/magnesium chloride (PTA, Roche, Mannheim, Germany), and HDL lipids were measured in the 
supernatant after LDL precipitation. Lipids in the LDL fraction were calculated as the difference 
between the concentrations in the density fraction d > 1.006 kg/L and the HDL fraction. 
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7.3.9. Cytochemical localization of catalase in liver sections 
Livers from control rats and rats treated with THP for 3 weeks were fixed by perfusion through 
the portal vein with a fixative containing 0.25% glutaraldehyde and 2% sucrose in 0.1 mol/L PIPES 
buffer, pH 7.4. The tissue was cut into 70 µm sections with a DSK-Microslicer (Dosaka EM Co., Kyoto, 
Japan). The sections were incubated in alkaline diaminobenzidine (DAB) medium for cytochemical 
visualization of catalase (38), followed by osmication and embedding in Epon 812. 
 
7.3.10. SDS-PAGE and immunoblotting 
For Western blotting, tissues were homogenized in a buffer containing 250 mmol/L sucrose, 5 
mmol/L MOPS, 1 mmol/L EDTA, 0.1 % ethanol, pH 7.4, using an Ultra-Turrax (IKA Labortechnik, 
Staufen, Germany). Equal amounts of protein (20 µg per sample) were subjected to SDS-PAGE. After 
electrotransfer of the polypeptides onto nitrocellulose the sheets were incubated overnight with the 
primary antibody at a concentration of 1 µg protein/mL. The polyclonal antibody against acyl-CoA 
oxidase (AOX) was a generous gift of Prof. Dr. A. Völkl, Institute of Anatomy and Cell Biology, 
University of Heidelberg. Its specificity was assessed as described previously (39). After repeated 
washing, a peroxidase conjugated goat anti-rabbit antibody (Sigma, München, Germany) was added 
for 1 h at room temperature. The immunoreactive bands were visualized by enhanced 
chemoluminescence (ECL, Amersham International, Little Chalfont, England) according to the 
manufacturer’s protocol. 
The blots for subunit IV of cytochrome c oxidase and apolipoprotein B were performed 
according to the method described above. The polyclonal antibody against subunit IV of cytochrome c 
oxidase was obtained from molecular probes (Juro Supply, Lucerne, Switzerland) and used at a 
dilution of 0.5µg/mL. The polyclonal antibody against apolipoprotein B was obtained from LabForce 
AG (4208 Nunningen, Switzerland) and used at a dilution of 0.5µg/mL. 
 
7.3.11. Determination of acyl-CoA oxidase activity 
Acyl-CoA oxidase activity was determined according to a previously described method (40). 
This method is based on the production of hydrogen peroxide by the action of acyl-CoA oxidase which 
is measured spectrophotometrically at 502 nm using dichlorofluorescein diacetate as a chromophore. 
Briefly, 50 mg of frozen liver tissue were homogenized in 20 mmol/L potassium phosphate buffer, pH 
7.4, and the volume made up to 2.0 mL. 100 µL of this homogenate were preincubated in 1.9 mL of 10 
mmol/L potassium phosphate buffer pH 7.4 containing 0.05 mg 2’,7’ dichlorfluorescein diacetate, 5.2 
mg sodium azide, 74 mU horse radish peroxidase and 0.01% Triton-X at 37° C for 5 minutes. The 
reaction was started by the addition of 15 µmol/L palmitoyl-CoA and the increase in absorbance was 
recorded spectrophotometrically over 3 minutes at 502 nm. Activities were calculated using an 
extinction coefficient of 91’000 l x mol-1 x cm-1. 
 
7.3.12. Statistics 
Data are presented as mean SD. Groups were compared using the Student’s t-test 
(comparison of two groups) or ANOVA followed by Tukey’s protected Student’s t-test ( > 2 groups). 
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Since the values of control animals were generally not different between 3 and 6 weeks, they were 
pooled unless indicated otherwise. 
 
7.4. Results 
The studies were carried out to find out the principle mechanisms leading to liver steatosis in 
rats with systemic carnitine deficiency due to treatment with THP. Rats were treated with THP for 3 or 
6 weeks and studied after starvation for 24 hours. As shown in Figure 2, and in agreement with 
previous studies (12, 13), rats treated with THP for 3 weeks developed micro- and macrovesicular liver 
steatosis predominantly in zone I and II of the liver lobules. Similar findings were obtained after 6 
weeks of treatment with THP (results not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Liver steatosis in rats treated with THP for 3 weeks. Cryosections stained with Sudan Black for 
specific labeling of lipids. As shown in A (enlargement 64x), lipids accumulate predominantly in zones 1 
and 2 of the liver lobules, while zone 3 is spared. A higher enlargement (Fig. 2B, enlargement 160x) 
shows that the size of the lipid droplets varies, small and larger droplets can be detected in most 
hepatocytes, in particular in the periportal regions. Similar findings were present after 6 weeks of 
treatment with THP. In comparison, livers from control animals contained no fat (not shown). P, portal 
vein; C, central vein. 
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Palmitate metabolism was assessed in vivo in rats treated with THP for 3 weeks and 
corresponding control rats by injecting l-[14C]palmitate ip and measuring the amount of 14CO2 exhaled 
over the next 2 h. The percentage of radioactivity exhaled was decreased in THP treated rats (28.2 ± 
6.3% vs. 54.8 ± 8.2% of the dose injected, P < 0.05), compatible with reduced hepatic metabolism of 
long-chain fatty acids. Accordingly, the hepatic lipid content was increased significantly (P < 0.05) in 
rats treated with THP for 6 weeks for all lipid classes investigated [cholesterol 0.77 ± 0.09 vs. 0.58 ± 
0.09 mg/g liver (THP-treated vs. control), triglycerides 4.63 ± 2.78 vs. 1.54 ± 0.46 mg/g liver, and free 
fatty acids 0.80 ±0.09 vs. 0.58 ± 0.02 µmol/g liver]. As can be seen in Fig. 1, reduced metabolism of 
longchain fatty acids can be due to impaired activation of fatty acids, impaired transport of fatty acids 
into the mitochondrial matrix, impaired β-oxidation and/or an impaired function of the respiratory chain. 
As expected from the mechanism by which THP reduces the body carnitine content, namely inhibition 
of carnitine biosynthesis and increased renal excretion of carnitine (12), the liver carnitine pool was 
reduced in THP-treated rats, showing a drop by ~ 70% in comparison to control rats (Table 1). Since 
carnitine is essential for the function of CPT I (Fig. 1), this finding may explain liver steatosis in THP-
treated rats. Interestingly, both the short-chain acylcarnitine to free carnitine and the longchain 
acylcarnitine to free carnitine ratios were increased in livers of rats treated for 6 weeks, compatible 
with accumulation of β-oxidation intermediates due to impaired β-oxidation of fatty acids (23).  
 
Table 1: Liver and plasma carnitine pool 
 Control  
(n=12) 
THP 3 weeks  
(n=6) 
THP 6 weeks  
(n=6) 
Liver (nmol/g liver wet weight)   
 Free Cn 266 ± 73 74 ± 31a 75 ± 16 a 
 SCA Cn 127 ± 52 38 ± 20 a 51 ± 17 a 
 LCA Cn 50 ± 21 14 ± 12 a 26 ± 8 a 
 Total Cn 442 ± 75 125 ± 3 a 153 ± 27 a 
 SCA Cn/Free Cn 0.48±0.13 0.51±0.15 0.68±0.15 a 
 LCA Cn/Free Cn 0.19±0.07 0.19±0.12 0.35±0.09 ab 
    
Plasma (µmol/L)    
 Free Cn 29.8 ± 9.3 5.6 ± 0.8 a 4.6 ± 1.6 a 
 SCA Cn 33.4 ± 12.9 5.4 ± 0.8 a 4.9 ± 1.3 a 
 LCA Cn 9.3 ± 1.5 1.6 ± 0.7 a 1.6 ± 2.7 a 
 Total Cn 72.6 ± 24.9 12.6 ± 0.7 a 11.0 ± 4.2 a 
Cn, carnitine; LCA Cn, long-chain acylcarnitine; SCA Cn, short-chain acylcarnitine. Control and 
THP-treated rats (20 mg/100 g body weight) were studied after 3 or 6 weeks of treatment in the 
fasted state. The carnitine pools were determined by a radioenzymatic assay as described in 
Materials and Methods. Data are presented as mean ± SD.  
a P < 0.05 versus control. 
b P < 0.05 THP 6 weeks versus THP 3 weeks. 
 
Since β-oxidation is primarily a mitochondrial function, these findings prompted us to study the 
function of the respiratory chain and oxidative metabolism of fatty acids in isolated mitochondria (Table 
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2). Surprisingly, state-3 oxidation rates tended to be higher in rats treated with THP for 3 weeks but 
were generally decreased in rats treated for 6 weeks. This decrease was observed particularly for 
succinate, palmitic acid, palmitoyl-CoA, and palmitoylcarnitine, suggesting a defect in the activity of 
complex II of the electron transport chain and of β-oxidation. It is noteworthy that the experiments with 
palmitate and palmitoyl-CoA were performed in the presence of exogenous carnitine. When no 
exogenous carnitine was added to these substrates, state-3 oxidation rates were not different between 
mitochondria of control and THP-treated rats, and were approximately only 10% of the rates obtained 
with control mitochondria in the presence of exogenous carnitine. 
 
Table 2: State 3 oxidation rates by isolated rat liver mitochondria 
 Control 
(n=12) 
THP 3 weeks (n=6) THP 6 weeks 
(n=6) 
    
L-Glutamate (20mM)    82 ± 24 101 ± 17 80 ± 23 
Succcinate (20mM) 150 ± 40 207 ± 31a 123 ± 31b 
Palmitoyl-L-carnitine (40µM) 82 ± 26 116 ± 18a 62 ± 13b 
Palmitoyl-CoA (20µM) 83 ± 17 97 ± 28 68 ± 14b 
Palmitate (80µM) 46 ± 10 63 ± 14a 29 ± 10ab 
    
Control and THP-treated rats (20 mg/100 g body weight) were studied after 3 or after 6 weeks of 
treatment in the fasted state. Mitochondria were isolated by differential centrifugation and state 3 
oxidation rates were determined in the presence of the substrates indicated using a Clark-type 
oxygen electrode as described in Materials and Methods. Units are natoms oxygen x minute x 1 x 
milligram of mitochondrial protein-1. Results are presented as mean ± SD. 
a P < 0.05 versus control rats. 
b P < 0.05 THP 6 weeks versus THP 3 weeks. 
 
In order to exclude a major effect of carnitine deficiency on the mitochondrial electron transport 
chain, the activity of the enzyme complexes of the electron transport chain was determined. As shown 
in Table 3, the activities of complexes I to IV were unchanged or increased after 3 weeks of treatment 
with THP, when compared with control values. After 6 weeks of treatment, the activity of complex II 
was significantly decreased, whereas the activities of complex I, III, and IV were not altered in 
comparison to control rats. These findings agree well with the data obtained by the oxygen electrode. 
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Table 3: Activities of enzyme complexes of the electron transport chain in isolated rat liver  
mitochondria 
 Control 
(n=12) 
THP 3 weeks 
(n=6) 
THP 6 weeks 
(n=6) 
    
Complex I 17.5 ± 6.8 22.3 ± 12.6 15.5 ± 5.6 
Complex II 12.0 ± 3.0 15.1 ± 5.9a 10.5 ± 4.1b 
Complex III 1780 ± 440 1560 ± 340 1560 ± 420 
Complex IV 419 ± 149 381 ± 195 367 ± 129 
Control and THP treated rats (20 mg/100 g body weight) were studied after 3 or 6 weeks of treatment in 
the fasted state. Enzyme activities were determined using spectrophotometric methods as described in 
Materials and Methods. Units are mU x mg mitochondrial protein-1. Data are presented as mean ± SD. 
a P < 0.05 versus control rats. 
b P < 0.05 THP 6 weeks versus THP 3 weeks. 
 
Since reduced fatty acid oxidation could not be explained entirely by a reduced activity of the 
electron transport chain, we investigated the function of CPT I and of mitochondrial β-oxidation (Table 
4). A direct toxic effect of THP on mitochondrial fatty acid metabolism was excluded, since THP did 
not impair CPT I activity or mitochondrial β-oxidation up to a concentration of 500 µmol/l and the 
addition of L-carnitine to THP prevented the development of liver steatosis in vivo (Fig. 3). CPT I 
activity, which can be rate-limiting for mitochondrial β-oxidation (41), was not different between 
mitochondria from THPtreated or control animals at 3 weeks, but showed a significant reduction in 
THP-treated rats at 6 weeks. Considering mitochondrial β-oxidation, no differences between THP-
treated and control rats were observed after 3 weeks of treatment, whereas β-oxidation was reduced 
in rats treated with THP for 6 weeks. In contrast, ketogenesis was not affected at both time points. In 
agreement with ketogenesis, the β-hydroxybutyrate concentrations in liver and plasma were not 
different between control and THPtreated rats. 
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Table 4: In vitro β-oxidation and ketogenesis 
 Control 
(n=12) 
THP 3 weeks 
(n=6) 
THP 6 weeks 
(n=6) 
    
CPT I    
β-oxidation 0.86 ± 0.22 0.84 ± 0.2 0.45 ± 0.14ab 
ketogenesis 15.0 ± 4.0 16.7 ± 6.3 16.4 ± 5.7 
ketone bodies    
 liver 1.96 ± 0.4 2.11 ± 0.5 1.94 ± 0.1 
 plasma 903 ± 189 829 ± 172 805 ± 165 
Control rats and THP treated rats (20 mg/100 g body weight) were studied after 3 or 6 weeks of 
treatment in the fasted state. Activities were determined using radioactive substrates as described 
in Materials and Methods. Units are mU x mg mitochondrial protein-1 for CPT I activity, β-oxidation 
and ketogenesis and nmol x mg liver wet weight-1 and µmol x l-1 for ketone bodies in liver and 
plasma, respectively. Data are presented as mean ± SD. 
a P < 0.05 versus control rats. 
b P < 0.05 THP 6 weeks versus THP 3 weeks. 
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Figure 3: Effect of l-carnitine on liver steatosis in rats treated with THP for 3 weeks. Cryosections stained 
with Sudan Black for specific labeling of lipids (enlargement 44x). Treatment of l-carnitine (50 mg/100 
g/day for 3 weeks) is not associated with accumulation of fat (A). Similar to Fig. 2, treatment with THP 
(20 mg/100 g/day for 3 weeks) is associated with fat accumulation in the periportal region (B). The 
addition of L-carnitine (50 mg/100 g/day for 3 weeks) to THP (20 mg/100 g/day for 3 weeks) prevents 
the accumulation of fat almost completely (C). 
 
The results obtained so far show a decrease in the hepatic carnitine pool, impaired metabolism 
of palmitic acid, accumulation of hepatic fat at 3 weeks and 6 weeks of treatment with THP, and 
impaired hepatic mitochondrial β-oxidation and activity of CPT I at 6 weeks. These results therefore 
suggest that carnitine deficiency, which is present at both time points, is the major cause for liver 
steatosis in THP-treated rats, whereas decreased mitochondrial β-oxidation/CPT I activity may 
contribute at 6 weeks of treatment with THP. In order to investigate the consequences of carnitine 
deficiency in more detail, we determined the cytosolic and the mitochondrial CoA pools (Table 5). 
Expressed per gram of liver, the CoA pool was increased in THP treated rats at both time points. This 
increase could be explained by a rise in free and acetyl-CoA, whereas the short- and long-chain acyl-
CoA contents were not different from control rats. In contrast to total liver, the mitochondrial CoA 
content was decreased in THPtreated rats both when expressed per mitochondrial protein content or 
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per mitochondria contained in 1 g of liver. This decrease could be explained by a reduced 
mitochondrial content in short- and long-chain CoAs. Consequently, the cytosolic CoA content 
(calculated as the difference between the total content and the content in the mitochondria per g liver) 
was increased in THP-treated rats and this increase was found for all CoA fractions determined. 
 
Table 5: Liver CoA pool 
 Control 
(n=12) 
THP 3 weeks 
(n=6) 
THP 6 weeks 
(n=6) 
Total liver    
 CoASH + acetyl-CoA 223 ± 73 301 ± 89 a 365 ± 64 a 
 Short-chain acyl-CoA 68 ± 57 63 ± 27 68 ± 47 
 Long-chain acyl-CoA 90 ± 31 102 ± 32 97 ± 13 
 Total CoA 380 ± 84 466 ± 61 a 528 ± 90 a 
Liver cytosol    
 CoASH + acetyl-CoA 172 ± 63 n.d. 323 ± 62 a 
 Short-chain acyl-CoA 26 ± 15 n.d. 52 ± 23 a 
 Long-chain acyl-CoA 55 ± 16 n.d. 75 ± 10 a 
 Total CoA 251 ± 46 n.d. 446 ± 43 a 
Liver mitochondria    
 CoASH 381 ± 156 n.d. 365 ± 64 
 Acetyl-CoA 76 ± 15 n.d. 51 ± 22 a 
 Short-chain acyl-CoA 379 ± 129 n.d. 159 ± 91 a 
 Long-chain acyl-CoA 315 ± 92 n.d. 212 ± 55 a 
 Total CoA 1160 ± 160 n.d. 793 ± 108 a 
Control and THP treated rats (20 mg/100 g body weight) were studied after 3 or 6 weeks of 
treatment in the fasted state. CoASH and acyl-CoAs (except acetyl-CoA) were determined 
fluorimetrically, and acetyl-CoA by a radioenzymatic method as described in Materials and 
Methods. Units are nmol x g liver wet weigh-1 (total liver and liver cytosol) or nmol xg 
mitochondrial protein-1. The cytosolic CoA content was calculated by subtracting the 
mitochondrial from the total liver content as described in Materials and Methods. Data are 
presented as mean ± SD. a P < 0.05 versus control rats. 
 
Mitochondrial dysfunction can be associated with secondary hepatic changes such as 
mitochondrial proliferation (21, 23). Mitochondrial proliferation was assessed by determining the 
mitochondrial protein content per gram of liver and by performing Western blots of subunit IV of 
cytochrome c oxidase. Mitochondrial protein content was not significantly different between control 
and THP treated rats (111 ± 25 mg /g in control rats, and 89  ±16 and 103 ± 23 mg/g in rats treated 
with THP for 3 and 6 weeks, respectively). In addition, the protein content of COX subunit IV, as 
assessed by Western blotting, was not different between THP and control rats (results not shown), 
excluding mitochondrial proliferation. When mitochondrial fatty acid metabolism is impaired, 
peroxisomal proliferation could be a consequence due to hepatic accumulation of long-chain fatty 
acids and fatty acid metabolites that may stimulate peroxisome proliferator-activated receptor 
(PPAR)α (42). Indeed, a significant panlobular peroxisomal proliferation occurred in livers of THP-
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treated rats (Fig. 4). In agreement with these results, peroxisomal fatty acyl-CoA oxidase activity and 
protein content were both increased in THP-treated rats (Fig. 5). In comparison to lipid accumulation 
(Fig. 2), the increase in the number of peroxisomes shows no significant lobular gradient (enlargement 
640x). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Hepatic peroxisomal proliferation in rats treated with THP for 3 weeks. Peroxisomes were 
stained with the alkaline DAB method for cytochemical localization of catalase. Hepatocytes of rats 
treated with THP contain an increased number of peroxisomes. In comparison to lipid accumulation (Fig. 
2), the increase in the number of peroxisomes shows no significant lobular gradient (enlargement 640x). 
a P < 0.05 versus control rats. 
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Figure 5: Protein expression and activity of acyl-CoA oxidase. Similar to earlier observations, the 
Western blot of liver homogenate with polyclonal antibodies against acyl-CoA oxidase (AOX) reveals 
three bands (58, 59). These three bands correspond to AOX subunits A (71.9 kDa), B (51.7 kDa), and C 
(20.5 kDa). All three bands exhibited a significant (P _ 0.05) augmentation in livers from THP-treated 
rats. The densitometric analysis yielded 3.52 ± 1.29 versus 1.00 ± 0.43 for band A (THP-treated vs. 
control), 1.55 ± 0.12 versus 1.00 ± 0.27 for band B, and 1.70 ± 0.39 versus 1.00 ± 0.17 for band C. The 
activity for AOX was increased ~ 1.5-fold, corresponding well with the densitometric results for bands B 
and C. 
 
A third consequence of decreased mitochondrial fatty acid oxidation could be an increase in 
the hepatic VLDL production. This was assessed indirectly by measuring the plasma lipid composition. 
As shown in Table 6, VLDL triglycerides and phospholipids were all increased in THPtreated versus 
control rats, which may reflect increased hepatic availability of activated fatty acids (as shown above) 
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with increased hepatic VLDL synthesis. On the other hand, Western blot analysis revealed that the 
hepatic content of apoB was not different between THPtreated and control rats (results not shown). 
 
Table 6: Plasma lipid and lipoprotein analysis 
 CON (n=6) THP (n=6) 
Lipids and glycerol 
 Triglycerides 0.47 ± 0.12 0.58 ± 0.12 
 Phospholipids 1.17 ± 0.17 1.51 ± 0.35a 
 Cholesterol 0.12 ± 0.0.03 0.13 ± 0.0.02 
 Free fatty acids 0.72±0.10 0.71±0.20 
 Glycerol 0.023±0.004 0.023±0.005 
   
Very low density lipoproteins (VLDL) 
 Triglycerides 0.49 ± 0.15 0.72 ± 0.15a 
 Phospholipids 0.10 ± 0.03 0.16 ± 0.03a 
 Cholesterol 0.11 ± 0.02 0.08 ± 0.03 
   
Low density lipoproteins (LDL) 
 Phospholipids 0.23 ± 0.03 0.31 ± 0.14 
 Cholesterol 0.25 ± 0.05 0.28 ± 0.12 
   
High density lipoproteins (HDL) 
 Triglycerides 0.15 ± 0.01 0.15 ± 0.02 
 Phospholipids 0.90 ± 0.09 1.09 ± 0.31 
 Cholesterol 0.52 ± 0.07 0.55 ± 0.18 
Control and THP treated rats (20 mg/100 g body weight) were studied after weeks of treatment in 
the fasted state. Plasma lipoproteins were isolated using a combined centrifugation/precipitation 
technique and lipids were analyzed enzymatically as described in Materials and Methods. Data 
are presented as mean ± SD. Units are mmol/l for free fatty acids and g x l-1 for all other lipids or 
metabolites. 
a P < 0.05 THP versus CON. 
 
7.5. Discussion 
Our study demonstrates that THP-treated rats have an ~70% reduction in the hepatic carnitine 
content, reduced in vivo metabolism of palmitate, liver steatosis, accumulation of long-chain acyl-CoAs 
in the cytosol of the hepatocytes, hepatic proliferation of peroxisomes, and increased plasma VLDL.  
The study was designed to find out the mechanisms leading to micro- and macrovesicular 
steatosis THPtreated rats. Liver steatosis was present already at 3 weeks of treatment, a time point 
when THP-treated rats had developed systemic carnitine deficiency, and had reduced in vivo 
metabolism of palmitate, whereas oxidative metabolism and β-oxidation of isolated liver mitochondria 
was normal or even higher in mitochondria from THP-treated as compared with control rats. Since 
Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate 
  49 
THP has no apparent toxicity on liver mitochondria, liver steatosis is explained, at least at this early 
time point, entirely by a reduction in the hepatic carnitine pool.  
After 6 weeks of treatment with THP, oxidative metabolism of different substrates (including 
fatty acids) as well as β-oxidation and activity of CPT I were reduced in THPtreated rats, suggesting 
that impaired mitochondrial function could contribute to the development of liver steatosis. Although 
the study was not designed to find out the mechanisms leading to mitochondrial dysfunction at this 
time point, it can be speculated that it may reflect changes in the lipid composition of mitochondrial 
membranes and/or oxidative damage to mitochondria, as observed in other animal models with 
alterations in hepatic fatty acid metabolism (43) or liver steatosis (44, 45).  
In THP-treated rats, the hepatic content of long-chain acyl-CoAs was increased at 3 and 6 
weeks, compatible with a decreased cytosolic conversion of long-chain acyl-CoAs to the respective 
carnitine derivatives due to carnitine deficiency and/or reduced activity of CPT I (see Fig. 1 for 
explanation). Peroxisomal proliferation may result from stimulation of PPARα by accumulated fatty 
acids and fatty acid derivatives in THP-treated rats (42), and may represent a mechanism to 
compensate for decreased mitochondrial metabolism of fatty acids. In support of this interpretation, a 
significant increase in the surface density of peroxisomes has been described in humans with liver 
steatosis (46). Since peroxisomes produce also medium chain acyl-CoAs during β-oxidation, the 
observed increase in the cytosolic content of short-chain acyl-CoAs and of the short-chain 
acylcarnitine to carnitine ratio may result from increased peroxisomal metabolism of long-chain fatty 
acids. Mediumchain acylcarnitines may serve as additional substrates for mitochondrial β-oxidation in 
THP-treated rats since they can enter the mitochondria without the action of CPT I.  
In THP-treated rats, carnitine deficiency was associated with a significant increase in the 
cytosolic CoA content of the hepatocytes, whereas the mitochondrial content decreased. CoA is 
synthesized from pantothenate, cysteine, and ATP, with the rate-limiting step being phosphorylation of 
pantothenate located in the cytosol (47). Mitochondria obtain CoA either by endogenous biosynthesis 
[the final steps in CoA synthesis are also found in mitochondria (48) or by transport across the inner 
mitochondrial membrane by a specific transport system (49). In comparison, degradation of CoA 
appears to be a cytosolic process (50). Interestingly, rats treated with clofibrate, a ligand for PPARα 
leading to peroxisomal proliferation (51), also reveal an increase in the hepatic CoA pool (52-54), 
suggesting that an increase in the hepatic CoA pool and peroxisomal proliferation may somehow be 
connected. The rise in the hepatic CoA pool by clofibrate has clearly been shown to result from 
increased biosynthesis (54) and the distribution of CoA between the mitochondria and the cytosol was 
not affected in clofibrate-treated rats (53). In contrast, in THP treated rats, the total hepatic CoA pool is 
increased due to a rise in the cytosolic content of CoA, whereas the mitochondrial content is 
decreased. Since the changes in the hepatic CoA pool could already be observed at 3 weeks of 
treatment with THP, a time point when β-oxidation was not impaired, these alterations in the CoA pool 
did probably not affect significantly hepatic fatty acid metabolism in THP-treated rats.  
In THP-treated rats, the phospholipid and triglyceride contents were increased in the VLDL 
fraction in plasma and also per gram of liver, whereas the hepatic apoB content was unchanged. 
These findings are compatible with increased loading of VLDL with triglycerides and phospholipids in 
the liver, which is most probably a consequence of increased cytosolic availability of fatty acids and 
acyl-CoAs due to impaired mitochondrial fatty acid metabolism. Hepatic accumulation of triglycerides 
has been associated with the development of macrovesicular steatosis of the liver (9, 11). Since 
isolated inhibition of mitochondrial fatty acid metabolism is considered to result in microvesicular 
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steatosis (11), secondary accumulation of cytosolic triglycerides and phospholipids in the presence of 
initial mitochondrial damage may explain the development of a mixed type of liver steatosis over time. 
Despite reduced in vivo metabolism of palmitate and decreased activity of CPT I, as well as 
mitochondrial β-oxidation in THP-treated rats, the plasma and liver β-hydroxybutyrate concentrations 
were not different from control rats. Hepatic long-chain fatty acid metabolism is controlled at two sites, 
namely at CPT I and mitochondrial HMG-CoA synthase (55, 56), both of them regulated enzymes. 
Since ketogenesis was assessed specifically and was not different between mitochondria from THP-
treated and control rats, the activity of the HMG-CoA synthase can be assumed to be identical in THP-
treated and control rats. The observed decrease of palmitate metabolism in THP rats in vivo, which is 
explained primarily by hepatic carnitine deficiency and, at 6 weeks, also reduced activity of 
CPTI/mitochondrial β-oxidation, could therefore be expected to result in decreased hepatic production 
of ketone bodies, e.g., β-hydroxybutyrate. Indeed, in agreement with reduced CPT I 
activity/mitochondrial β-oxidation, liver mitochondria from THP-treated rats contained less acetyl-CoA 
than control mitochondria. On the other hand, the plasma and liver β-hydroxybutyrate concentrations 
were not different between THP-treated and control rats. Among the possibilities to explain this 
discrepancy are decreased consumption of ketone bodies by peripheral tissues such as skeletal 
muscle, or increased production of ketone bodies by extrahepatic tissues such as kidneys in THP-
treated rats. These two possibilities are unlikely, however, since not only plasma, but also the hepatic 
β-hydroxybutyrate concentration was unaffected by treatment with THP. The most likely possibility is 
therefore that during starvation, the HMG-CoA cycle becomes rate-limiting for ketogenesis. During 
starvation, the activity of CPT I increased due to a decrease in the hepatic concentration of malonyl-
CoA, an endogenous inhibitor of CPT I (55). This increase in CPT I activity during starvation may be 
sufficient so that ketogenesis is controlled solely by the HMG-CoA cycle, as suggested by our findings. 
In support of this interpretation, starved rats with acute cholestasis have reduced production of ketone 
bodies and a reduced activity of HMG-CoA synthase, the ratelimiting enzyme of the HMG-CoA cycle, 
while the function of CPT I is normal (25). On the other hand, ketogenesis is reduced in JVS mice, an 
animal model with severe systemic carnitine deficiency (57). The hepatic carnitine content in JVS mice 
is less than 5% of normal, limiting the activity of CPT I to a higher extent than in THP-treated rats. In 
JVS mice, ketogenesis was maximal at carnitine concentrations above 100 nmol/g liver wet weight 
(57), a value which is just reached in THP-treated rats. 
We conclude that a reduction in the hepatic carnitine pool is the principle mechanism leading 
to impaired hepatic fatty acid metabolism and liver steatosis after 3 weeks of treatment with THP. After 
6 weeks of treatment, impaired activity of CPT I and mitochondrial β-oxidation may contribute. 
Cytosolic accumulation of fatty acids and long-chain acyl-CoAs is associated with increased plasma 
VLDL triglyceride and phospholipid concentrations and peroxisomal proliferation. 
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8.1. Abstract 
Rationale: Treatment with benzarone or benzbromarone can be associated with hepatic injury. 
Both drugs share structural similarities with amiodarone, a well known mitochondrial toxin. 
Hepatotoxicity of benzarone and benzbromarone, and of the analogues benzofuran and 2-
butylbenzofuran was therefore investigated. 
Main results: In isolated rat hepatocytes, amiodarone, benzarone or benzbromarone 
(20µmol/L) the mitochondrial membrane potential was 67%, 41% or 18% of the initial value. 
Benzofuran and 2-butylbenzofuran had no effect up to 100 µmol/L. In isolated rat liver mitochondria, 
amiodarone, benzarone and benzbromarone, but not benzofuran, decreased state 3 oxidation and 
respiratory control ratios for L-glutamate (50% decrease of RCR at: amiodarone 9.3µmol/L, benzarone 
11.2µmol/L, benzbromarone <1µmol/L). Amiodarone, benzarone and benzbromarone, but not 
benzofuran, also uncoupled oxidative phosphorylation. Mitochondrial β-oxidation was decreased by 
76, 83 or 57% with 100µmol/L amiodarone, benzarone or 50µmol/L benzbromarone, respectively, but 
was unaffected by benzofuran, whereas ketogenesis was not affected. 2-Butylbenzofuran weakly 
inhibited state 3 oxidation and β-oxidation only at 100µmol/L. In the presence of 100 µmol/L 
amiodarone, benzarone or benzbromarone, Generation of reactive oxygen species was increased and 
mitochondrial leakage of cytochrome c was induced in HepG2 cells, and permeability transition was 
induced in isolated rat liver mitochondria. At the same concentrations, amiodarone, benzarone and 
benzbromarone induced apoptosis and necrosis of isolated rat hepatocytes. 
In conclusion, hepatotoxicity associated with amiodarone, benzarone and benzbromarone can 
at least in part be explained by their mitochondrial toxicity and the subsequent induction of apoptosis 
and necrosis. Side chains attached to the furan moiety are necessary for rendering benzofuran 
hepatotoxic. 
 
8.2. Introduction 
Drug-induced hepatic injury is often regarded as a consequence of the formation and toxicity of 
reactive metabolites. In recent years, mitochondrial damage has been recognized as an additional 
important mechanism of drug-induced hepatotoxicity (1). Mitochondrial β-oxidation and oxidative 
phosphorylation are fundamental physiological processes. Acquired or inherited impairment of these 
processes can affect the function of many organs, in the liver typically leading to microvesicular 
steatosis, a potentially fatal disease (2, 3). Microvesicular steatosis has been observed in patients 
and/or animals being treated with the antiarrhythmic amiodarone (4). Amiodarone is composed of a 
diiodobenzene ring carrying a diethylaminoethoxy side chain and a benzofuran ring carrying a C4H9 
side chain (see Figure 1). Amiodarone is a well characterized hepatic mitochondrial toxin. It inhibits 
enzyme complexes of the electron transport chain, impairs β-oxidation and uncouples oxidative 
phosphorylation (4-6). 
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Figure 1: Chemical structures of the substances investigated. 
 
Benzbromarone is another benzofuran derivative acting as an uricosuric agent by reducing the 
proximal tubular reabsorption of uric acid (7). Benzarone is a non-halogenated benzbromarone 
derivative used for the treatment of venous vascular disorders (8). As shown in Figure 1, the 
structures of benzbromarone as well as benzarone are closely related to that of amiodarone. This 
structural relationship and the fact that these two drugs can also cause hepatic injury (9), in some 
patients with fatal outcome (8, 10), led us to hypothesize that their mechanism of toxicity may be 
similar to that of amiodarone. In support of our hypothesis, it has been shown that benzbromarone can 
inhibit several enzyme complexes of the electron transport chain in isolated mouse liver mitochondria 
(11).  
Many studies during the last couple of years revealed that mitochondria not only provide 
energy for the cell, but can also “unleash machineries of death” (12). A variety of key events in cell 
death focus on mitochondria, in particular initiation of apoptosis and necrosis (12-14). Following these 
considerations, we decided to study the mechanisms of the suspected mitochondrial toxicity of 
benzarone and benzbromarone and to compare them with those of amiodarone. In particular, we were 
interested in mitochondrial mechanisms leading to cell damage or even death. We also investigated 
the structure-toxicity relationship by including the molecular analogues benzofuran and 2-
butylbenzofuran along with amiodarone, benzarone and benzbromarone in our studies. 
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8.3. Materials and Methods 
8.3.1. Reagents 
Benzarone was obtained from Norchim (Saint Leu d’Esserent, France), benzofuran from Merck 
(Darmstadt, Germany) and [1-14C]palmitic acid from Amersham Pharmacia Biotech (Dübendorf, 
Switzerland). 2-Butylbenzofuran was kindly provided by Dr. Huy Riem from the Cardiovascular 
Therapy Research Unit, University Hospital Zurich (Switzerland). Fetal calf serum and all culture 
medium supplements were from Gibco (Paisley, UK). Williams E media was from Cambrex (Verviers, 
Belgium). The 96-well plates were purchased from Becton Dickinson (Franklin Lakes, NJ, USA), the 8-
chamber slides from Nalge Nunc (Rochester, NY, USA) and the unifilters as well as the scintillation 
cocktail from Packard (Meriden, CT, USA). The VybrantTM Apoptosis Assay Kit #2 was purchased from 
Molecular probes (Eugene, OR, USA). All other chemicals used were of best quality available and 
purchased from Sigma–Aldrich (Schnelldorf, Germany).  
 
8.3.2. Cell lines 
The hepatocarcinoma cell line HepG2 was kindly provided by Prof. Dietrich von Schweinitz 
(Department of Pediatric Surgery, University Hospital Basel, Switzerland). The cell line was cultured in 
Dulbecco’s Modified Eagle Media, supplemented with 10% (v/v) inactivated fetal calf serum, 10mmol/L 
HEPES buffer (pH 7.4), 2mmol/L GlutaMAX®, non-essential amino acids and penicillin/streptomycin 
(100U/mL). Culture conditions were 5% CO2 and 95% air atmosphere at 37°C. 
 
8.3.3. Animals 
Male Sprague Dawley rats (Iffa Credo /Charles River, Les Onins, France) were used for all 
experiments. They were fed ad libitum and hold on a 12-hour dark and light cycle. The study protocol 
had been accepted by the Cantonal Animal Ethics Committee. 
 
8.3.4. Isolation of rat liver mitochondria 
At the time of killing, the rats weighed 314 ± 61g. The animals were anesthetized with carbon 
dioxide and killed by decapitation. The liver (14.2 ± 1.9g) was extirpated, rinsed, weighed, minced and 
washed with ice-cold MSM buffer (220mmol/L mannitol, 70mmol/L sucrose, 5mmol/L 3-[N-
morpholino]propanesulfonic acid (Mops), pH 7.4). All subsequent procedures were carried out on ice. 
Mitochondria were isolated by differential centrifugation according to the method of Hoppel et al (15). 
The final mitochondrial pellets were resuspended in MSM buffer and frozen at -70°C if not used 
freshly. The mitochondrial protein content was determined using the biuret method with bovine serum 
albumin as standard (16). 
 
8.3.5. Isolation of rat hepatocytes 
Hepatocytes were isolated from male rats weighing 200 to 250g by a two step collagenase 
perfusion of the liver (17) and suspended in Williams E medium (Cambrex, East Rutherforn, NJ, USA) 
supplemented with 10% heat-inactivated fetal bovine serum, 10mmol/L HEPES buffer, 2mmol/L 
GlutaMAX®, 1000U/mL penicillin/streptomycin, 0.25µg/mL amphotericin B, 4µg/mL insulin and 
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0.1µmol/L dexamethasone. Culture conditions were an atmosphere of 5% CO2 and 95% air at 37°C. 
In all experiments, initial hepatocyte viability, determined by trypan blue exclusion, was more than 
85%. 
 
8.3.6. Mitochondrial membrane potential 
The mitochondrial membrane potential was determined as described by Wan et al (18). Briefly, 
freshly isolated cells were washed twice with incubation buffer containing 137mmol/L sodium chloride, 
4.74mmol/L potassium chloride, 2.56mmol/L calcium chloride, 1.18mmol/L potassium phosphate, 
1.18mmol/L magnesium chloride, 10mmol/L HEPES and 1g/L glucose, pH 7.4. After labeling the cells 
with 40nmol/L [3H]- tetraphenylphosphonium bromide ([3H]-TPP+), the cells were seeded in a 96-well 
plate and incubated with the test compounds for 1hour at 37°C. The cells were harvested on a unifilter 
GF/B (Packard, Meriden, CT, USA), which was mixed with 50µL/well scintillation cocktail (Top count, 
Packard, Meriden, CT, USA), covered with a plate sealer and counted for [3H]-radioactivity. 
 
8.3.7. Oxygen uptake  
Oxygen uptake was monitored polarographically using a 1mL chamber equipped with a Clark-
type oxygen electrode (Yellow Springs Instruments, Yellow Springs, OH, USA) at 30°C as described 
previously (15). The oxygen content of respiration buffer equilibrated with air was assumed to be 
223nmol O2/mL at 30°C (19). The final concentrations of the substrates used were 20mmol/L for L-
glutamate and succinate. Amiodarone, benzarone, benzbromarone, benzofuran and 2-
butylbenzofuran at concentrations given in the tables were dissolved in dimethylsulfoxide (DMSO). 
Control experiments were carried out in the presence of the solvent containing no inhibitor. 
In isolated mitochondria, state 3, state 4 and the respiratory control ratio (RCR) were 
determined as described previously (20) and as defined by Estabrook (21). The test compounds were 
added to the mitochondrial incubations before the addition of the respective substrate. 
For the determination of oxygen consumption by isolated hepatocytes, 1 x 106 cells were 
treated with oligomycin (final concentration 5µg/mL) in order to inhibit mitochondrial ATPase. After 2 
minutes, the test compounds were added to the incubation chamber and the oxygen consumption was 
determined as a marker for the uncoupling potential of the test compounds. Control experiments were 
carried out with solvent only.  
 
8.3.8. Mitochondrial β-oxidation and formation of ketone bodies 
Beta-oxidation by freshly isolated liver mitochondria was assessed by the formation of 14C-
acid-soluble β-oxidation products from [1-14C]palmitic acid in the presence of the test compounds. 
Experiments were performed as described previously (22) with the modifications described by Spaniol 
et al (5). 
Ketone body formation by liver mitochondria was measured in the presence of an acetyl-CoA-
generating system using freeze-thawed mitochondria according to Chapman et al (23) with the 
modifications described by Spaniol et al (5). The supernatants of the incubations were analyzed for 
acetoacetate according to Olsen (24), using an enzyme-catalyzed reaction inducing changes in the 
concentration of β-nicotinamide adenine dinucleotide (NADH). 
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8.3.9. Activities of mitochondrial β-oxidation enzymes 
All enzyme activities were determined using spectrophotometric assays at 37°C. Freeze-
thawed mitochondria were treated 1:1 with 5% cholic acid in order to disrupt the mitochondrial 
membranes. The solution was then diluted one hundred times with 50mmol/L potassium phosphate 
buffer (pH 7.4). The effects on the enzymes of β-oxidation were only investigated with amiodarone, 
benzarone, benzbromarone and 2-butylbenzofuran, as they had an inhibitory effect on β-oxidation. 
The concentrations of the inhibitors were 20 or 100µmol/L. The activities of acyl-CoA dehydrogenase 
and -ketothiolase were both determined spectrophotometrically as described by Hoppel et al. (15). 
 
8.3.10. Reactive oxygen species (ROS) 
Confluent cultures of HepG2 cells, seeded in 96-well plates, were incubated with Dulbecco’s 
Modified Eagle Media without fetal bovine serum in the presence of 5mmol/L 2,7-dichlorofluorescin 
diacetate. After incubation, the medium was replaced by phosphate buffered saline (PBS) and cellular 
fluorescence (λex = 485nm, λem = 520nm) was determined at room temperature using a microtiter plate 
reader (HTS 7000 Plus Bio Assay Reader, Perkin Elmer, Buckinghamshire, UK).  
 
8.3.11. Mitochondrial swelling 
Measurements of mitochondrial swelling were performed using flow cytometry (FACScalibur, 
Becton Dickinson, NJ, USA) by recording histograms. The mitochondrial suspension containing 1mg 
of mitochondrial protein was mixed with 200µL of MSM-buffer and subsequently the test compounds 
added. As Ca2+ is a well known inducer of swelling, the effect of 1mmol/L CaCl2 was used as a 
positive control. Where indicated, 2µL of cyclosporin A (final concentration 2µmol/L) was added as an 
inhibitor of mitochondrial swelling. For quantification purposes, mean forward scatter was determined. 
 
8.3.12. Hepatocellular ATP content 
After having settled down in a 12-well plate (Becton Dickinson, Franklin Lakes, NJ, USA), the 
freshly isolated hepatocytes (200’000 cells/well) were treated for 8 hours with test compounds. 
Following treatment, cells were once washed with PBS (pH 7.4), suspended in 1 mL of reagent grade 
water inside an Eppendorf tube, snap-frozen in liquid nitrogen and stored at –80oC. For the 
determination of ATP, cells were extracted according to Yang et al. (25). In brief, 500µl of the cellular 
suspension was added to a tube containing 500µl of boiling Millipure water and vortexed. The diluted 
cellular suspension was then boiled for 10 min to disrupt the cellular membranes and to release their 
natant ATP into solution. Samples were cooled on ice for 30 s, prior to the removal of cellular debris 
by centrifugation (12000 rpm, 4oC, 5 min). The concentration of ATP was determined in the 
supernatant with the well-established luciferin-luciferase method and by use of a commercially 
prepared reagent kit (FL-AA, Sigma, Deisenhofen, Germany) in accordance with the manufacturers 
instructions. Values obtained were compared against a linear ATP standard curve, in duplicate at the 
same time as the unknown samples were analyzed. 
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8.3.13. Apoptosis and necrosis 
Both assays were performed using freshly isolated rat hepatocytes cultured on poly-D-lysine 
coated (0.1mg/mL, 30min) glass slides. As a positive control for apoptosis, soluble Fas-ligand 
supernatant was used. Soluble Fas-ligand supernatant was produced by Fas-ligand-transfected N2a 
cells. The supernatant of mock-transfected of N2a cells was used as a negative control. The soluble 
Fas-ligand supernatant and the supernatant of mock-transfected N2a cells were both a kind gift of Dr. 
Felix Bachmann (Aponetics AG, Witterswil, Switzerland). As a positive control for induction of 
necrosis, the detergent NP 40 was used at a concentration of 0.1%. 
Hoechst 33342 nuclear staining: Cells were treated for 8h with different concentrations of test 
compounds, were then incubated for 30 minutes at room temperature with Hoechst 33342 dye 
(50µmol/L in PBS) and visualized by fluorescence microscopy (Olympus IX 50, Hamburg, Germany).  
Annexin V and propidium iodide (PPI) staining: An in situ Apoptosis Detection Kit was used for 
Annexin V binding and propidium iodide staining (VybrantTM Apoptosis Assay Kit #2, Molecular probes, 
Eugene, OR, USA). Cells were treated with the test compounds in a concentration-dependent manner. 
After an 8h-incubation period, cells were stained with 25µL Annexin V-Alexa Fluor® 488 and 2µL 
propidium iodide (PPI) (final concentration: 1.5µg/L ). After 15 minutes of incubation at room 
temperature, samples were analyzed by flow cytometry.  
 
8.3.14. Mitochondrial release of cytochrome c 
For immunocytochemistry, HepG2 cells were grown in an 8 chamber-slide (coated with poly-D-
lysine) for 12 hours at 37°C and then treated with the test compounds for 8 hours. Afterwards, 
cytochrome c was visualized using an anti-cytochrome c antibody (Sigma, Buchs, Switzerland) and an 
anti-sheep IgG antibody conjugated with Cy3TM (Jackson Laboratories, West Grove, PA, USA) 
according to manufacturer’s protocol.  
 
8.3.15. Statistical methods 
Data are presented as mean ± standard error of the mean±SEM. For statistical comparisons, 
data of groups were compared by analysis of variances (ANOVA). The level of significance was p ≤ 
0.05. If ANOVA revealed significant differences, comparisons between the control and the other 
incubations were performed by Dunnett’s post test procedure. T-test (unpaired, two-tailed) was 
performed if only two groups were analyzed.  
 
8.4. Results 
8.4.1. Mitochondrial membrane potential 
As shown in Figure 2, increasing concentrations of amiodarone, benzbromarone or benzarone 
resulted in a progressive decrease in the mitochondrial membrane potential. At 20µM, the 
mitochondrial membrane potential was 18% of the initial value for benzbromarone, 41% for benzarone 
or 67% for amiodarone. In contrast, benzofuran and 2-butylbenzofuran did not affect the potential up 
to 100µmol/L. Since these results confirmed that amiodarone, benzarone and benzbromarone are 
mitochondrial toxins, their effect on mitochondria was characterized further. 
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Figure 2: Effect on mitochondrial membrane potential. Rat hepatocytes were labeled with [3H]TPP+ and 
mitochondrial accumulation of radioactivity was determined. 1% DMSO served as a control and was set 
at 100%. Means ± SEM of three individual preparations *P < 0.05 vs. control, ** p < 0.01 vs. control. 
 
8.4.2. Oxidative metabolism of mitochondria 
The next step was to assess the toxicity of these substances on oxidative metabolism of 
isolated rat liver mitochondria using L-glutamate or succinate as substrates (Table 1). In the presence 
of L-glutamate or succinate, amiodarone, benzarone and benzbromarone induced a progressive 
depression of the RCR. The corresponding concentrations associated with a 50% decrease in the 
RCR were 9.3 µmol/L for amiodarone and 11.2 µmol/L for benzarone in the presence L-glutamate, 
and 23.9 µmol/L for amiodarone and 23.3 µmol/L for benzarone in the presence of succinate. For 
benzbromarone, this concentration was <1µmol/L for both substrates used, whereas 2-
butylbenzofuran decreased the RCR less potently (50% decrease at 50 - 100µmol/L) and benzofuran 
did not affect mitochondrial respiration at all. In contrast to the effects on the RCR, state 3 respiration, 
reflecting the activity of the respiratory chain, was decreased only at the highest concentration 
(100µmol/L) of amiodarone, benzarone and benzbromarone, but not by 2-butylbenzofuran or 
benzofuran. The RCR values were decreased mainly due to an increase in state 4, suggesting 
uncoupling of oxidative phosphorylation. 
 
Mechanisms of benzarone and benzbromarone induced hepatic toxicity  
  63 
Table 1:Effects of the test compounds on oxidative metabolism by isolated rat liver mitochondria. 
Mean ± SEM of at least 3 experiments using different mitochondrial preparations. *P < 0.05 vs. 
1% DMSO; ** p < 0.01 vs. 1% DMSO. 
 
L-glutamate (20mmol/L) 
[natoms O2 x·min-1 x·mg-1] 
Succinate (20mmol/L)  
[natoms O2 x min-1 x mg-1] 
 State 3 RCR State 3 RCR 
Control (no inhibitor) 86 ± 3 6.5  ± 1.0 163  ± 28 4.1  ± 0.4 
     
Amiodarone (µmol/L)     
10 95 ± 22 3.0  ± 0.5** 167  ± 44 2.4  ± 0.3** 
20 81 ± 10 2.6  ± 0.0** 170  ± 39 2.1  ± 0.3** 
50 82 ± 9 1.7  ± 0.2** 157  ± 49 1.6  ± 0.6** 
100 34 ± 28** 1.2  ± 0.3** 135  ± 37 1.3  ± 0.5** 
     
Benzarone (µmol/L)     
10 80  ± 34 3.6  ± 0.8 167 ± 16 3.2  ± 0.1 
20 65  ± 29 2.0  ± 0.5** 161  ± 27 2.3  ± 0.5** 
50 59  ± 28 1.0  ± 0.0** 136  ± 18 1.0  ± 0.0** 
100 30  ± 11 ** 1.0  ± 0.1** 64  ± 23** 1.0  ± 0.0** 
     
Benzbromarone (µmol/L)     
0.1 114  ± 12 6.3  ± 1.9 190  ± 29 3.0  ± 1.2 ** 
1 113  ± 19 2.0 ± 0.3** 194  ± 2 1.9  ± 0.1** 
10 105  ± 18 1.0  ± 0.0** 121  ± 62 1.2 ± 0.3** 
100 34  ± 34** 1.0  ± 0.0** 33  ± 7** 1.0  ± 0.1** 
     
Benzofuran (µmol/L)     
10 76  ± 11 5.9 ± 2.0 161 ± 47 4.1 ± 0.5 
20 78  ± 25 5.1 ± 1.0 151 ± 44 3.7 ± 0.4 
50 75 ± 15 5.9 ± 1.3 138 ± 38 3.5 ± 0.7 
100 72 ± 19 4.9 ± 1.0 172 ± 16 3.5 ± 0.1 
     
2-Butylbenzofuran (µmol/l)     
10 122 ± 53 5.4 ± 0.6 200 ± 51 3.8 ± 0.6 
20 114 ± 21 4.9 ± 1.0 211 ± 7 4.4 ± 0.2 
50 104 ± 14 4.7 ± 0.8* 192 ± 10 4.4 ± 0.4 
100 75 ± 5 3.3 ± 0.5** 183 ± 10 2.2 ± 0.5** 
 
 
Uncoupling of oxidative phosphorylation was investigated directly using isolated hepatocytes in 
the presence of oligomycin to block mitochondrial conversion of ATP to ADP (Figure 3).  
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Figure 3: Uncoupling of oxidative phosphorylation using isolated, intact rat hepatocytes. In coupled 
mitochondria, blocking of the F0F1-ATPase by oligomycin results in a restricted electron transport similar 
to state 4. Uncouplers increase oxygen consumption under these circumstances (panel A). 
Benzbromarone acts as an uncoupler at concentrations ≤20 mol/L. At higher concentrations, it also 
inhibits electron transport. In panel B, respiration rates in the presence of amiodarone (1, 10, 20, 50, 80, 
100µmol/L), benzarone (1, 20, 50, 80, 100µmol/L), benzbromarone (0.1, 1, 10, 20, 50, 80, 100µmol/L), 
benzofuran (1, 10, 20, 50, 80, 100µmol/L) or 2-butylbenzofuran (1, 10, 20, 50, 80, 100µmol/L) are 
presented. 1% DMSO serves as control. Means ± SEM of four individual mitochondrial preparations. *P 
< 0.05 vs. 1% DMSO; ** p < 0.01 vs. 1% DMSO. 
 
Benzbromarone increased oxygen consumption by hepatocytes starting at 10µmol/L, showing 
that it is a potent uncoupler. For concentrations higher than 20µmol/L, the respiration rate was 
decreasing, reflecting progressive inhibition of the respiratory chain. Amiodarone stimulated 
respiration only at the highest concentration (100µmol/L) and benzarone from 50µmol/L upwards. 
Benzofuran and 2-butylbenzofuran did not stimulate state 4 respiration and therefore did not induce 
uncoupling. These results demonstrate that amiodarone, benzarone and benzbromarone are 
uncouplers of oxidative phosphorylation and are in agreement with those obtained using isolated 
mitochondria. 
 
8.4.3. Mitochondrial β-oxidation and formation of ketone bodies 
As already known for amiodarone (5), also benzarone and benzbromarone inhibited the 
formation of acid soluble β-oxidation products in a dose-dependent manner (Table 2). The 
corresponding IC50 values were 34µmol/L for amiodarone, 34µmol/L for benzarone and 2µmol/L for 
benzbromarone. In comparison, 2-butylbenzofuran was only a weak inhibitor (28% inhibition at 
100µmol/L), whereas benzofuran showed no inhibition up to 100µmol/L. Since the formation of acid-
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soluble products reflects both, β-oxidation and ketogenesis, ketogenesis was assessed directly. In 
contrast to the formation of acid soluble products, ketogenesis was not affected by any of the 
substances investigated (data not shown). 
 
Table 2:Effects of the test compounds on β-oxidation in isolated rat liver mitochondria. Mean ± 
SEM of at least 3 experiments using different mitochondrial preparations. *P < 0.05 vs. 1% 
DMSO; ** p < 0.01 vs. 1% DMSO. 
Compound Activity [nmol x·min-1 
x·mg-1] 
Compound Activity [nmol x·min-1 
x·mg-1] 
    
Amiodarone (µmol/l)  Benzofuran (µmol/l)  
 control 0.64 ± 0.10  control 0.75 ± 0.10 
 10 0.48 ± 0.10  10 0.73 ± 0.10 
 20 0.42 ± 0.06 **  20 0.70 ± 0.08 
 50 0.19 ± 0.04 **  50 0.69 ± 0.09 
 80 0.12 ± 0.02 **  80 0.73 ± 0.10 
 100 0.15 ± 0.03 **  100 0.72 ± 0.10 
    
Benzarone (µmol/l)  2-Butylbenzofuran 
(µmol/l) 
 
 control 0.60 ± 0.10  control 0.62 ± 0.10 
 5 0.70 ± 0.12  10 0.59 ± 0.10 
 10 0.64 ± 0.11  20 0.55 ± 0.09 
 20 0.34 ± 0.11 **  50 0.62 ± 0.11 
 50 0.24 ± 0.13 **  80 0.53 ± 0.10 
 100 0.10 ± 0.05 **  100 0.45 ± 0.08 ** 
    
Benzbromarone 
(µmol/l) 
   
 Control 0.61 ± 0.08   
 0.5 0.41 ± 0.10   
 2 0.30 ± 0.10 *   
 5 0.24 ± 0.08 **   
 10 0.19 ± 0.10 **   
 50 0.26 ± 0.06 **   
 
In order to localize the inhibitory effect of β-oxidation more precisely, two enzymes of the β-
oxidation cycle were investigated. In the presence of 100µmol/L amiodarone, benzarone, 
benzbromarone or 2-butylbenzofuran, acyl-CoA dehydrogenase activity was inhibited by 28%, 33%, 
34% or 22%, respectively, as compared to control values. For β-ketothiolase, the last enzyme of the β-
oxidation cycle, the average decrease in the presence of 100µmol/L benzarone or benzbromarone 
was 11% or 25%, respectively, whereas amiodarone and 2-butylbenzofuran revealed no inhibitory 
effect. The discrepancy between inhibition of β-oxidation (determined using intact mitochondria) and 
individual enzymes of the β-oxidation cycle as well as ketogenesis (both determined using broken 
mitochondria) may be explained by an inhibition of the activation of palmitate and/or transport across 
the inner mitochondrial membrane. It is well established that CPT I, an enzyme involved in the import 
of long-chain fatty acids into the mitochondrial matrix, can be rate-limiting for hepatic fatty acid 
metabolism (26, 27). 
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8.4.4. Production of ROS  
As a byproduct of the formation of ATP by oxidative phosphorylation, mitochondria produce 
also ROS (12, 28). Blockade of the electron flow through the electron transport chain stimulates ROS 
production, particularly in the presence of an uncoupler (29). In contrast, in the presence of an 
uncoupler only, the electron transport chain works more efficiently and leads to less leakage of 
electrons and therefore lower levels of ROS are generated (30-32). ROS generation is claimed to play 
an important role in induction of mitochondrial mediated cell death (33-36). Since amiodarone, 
benzarone or benzbromarone inhibit the electron transport chain and are uncouplers of oxidative 
phosphorylation (Table 1), their effect on ROS generation was investigated in HepG2 cells, using 2,7-
dichlorofluorescin diacetate as an indicator (37). These investigations showed a concentration-
dependent production of ROS in the presence of these substrates, which started to be detectable at 
concentrations of 0.1nmol/L for benzbromarone, 10nmol/L for benzarone and 1µmol/L for amiodarone 
(Figure 4). In contrast, 2-butylbenzofuran and benzofuran were not associated with an increase in 
ROS production. Antimycin (1µmol/L), an inhibitor of the electron transport from cytochrome b to 
ubiquinone, led to a significant increase in the ROS production, whereas dinitrophenol (100µmol/L), an 
uncoupler of oxidative phosphorylation, did not augment ROS generation. To ensure the specificity of 
the assay used, we blocked ROS generation by adding ascorbic acid at a concentration of 250µmol/L 
(38) to selected incubations (Figure 4). 
 
Figure 4: ROS formation by HepG2 cells. Confluent monolayers of HepG2 cells were exposed to 
different compounds for 1h at 37°C (A), in the presence or absence of ascorbate (250 mol/L) (B). ROS 
formation was detected using 2,7-dichlorofluorescin diacetate (indicated as fluorescence units, FU). 
Mean ± SEM of at least three independent experiments in quadruplicate. Asterisks indicate values 
significantly different from control (panel A) or from the incubation in the absence of ascorbate (panel B). 
*P< 0.05 or at **p< 0.01. FU= fluorescence units. 
 
8.4.5. Mitochondrial swelling 
Since production of ROS can be associated with opening of the mitochondrial membrane pore 
(13) mitochondrial swelling was investigated as an indicator for mitochondrial permeability transition 
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(mpt). As shown in Figure 5, addition of Ca2+-ions (1mmol/L) induced swelling which could be partially 
inhibited by the addition of cyclosporin A, indicating that swelling was dependent on mpt. A significant 
increase in mitochondrial size (at least partially inhibitable by cyclosporin A, results not shown) was 
also detectable for amiodarone, benzbromarone and benzarone at 100µmol/L (Figure 5). 
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Figure 5: Mitochondria studied by flow cytometry. Left panel: Histograms (forward scatter vs. counts) of 
flow cytometry analyses of freshly isolated rat liver mitochondria. The forward scatter assesses the 
mitochondria’s size, and “counts” the number of mitochondria of this size. Right panel: Quantification of 
the mitochondrial volume as the mean forward scatter (FSC). Mitochondrial volume was measured in the 
absence (A) or presence of Ca2+ (1mmol/L) (B), Ca2+/cyclosporin A (2µmol/L) (C) and with test 
compounds, i.e. amiodarone 100µmol/L (D). Ca2+, a known inducer of mitochondrial swelling, increases 
mitochondrial volume. Cyclosporin A partially blocks mitochondrial swelling by Ca2+. Amiodarone, 
benzarone and benzbromarone also induce swelling, but less pronounced than Ca2+ (E). Mean ± SEM of 
at least 3 independent experiments. *P < 0.05 vs. 1% DMSO; ** p < 0.01 vs. 1% DMSO. 
 
8.4.6. Apoptosis and necrosis 
Mtp-induced swelling can lead to a disruption of the outer mitochondrial membrane with 
consecutive release of cytochrome c, which can activate caspases and induce apoptosis (13, 39). As 
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shown in Figure 6, 100 µmol/L amiodarone, benzarone or benzbromarone were all associated with 
leakage of cytochrome c into the cytoplasm of HepG2 cells, whereas this was not the case for 
benzofuran or 2-butylbenzofuran. 
 
 
Figure 6: Mitochondrial cytochrome c release caused by treatment of HepG2 cells with test compounds 
(each 100µmol/L) for 8 h, and detected by immunocytochemistry. In the presence of 1% DMSO (control, 
panel A), benzofuran (panel B) or 2-butylbenzofuran (panel F) no leakage of cytochrome c into the 
cytoplasm occurred, as indicated by a diffuse, punctual pattern of immunoreactivity. In these 
incubations, immunoreactivity is linked to mitochondria (punctual pattern), rendering the nuclei clearly 
visible. After treatment with amiodarone (panel B), benzbromarone (panel C) or benzarone (panel D), 
cells may partially detach from the surface and the immunoreactivity is spread over the entire cells. The 
homogenous, diffuse pattern of immunoreactivity, which covers the nuclei, indicates release of 
cytochrome c from the mitochondrial intermembrane space followed by cytoplasmic spreading. 
 
Chromatin fragmentation and/or condensation occurring during apoptosis can be visualized by 
fluorescence microscopy upon staining with dyes intercalating with DNA. As shown in Figure 7, 
untreated cells showed an apoptosis rate of 3%. Apoptosis was induced by amiodarone, benzarone 
and by benzbromarone in a concentration-dependent manner (not shown). At a concentration of 
100µmol/L, the proportion of apoptotic cells was 10% for amiodarone, 13% for benzarone and 11% for 
benzbromarone. Fas-ligand, used as a positive control, induced DNA fragmentation in 9% of the cells, 
whereas 100µmol/L benzofuran or 2-butylbenzofuran showed DNA fragmentation frequencies similar 
to control incubations. 
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Figure 7: Illustration and quantification of apoptosis. Rat hepatocytes were treated with test compounds 
at a concentration of 100 µmol/L. After 8h of exposure, the cells were stained with Hoechst 33342 for 15 
min and analyzed by fluorescence microscopy. Apoptotic cells are characterized by chromatin 
condensation (arrow a) and/or chromatin fragmentation (arrow b). (A) untreated cells as a control, (B) 
benzarone 100µmol/L, (C) percentage of cells with apoptotic nuclei. Mean ± SEM of at least three 
independent experiments. * P < 0.05 vs. 1% DMSO; ** p < 0.01 vs. 1% DMSO. 
 
A hallmark of the early stages of apoptosis is the translocation of phosphatidylserine from the 
inner to the outer leaflet of the plasma membrane. Externalized phosphatidylserine can then be 
detected using Annexin V, a protein with high affinity for this phospholipid. Cells were co-stained with 
PPI as a marker of cell membrane permeability, which increases during the later stages of apoptosis 
and also of necrosis. Since PPI only enters cells with already disintegrated membranes, early 
apoptotic cells can be distinguished from late apoptotic and necrotic cells. Similar to staining with 
Hoechst 33342, flow cytometric analysis of the cells revealed progressive decrease of viable, 
unstained cells with increasing concentrations of amiodarone, benzarone or benzbromarone. At 
100µmol/L, only 38% of cells exposed to amiodarone, 53% exposed to benzarone and 11% exposed 
to benzbromarone were viable (Figure 8). These findings suggest that apart from apoptosis, also 
necrosis was initiated since the amount of cells undergoing cell death are considerably higher than the 
cells undergoing chromatin fragmentation and/or condensation. 
(A) (B) 
a 
b 
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Figure 8: Annexin V binding and PPI uptake by rat hepatocytes. Hepatocytes were incubated for 8h at a 
concentration of 1 or 100µmol/L of each test compound and subsequently stained with Annexin V and 
PPI. The samples were analyzed by flow cytometry (see graphs A, B, C and D). Region R3 represents 
the unstained, thus viable cells. In region R4, the cells are undergoing early apoptosis and are stained 
only with Annexin V. Region R2 represents the double stained cells undergoing necrosis or later stages 
of apoptosis. Under control conditions, the vast majority of cells are located in region R3 (A). Fas-ligand 
is inducing apoptosis (B), whereas benzbromarone is increasing the counts in region R2 in a 
concentration dependent manner (C: benzbromarone 1µmol/L, D: benzbromarone 100µmol/L). Graph E: 
percentage of cells undergoing necrosis or late stages of apoptosis relative to control values. NP 40 is a 
detergent used as a positive control for necrosis. Mean ± SEM of at least three independent 
experiments. *P<0.05 vs. 1% DMSO, **p<0.01 vs. 1% DMSO. 
 
Since ATP is a prerequisite for apoptosis (40, 41), the cellular ATP content was determined in 
hepatocytes incubated for 8h with compounds tested. The ATP content of control incubations was 
4.0±0.8 µmol/106 hepatocytes and remained stable in the presence of 1 or 100µmol/L benzofuran or 
2-butylbenzofuran. In the presence of 1µmol/L amiodarone, benzarone or benzbromarone, it was 
93±5%, 80±20% or 68±15% of the control incubations, respectively. In the presence of 100µmol/L 
amiodarone, benzarone or benzbromarone, it dropped to 30±13%, 68±8% or 18±5% of the control 
incubations, respectively. These results give further support to the notion that apoptosis and necrosis 
occur under these conditions, in particular in the presence of benzbromarone. 
If ROS generation were involved in initiation of cell death, addition of an antioxidant, which was 
proven to reduce ROS production, should lead to a decrease of cell death. Therefore, the above 
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mentioned experiments (Figure 4) were repeated in the presence or absence of 250µmol/L ascorbic 
acid. In the presence of ascorbate, the fraction of cells undergoing chromatin fragmentation and/or 
condensation was significantly reduced but not completely prevented (Figure 9). Similar results were 
obtained with the Annexin V PPI staining (data not shown). 
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Figure 9: Reduction of apoptosis in the presence of an antioxidant. In the presence of 250µmol/L 
ascorbate, the fraction of cells undergoing chromatin condensation/fragmentation during incubation with 
test compounds is diminished. Mean ± SEM of at least three independent experiments. Asterisks 
indicate values significantly different from the incubations in absence of ascorbate. *P < 0.05 and ** p < 
0.01. 
 
8.5. Discussion 
Our investigations demonstrate that amiodarone, benzarone and benzbromarone are inhibitors 
of the mitochondrial respiratory chain and of β-oxidation, and are uncouplers of oxidative 
phosphorylation. Furthermore they can induce production of ROS and mitochondrial swelling, and lead 
to apoptosis and necrosis of cells. 
The mitochondrial electron transport chain has been recognized as one of the major sources of 
reactive oxygen species, in particular complex I and complex III (42). Electrons passing across the 
electron transport chain can escape from this chain and can react with molecular oxygen to form 
superoxide (O2-). Under normal conditions, superoxide is degraded by intramitochondrial, antioxidative 
systems such as glutathione and superoxide dismutase (33, 34). In the presence of uncouplers, 
protons are transported into the mitochondrial matrix bypassing the F0F1-ATPase. During uncoupling, 
the respiratory chain works more efficiently to reestablish the proton gradient, and therefore, ROS 
production is usually not increased or can even be reduced (30). In the presence of inhibitors of the 
respiratory chain, generation of ROS is increased, since electrons may escape from the electron 
transport chain and react with molecular oxygen. Indeed, inhibitors of the electron transport chain, for 
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instance rotenone or antimycin, have been shown to increase ROS generation in mitochondria (30, 
42, 43). In this context, it is interesting to note that amiodarone, benzarone and benzbromarone are 
both uncouplers and inhibitors of the electron transport chain. Since inhibition of the electron transport 
chain may generate a higher amount of ROS in the presence of an uncoupler (42), such substances 
may be particularly toxic for mitochondria. 
It is well known that ROS within the mitochondrial matrix can trigger mpt pore opening (13). An 
increase in mpt is an important route by which mitochondrial toxins can activate cell death in 
mammalian cells (13, 44). ROS generation and induction of mpt and have been identified as possible 
common effectors of cell death by apoptotic as well as by necrotic stimuli (45, 46). Pore opening 
induces release of cytochrome c, which is located on the outer surface of the inner mitochondrial 
membrane (Figure 6). After release, cytochrome c triggers the subsequent effector steps for 
apoptosis, in particular caspase activation. ATP is critical for the action cytochrome c, since it is 
required for Apaf-1 oligomerization, which is followed by caspase activation. Low cellular ATP 
concentrations, as observed in hepatocytes incubated with 100 µmol/L amiodarone, benzbromarone 
or benzarone, can therefore switch apoptotic stimuli towards cell necrosis. Depending on the intensity 
of the oxidative stimuli, and the extent by which generation of ATP is impaired (e.g. by inhibition of the 
electron transport chain, uncoupling or impairment of β-oxidation) ROS generation can therefore be 
associated with both, apoptosis and necrosis. Further evidence for the before mentioned hypothesis 
that ROS generation works as a trigger for cell death induction was provided by demonstrating a 
reduction of cell death in the presence of ascorbate. 
Besides their effects on oxidative phosphorylation and mitochondrial electron transport, 
amiodarone, benzarone and benzbromarone are efficient inhibitors of mitochondrial β-oxidation. The 
inhibition of β-oxidation is independent from the inhibition of the electron transport chain, since the 
corresponding concentrations for 50% inhibition are clearly lower for β-oxidation than for state 3 
oxidation. After depletion of glycogen, e.g. during starvation, the liver depends mainly on β-oxidation 
for production of energy. It is therefore likely that under such circumstances and in the presence of 
inhibitors of mitochondrial β-oxidation, the cellular ATP content may decrease, possibly leading to 
necrosis of hepatocytes. 
Concerning the structure-toxicity relationship, our investigations demonstrate clearly that the 
benzofuran structure per se, which was assumed to mediate mitochondrial toxicity (5), is not 
hepatotoxic. Our studies show that the hepatotoxicity of benzofuran is dependent on the presence of 
sidechains in position 1 and/or 2 of the furan ring. Bromide atoms in the p-hydroxybenzene moiety are 
not essential for hepatotoxicity associated with these compounds but clearly enhance it. 
We conclude that benzarone, benzbromarone as well as amiodarone are toxic to isolated rat 
liver mitochondria as well as to whole hepatocytes. The benzofuran structure alone is not responsible 
for the hepatotoxic effects, sidechains at the furan ring are necessary. Hepatic injury associated with 
the ingestion of these drugs can be explained by mitochondrial damage with subsequent induction of 
apoptosis and necrosis. 
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9.1. Summary 
Background: Treatment with statins is rarely associated with myotoxicity, particularly 
rhabdomyolysis. Statin-induced rhabdomyolysis is a dose-dependent adverse reaction, but its 
mechanism could not be clarified entirely. Mitochondrial dysfunction may contribute to statin-induced 
rhabdomyolysis. Therefore we investigated mitochondrial toxicity of four lipophilic (cerivastatin, 
fluvastatin, atorvastatin, simvastatin) and one hydrophilic statin (pravastatin). 
Methods and results: Lactate dehydrogenase-leakage, mitochondrial membrane potential, 
uncoupling of oxidative phosphorylation, cytochrome c leakage and apoptosis were measured in L6 
rat skeletal muscle cells, whereas oxygen consumption, β-oxidation and mitochondrial swelling was 
assessed in isolated rat skeletal muscle mitochondria. In cells, lipophilic statins (100µmol/L) were 
cytotoxic, inducing death in 27-49% of the cells, whereas pravastatin did not show cytotoxicity up to 
1mmol/L. Additionally, cerivastatin, fluvastatin, and atorvastatin (100µmol/L) decreased the 
mitochondrial membrane potential in 35 %, 51%, and 40% of the cells whereas simvastatin caused a 
minor and pravastatin no effect. In mitochondria, all statins except pravastatin decreased state 3 
oxidation and the respiratory control ratio (IC50-values: cerivastatin 57µmol/L, fluvastatin 81µmol/L, 
simvastatin 78µmol/L, atorvastatin 136µmol/L). Beta-oxidation was decreased by 74-99% in the 
presence of 100µmol/L cerivastatin, fluvastatin, simvastatin and atorvastatin, but was not affected by 
pravastatin. Mitochondrial swelling, cytochrome c release, DNA fragmentation and phosphatidylserine 
exposure was induced by lipophilic statins. 
Conclusions: The lipophilic statins are potent toxins for skeletal muscle mitochondria, whereas 
the hyrdrophilic pravastatin did not reduce cell viability. Rhabdomyolysis in response to statin 
treatment can be explained by mitochondrial toxicity and subsequent apoptosis induction in myocytes. 
Underlying mitochondrial diseases may represent an additional risk factor for statin-induced 
rhabdomyolysis.  
 
9.2. Introduction 
Statins (3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, HMG-Co A reductase 
inhibitors) reduce cholesterol production by inhibiting the synthesis of mevalonate, a critical 
intermediary in the cholesterol pathway (see Figure 1 for chemical structures). They are well tolerated 
by most patients but can produce a variety of muscle-related, dose-dependent complaints, ranging 
from mild myopathy to frank rhabdomyolysis. The most serious risk for patients treated with statins is 
rhabdomyolysis, which occurs with a frequency of approximately 1:100’000 patient years (1). The 
economical importance of this adverse drug effect has been demonstrated recently by the withdrawal 
of cerivastatin (2, 3). 
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Figure 1: Chemical structures of the investigated statins 
 
The frequency of rhabdomyolysis is low, with a reported incidence of fatal rhabdomyolysis of 
0.15 deaths per million prescriptions (3, 4). The fact that the rate of rhabdomyolysis was higher for 
cerivastatin than for other statins raised the question of whether there are differences in the myotoxic 
potential of the different statins and whether such differences relate to physiochemical properties of 
the statins. Statins are either hydrophobic (cerivastatin, fluvastatin, atorvastatin, or simvastatin) or 
hydrophilic molecules (pravastatin) leading to different tissue bioavailabilities and/or tissue distribution 
patterns (Table 1) (5, 6), possibly accounting for differences in the toxic potential. Since some statins 
are metabolized by cytochrome P450 (CYP) isozymes, concomitant treatment with CYP inhibitors has 
been identified as a risk factor for statin-induced myotoxicity. However, rhabdomyolysis has been 
reported for all statins, indicating that the physiochemical properties of statins are not the only factors 
for explaining myotoxicity associated with statins.  
 
Table 1: Physiochemical properties, pharmakokinetics and metabolism of statins studied (1, 7-9) 
 Lipo-
philicity 
 
Metabolism Bioavailability 
[%] 
Protein 
binding 
[%] 
Renal/fecal 
elimination 
[%] 
Volume of 
distribution 
[L] 
Hepatic 
extraction 
[%] 
Cerivastatin high Cyp 3A4/2C8 60 99 30 / 70 50 < 40 
Fluvastatin high Cyp 2C9 6 98 6 / 90 99 > 68 
Atorvastatin high Cyp 3A4 12 80 2 / 70 381 > 70 
Simvastatin high Cyp 3A4 5 95 13 / 58 113 ~ 80 
Pravastatin low Conj 18 50 20 / 71 36 44-66 
CYP = cytochrome P450; Conj = conjugation 
 
Little is known regarding the mechanism by which statins produce muscle injury. A variety of 
different hypotheses have been suggested to account for the myotoxic effects. HMG-CoA reductase 
catalyses the formation of mevalonate from HMG-CoA. Mevalonate is an important precursor not only 
Fluvastatin Atorvastatin Cerivastatin 
Simvastatin Pravastatin 
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for cholesterol but also for ubiquinone, dolichols and isopentyl adenine (10). All these products are 
involved in various essential cell functions. A deficit in them may therefore adversely affect myocytes, 
predisposing them to cell death (6, 7). This was confirmed by the finding that the myotoxicity could be 
abolished by the addition of mevalonate in vitro (10, 11). Ubiquinone is a compound of the 
mitochondrial electron transport chain, responsible for the transport of electrons between the enzyme 
complexes. Reduced levels of ubiquinone could be found in patients with mitochondrial myopathies. 
Reduced synthesis of ubiquinone may result in an impaired function of the electron transport chain (7, 
12) and thus decreased ATP synthesis, predisposing cells for necrosis. Moreover, light microscopic 
changes in muscle biopsy tissue of patients with myopathy associated with either simvastatin or 
pravastatin, were similar to those observed in patients with mitochondrial myopathy (13, 14). 
Mitochondrial dysfunction, independently whether it originates from mutations in the mitochondrial 
genome or is drug-induced, appears to be associated with apoptosis. In skeletal muscle of patients 
with mitochondrial diseases, cells undergoing apoptosis have been described (15). In addition, 
mitochondrial permeability transition appears to be a key step in statin-associated cell damage (16).  
On the basis of the above considerations, the aim of the present study was to investigate the 
effect of five different statins on isolated skeletal muscle mitochondria and on myoblasts as well as to 
assess the role of the mitochondria in statin-induced cell death.   
 
9.3. Materials and Methods 
9.3.1. Materials 
Fluvastatin was a kind gift from Novartis Pharma AG (Basel, Switzerland), simvastatin from 
Merck Sharp Dohme Ltd (Rahaway, NJ, USA), cerivastatin from Bayer AG (Zürich, Switzerland) and 
pravastatin from Bristol-Meyers Squibb (Sankyo, Japan). Atorvastatin was kindly provided by Prof J. 
Drewe (Clinical Pharmacology & Toxicology, University Hospital Basel). JC-1 was obtained from 
Alexis Biochemicals (Lausen, Switzerland) and [1-14C]palmitic acid from Amersham Pharmacia 
Biotech (Dübendorf, Switzerland).  
The cell culture media, fetal calf serum and all supplements were from Gibco (Paisley, UK). 
The 96-well plates were purchased from Becton Dickinson (Franklin Lakes, NJ, USA) and the 8-
chamber slides from Nalge Nunc (Rochester, NY, USA). The VybrantTM Apoptosis Assay Kit #2 was 
purchased from Molecular probes (Eugene, OR, USA). All other chemicals used were of best quality 
available and purchased from Sigma–Aldrich (Schnelldorf, Germany).  
 
9.3.2. Animals 
Male Sprague Dawley rats (Charles River, Les Onins, France) were used for all experiments. 
They were fed ad libitum, hold on a 12-hour dark and light cycle and weighed before their use. The 
study protocol has been accepted by the Animal Ethics Committee of the Canton Basel-Stadt 
(Switzerland). 
 
9.3.3. Cells 
The L6 cell line (rat skeletal muscle myoblasts) was obtained from LGC Promochem (Wesel, 
Germany). The cell line was cultured in Dulbecco’s Modified Eagle’s Medium (Gibco 61965-026; with 
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4 mmol/L GlutaMAX®, 4.5 g/L glucose and 3.7g/L sodium bicarbonate) supplemented with 10% heat 
inactivated fetal calf serum, 1 mmol/L sodium pyruvate and penicillin-streptomycin (100U/mL). Culture 
conditions were 5 % CO2 and 95 % air atmosphere at 37°C. 
 
9.3.4. Preparation of simvastatin acid 
After dissolution in dimethylsulfoxide (DMSO), simvastatin lactone was hydrolyzed to 
simvastatin acid by hydrolysis with 0.05 N NaOH solution with stirring at 20°C for 30min. The 
hydrolysed solution was adjusted to pH 7.4 with 0.2mol/L HCl and stored at -20°C until used (17).  
 
9.3.5. Isolation of rat skeletal muscle mitochondria 
At the time of killing the rats weighed (mean 388.7g). The animals were put down with carbon 
dioxide and euthanized by decapitation. The skeletal muscle (mean 19.0g per rat) was prepared as 
described elsewhere (18) with minor modifications. After several rinses with isolation medium 
(100mmol/L KCl, 50mmol/L 3-[N-morpholino]propanesulfonic acid (MOPS), 5mmol/L MgSO4, 
0.8mmol/L ethylenediaminetetraacetic acid (EDTA) and 1mmol/L ATP) the skeletal muscle mince was 
suspended in 10 volumes (wt/vol) of the same medium and treated with the protease Nagarse (5 mg/g 
mince) for 10min on ice with constant stirring. Mitochondria were isolated by differential centrifugation 
as described by Chappell et al (19, 20).  
The mitochondrial protein content (mitochondrial protein/g muscle) was determined using the 
biuret method with bovine serum albumin (BSA) as standard (21).  
 
9.3.6. In vitro cytotoxicity assays 
Cell injury was assessed by the measurement of release of lactate dehydrogenase (LDH) in 
the supernatant as compared with LDH of lysed cells (treatment with Triton X-100 0.8%). LDH-leakage 
was analyzed as described previously (22) and calculated as described by Huang (23). The results 
were expressed in a dose-dependent manner. Different compound concentrations were added to the 
culture medium in a 96-well-plate for 24 hours before the supernatants were harvested.  
 
9.3.7. Mitochondrial membrane potential (∆Ψm) 
Cells were detached from cell culture flask by adding 10mmol/L EDTA in phosphate buffered 
saline pH 7.4 (PBS). After filtration, cells were adjusted to a density of 0.5 x 106 cells/mL and 
incubated in complete medium in the dark for 10 min with 4µg/mL JC-1. Flow cytometry was 
performed using a FACS Calibur flow cytometer (Becton Dickinson, San José, CA, USA). The 
fluorescence emission wavelength of JC-1 depends on the aggregation of the JC-1 molecules that in 
turn depends on the ∆Ψm (the greater the ∆Ψm, the greater the aggregation to J-complexes). Changes 
in ∆Ψm were measured by monitoring JC-1 fluorescence. Dinitrophenol (as an uncoupler) and 
benzbromarone (as a substance that induces depolarization of ∆Ψm) were used as positive controls. 
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9.3.8. Oxygen consumption 
Oxygen consumption was monitored polarographically using a 1mL chamber equipped with a 
Clark-type oxygen electrode (Yellow Springs Instruments, Yellow Springs, OH, USA) at 30°C as 
described previously (24). The oxygen content of incubation buffer equilibrated with air was assumed 
to be 223nmol O2/mL at 30°C (25). The final concentration for L-glutamate was 20mmol/L.  
Oxygen consumption by intact mitochondria: The respiratory control ratio (RCR), a marker of 
the functional integrity of the mitochondria and of the coupling of oxidative phosphorylation was 
calculated according to Estabrook (26) as the ratio between the rate of oxygen consumption in the 
presence of a substrate and added adenosine diphosphate (ADP) (state 3) and the rate obtained after 
complete conversion of ADP to adenosin triphosphate (ATP) (state 4). After depletion of endogenous 
substrates by the addition of ADP, a substrate was added to the incubation before state 3 respiration 
was initiated by adding ADP. The test compounds were added to the mitochondrial incubations before 
the addition of the respective substrate. Control experiments were carried out in the presence of the 
solvent (DMSO) containing no inhibitor. 
Oxygen consumption by L6 muscle cells: 1 x 106 cells were treated with oligomycin (final 
concentration 5µg/mL) in order to inhibit mitochondrial ATPase. After 2 minutes, the test compounds 
were added to the incubation chamber and the oxygen consumption was determined as a marker for 
the uncoupling potential of the test compounds. Control experiments were carried out with solvent 
only.  
 
9.3.9. Activity of NADH-oxidase 
The activity of NADH-oxidase was determined at 30°C with the oxygen electrode using freeze-
thawed mitochondria as described originally by Blair et al. (27). 
 
9.3.10. In vitro mitochondrial β-oxidation 
The β-oxidation of [1-14C] palmitic acid by skeletal muscle mitochondria was assessed by the 
CO2 trapping method according Lindstedt et al. (28) with modifications (29). In the incubation vials, 
which contained 900µl of incubation medium (pH 7.4) (30), a scoop with a folded filter paper was fixed. 
The filter paper was soaked in 90µl 0.1mol/L KOH in order to trap the volatile 14CO2. 
After 5min of preincubation at 37°C, the reaction was started by adding 100µL of incubation 
buffer containing [1-14C]palmitic acid (final concentration 40µmol/L) and bovine serum albumin (final 
concentration 2.5mg/mL) to the incubation medium. The incubations were carried out in closed vials 
for 30min at 37°C with slow shaking. Preliminary tests had shown that the reaction was in the linear 
phase at this time point. The reaction was stopped by adding 200µL of 30% perchloric acid (v/v) and 
by placing the vials on ice for 5min to precipitate the unchanged isotopically labeled palmitate. 
Subsequently the vials were left at room temperature for 1.5h to allow complete collection of 14CO2. 
The filters were then added to 5mL of scintillation fluid in a 20mL vial, the contents well mixed, and the 
radioactivity measured in a β-counter during 5min. The acidified contents of the incubation vials were 
centrifuged (9500g, 2min) and an aliquot (600µL) of the supernatant was used to determine the 
formed 14C-labeled acid soluble products (citric acid cycle intermediates such as α-ketoglutarate, 
succinate, oxalacetate). 
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9.3.11. Activities of mitochondrial β-oxidation enzymes 
All enzyme activities were determined using spectrophotometric assays at 37°C. Freeze-
thawed mitochondria were treated 1:1 with 5% cholic acid in order to disrupt the mitochondrial 
membranes. The solution was then diluted one hundred times with 50mmol/L potassium phosphate 
buffer (pH 7.4). The concentrations used for atorvastatin, fluvastatin and simvastatin were 50µmol/L 
and 200µmol/L, for cerivastatin 25µmol/L and of 100µmol/L, and for pravastatin 200µmol/L and of 
400µmol/L. 
Acyl-CoA Dehydrogenase: The activity was determined according to the method of Hoppel et al 
(24) using palmitoyl-CoA as a substrate. The incubations contained 50µg mitochondrial protein. The 
activity was calculated using an extinction coefficient of 21mmol · L-1 cm-1 for reduced cytochrome c. 
Beta-hydroxy acyl-CoA dehydrogenase: Beta-hydroxy-acyl-CoA dehydrogenase activity was 
determined essentially according to Brdiczka et al. (31)  
Beta-ketothiolase: Thiolysis of acetoacetyl-CoA was followed at pH 8.1 and 37°C in a final 
volume of 0.5mL according to Hoppel et al (24). The slow decrease in extinction due to alkaline 
hydrolysis was followed for about 30sec (32) before the reaction was started by the addition of 
0.25mmol/L CoA. The decrease of absorbance was monitored at 303nm as 3-oxoacyl thioesters have 
a strong absorption at this wavelength with an apparent extinction coefficient of 12.2 mmol · L-1 cm-1.  
Enzyme activities are expressed as mU (nanomoles per minute) per mg mitochondrial protein. 
 
9.3.12. Determination of mitochondrial swelling 
Mitochondrial permeability transition pore opening in vitro results in mitochondrial swelling. 
Permeability transition was monitored by measuring the decrease in light scattering at 540nm using a 
SpectraMAX 250 plate reader (Paul Bucher Analytik und Biotechnologie, Basel, Switzerland). The 
decrease in light scattering has been shown to closely relate to the percentage of the mitochondrial 
population undergoing permeability transition (33). Experiments were run within 4 hours following 
decapitation of the rat. Experiments were initiated by addition of test compounds to a fixed amount of 
mitochondria in an isotonic swelling buffer pH 7.3, containing 150mmol/L KCl, 20mmol/L MOPS, 
10mmol/L Tris(hydroxymethyl)-aminomethan (TRIS), 2mmol/L nitrilotriacetic acid and 2µmol/L calcium 
ionophore, A23187. Swelling was calculated from the slope between 60 sec and 2000 sec after 
addition of test compounds. 
 
9.3.13. Cytochrome c immunocytochemistry 
For immunocytochemistry cells were grown in an 8 chamber-slide for 24 hours at 37°C and 
then treated with test compounds, each in a concentration of 100µmol/L, for 24 hours. Afterwards the 
cells were fixed in 4% paraformaldehyde in PBS for 15min at 37°C and then washed three times with 
blocking buffer (0.05% saponin, 3% BSA, in PBS). The cells were incubated with 50µL anti-
cytochrome c antibody diluted 1:300 (3.33 µL/mL) in blocking buffer and incubated for one hour in a 
humidified chamber at 37°C. The cells were again washed three times with blocking buffer and 
incubated for one hour at 37°C in a humidified chamber with 50µL anti-sheep IgG conjugated with 
Cy3TM diluted 1:200 (5µL/mL) in blocking buffer. The cells were then washed once with blocking buffer 
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and twice with PBS. To mount each chamber slide, 10-15µL Fluor SaveTM reagent was added and the 
slides were sealed with a clear coverslip. The cells were examined under a fluorescence microscope 
(Olympus IX 50, Hamburg, Germany) and images were taken. 
 
9.3.14. Determination of apoptosis  
Both assays were performed using L6 muscle cells cultured on poly-D-lysine coated 
(0.1mg/mL, 30min) cell culture dishes.  
Hoechst 33342 nuclear staining: A confluent cell layer was treated for 24h with test 
compounds, then incubated for 30 minutes at room temperature with Hoechst 33342 dye (50µmol/L in 
PBS) and visualized by fluorescence microscopy (Olympus IX 50, Hamburg, Germany).  
Annexin V and propidium iodide (PPI) staining: An in situ Apoptosis Detection Kit was used for 
Annexin V binding and propidium iodide staining (VybrantTM Apoptosis Assay Kit #2). Cells were 
treated with the test compounds in a concentration-dependent manner. After a 24h-incubation period, 
cells were stained with 25µL Annexin V-Alexa Fluor® 488 and 2µL PPI (final concentration: 1.5µg/L ). 
After 15 minutes of incubation at room temperature, samples were analyzed by flow cytometry, using 
a FACS Calibur flow cytometer (Becton Dickinson, San José, USA).  
 
9.3.15. Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM). For statistical comparisons, 
data of groups were compared by analysis of variances (ANOVA). If ANOVA revealed significant 
differences, comparisons between the control and the other incubations were performed by Dunnett’s 
post test procedure. T-test (unpaired, two-tailed) was performed, if only two groups were analyzed. 
The level of significance was p ≤ 0.05.  
 
9.4. Results 
9.4.1. In vitro cytotoxicity assays 
The cellular toxicity of the different statins was investigated by treating L6 cells with various 
concentrations of each compound for 24 hours. The extent of muscle cell LDH leakage, an indicator of 
cell damage, is shown in figure 2. At 100µmol/L, cerivastatin, fluvastatin, atorvastatin and simvastatin 
showed significant toxicity. In contrast, pravastatin did not cause any cell damage up to 1mmol/L. In 
order to gain more insight into the mechanism associated with statin toxicity, we performed the 
following investigations.  
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Figure 2: Cytotoxicity of the test compounds was assessed by extracellular LDH in percent of total LDH. 
Cerivastatin, fluvastatin, atorvastatin and simvastatin caused a concentration-dependent release of LDH 
from the cytoplasm into the cell culture media. In contrast, the cell membrane remained tight under 
treatment with pravastatin up to 1mmol/L. Data are given as mean ± SEM of at least three individual 
experiments. *p<0.05 vs. control, **p<0.01 vs. control. 
 
9.4.2. Mitochondrial membrane potential 
In recent years, mitochondrial damage has been recognized as an important mechanism of 
drug-induced toxicity (34). Moreover, statin induced myopathie has been associated with 
mitochondrial dysfunction (13, 14). Therefore, we investigated whether mitochondria are involved in 
the statin-mediated toxicity. In a first step, we measured the mitochondrial membrane potential which 
can be used as a broad indicator for mitochondrial damage. Furthermore, it has been demonstrated 
that maintenance of the mitochondrial membrane potential is critical for myocyte survival (35) and also 
plays a crucial role in the induction of apoptosis (36). Cerivastatin, fluvastatin, atorvastatin and 
simvastatin led to a concentration dependent loss of the mitochondrial membrane potential (Figure 3). 
At a concentration of 100µmol/L 35% of the cells showed a dissipated potential with cerivastatin. The 
corresponding values for fluvastatin, atorvastatin and simvastatin were 51%, 40% and 26%, 
respectively. In comparison, pravastatin was not toxic up to 1mmol/L. 
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Figure 3: The mitochondrial membrane potential was determined by an ion distribution technique. Cells 
were labeled with the cationic dye JC-1. Mitochondrial depolarization is indicated by a shift of the 
fluorescence emission from green to red. Distinct populations of cells with different extents of 
mitochondrial depolarization were detectable with different treatment. In the upper left quadrant, cells 
with polarized mitochondria are located (panel A; DMSO 1%), whereas cells with dissipated potential are 
found in the upper or lower right panel (panel B-D for fluvastatin 10µmol/L, 100µmol/L or 1000µmol/L). 
The results of the counts in the upper left quadrant are given as rates compared to total counts defined 
as 100%. Data are given as mean ± SEM of at least three individual experiments. *p<0.05 vs. control, 
**p<0.01 vs. control. 
 
9.4.3. Oxygen consumption 
In order to further specify the mitochondrial dysfunction induced by statins we assessed the 
toxicity of these substances on oxidative metabolism of isolated rat skeletal muscle mitochondria. In 
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the presence of L-glutamate as a substrate cerivastatin, fluvastatin, atorvastatin and simvastatin 
induced a progressive depression of the RCR, which reflects in part the integrity of the inner 
mitochondrial membrane and the tightness of the coupling of oxidative phosphorylation (37) (see table 
2). The corresponding IC50 values were: 57µmol/L for cerivastatin, 81µmol/L for fluvastatin , 136µmol/L 
for atorvastatin and 78µmol/L for simvastatin. For pravastatin, no inhibition was detected up to 
400µmol/L and therefore no IC50 value was determined. 
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Table 2: Effects of cerivastatin, fluvastatin, atorvastatin, simvastatin and pravastatin on 
oxidative metabolism by isolated rat skeletal muscle mitochondria. See method section for 
experimental details. Mean ± SEM of three experiments using different mitochondrial 
preparations. 
    
 State 3 State 4  RCR 
Control (no inhibitor)  232.66 ± 20.85  66.16 ± 14.12  3.7 ± 0.77 
    
Cerivastatin 
(µmol/L) 
   
2  255.56 ± 22.61  69.13 ± 9.57  3.96 ± 0.60 
5  239.50 ± 30.70  69.13 ± 5.77  3.48 ± 0.43 
25  288.56 ± 34.99  87.86 ± 10.16  3.37 ± 0.45 
50  273.84 ± 34.99  136.92 ± 15.31 *  1.98 ± 0.04 
100  186.87 ± 19.39  186.87 ± 19.40 **  1.00 ± 0.00 ** 
    
Fluvastatin 
(µmol/L) 
   
5  240.84 ± 14.57  62.44 ± 7.28  3.90 ± 0.22 
25  224.49 ± 8.28  41.63 ± 21.44  3.52 ± 0.28 
50  266.11 ± 24.34  64.67 ± 6.44  2.27 ± 0.44 
100  191.78 ± 41.20  126.37 ± 28.25  1.73 ± 0.52 
200  31.22 ± 17.42 **  115.96 ± 10.54  1.00 ± 0.00 ** 
    
Atorvastatin 
(µmol/L) 
   
5  170.97 ± 28.28  49.06 ± 3.41  3.44 ± 0.33 
25  173.20 ± 19.71  56.49 ± 1.49  3.06 ± 0.30 
50  161.30 ± 45.23  45.34 ± 8.76  3.46 ± 0.64 
100  149.41 ± 5.90  71.36 ± 11.00  2.19 ± 0.32 
200  45.34 ± 4.52 **  45.34 ± 4.52  1.00 ± 0.00 ** 
    
Simvastatin 
(µmol/L) 
   
5  199.96 ± 32.28  56.41 ± 6.48  3.03 ± 0.31 
25  213.34 ± 56.42  74.33 ± 15.52  2.79 ± 0.36 
50  156.84 ± 40.64  86.23 ± 18.09  1.94 ± 0.53 
100  122.65 ± 14.51  80.28 ± 13.38  1.68 ± 0.47 * 
200  82.51 ± 9.01 *  82.51 ± 9.01  1.00 ± 0.00 ** 
    
Pravastatin 
(µmol/L) 
   
50  272.06 ± 24.56  92.17 ± 10.41  3.03 ± 0.43 
100  338.22 ± 40.60  95.00 ± 27.68  2.77 ± 0.51 
200  270.57 ± 35.53  81.77 ± 5.36  3.35 ± 0.52 
300  246.79 ± 41.31  89.94 ± 12.24  2.72 ± 0.09 
400  278.01 ± 73.48  87.71 ± 10.72  3.05 ± 0.49 
    
*p < 0.05 vs. control; ** p < 0.01 vs. control 
 
 
 
While the depression of the RCR by fluvastatin, atorvastatin and simvastatin was mainly due to 
an inhibition of the state 3 respiration rate, i.e. inhibition of the electron transport chain, for cerivastatin 
the decrease was mostly because of induction of state 4 oxygen consumption. An induction of state 4 
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can be due to either uncoupling of oxidative phosphorylation or conversion of ATP to ADP in the 
mitochondrial matrix. Therefore, oxygen consumption of muscle cells was determined in order to 
investigate uncoupling directly. Figure 4 shows the influence of the statins on glutamate-supported 
state 4 respiration of rat skeletal muscle cells in the presence of the phosphorylation inhibitor 
oligomycin. Under these conditions only cerivastatin showed an induction of state 4, corresponding 
well with oxygen consumption by isolated mitochondria. Figure 4 convincingly demonstrates that 
cerivastatin behaved differently among the lipophilic statins, being the only statin acting as an 
uncoupler of oxidative phosphorylation.  
 
 
Figure 4: Effects on glutamate-supported oligomycin induced mitochondrial state 4 
respiration in rat skeletal myoblasts. In a normal, hence coupled mitochondrion, blocking of F0F1-ATPase 
by oligomycin results in a restricted electron transport and restricted oxygen consumption (state 4). If a 
test compound works as an uncoupler, oxygen consumption increases, in spite of inhibited 
phosphorylation (see panel A). Of the tested statins only cerivastatin worked as an uncoupler, whereas 
fluvastatin, atorvastatin, simvastatin or pravastatin did not increase oxygen consumption. Dinitrophenol 
and benzbromarone served as positive controls. *p<0.05 vs. control, **p<0.01 vs. control. 
 
 
9.4.4. Activities of mitochondrial NADH-oxidase 
In order to exclude the possibility that the observed lack of toxicity of pravastatin is only due to 
differences in physiochemical properties of the molecule and in membrane permeability, activity of the 
mitochondrial NADH oxidase, an enzyme of the electron transport chain, was measured with broken 
mitochondria. The substrates and test compounds used can therefore interact directly with the 
complex of the electron transport chain and no membrane barrier has to be overcome. As shown in 
table 3, pravastatin showed no inhibition up to 1mmol/L, whereas cerivastatin and fluvastatin 
significantly inhibited NADH oxidase. A tendency was seen for atorvastatin and simvastatin at 
100µmol/L. We could show that also in absence of membrane barriers pravastatin didn’t affect the 
electron transport chain.  
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Table 3: Activity of mitochondrial NADH-oxidase measured in freeze-
thawed mitochondrial preparations. Activities are expressed relative to 
control values Data are given as mean SEM of at least three individual 
mitochondrial preparations.  
    
   Activity (in %) 
Control (no inhibitor)   100.0 ± 11.5  
Rotenone 10µmol/L   9.8 ± 1.0  **  
Antimycin 10µmol/L   6.6 ± 3.3 **  
Benzbromarone 100µmol/L   55.4 ± 4.2 **  
    
Cerivastatin (µmol/L)    
 0.1   100.3 ± 9.2  
 1.0   91.5 ± 3.9  
 10.0   88.2 ± 6.7  
 100.0   87.9 ± 6.6  
 1000.0   51.1 ± 0.8  **  
    
Fluvastatin (µmol/L)    
 0.1   89.9 ± 7.0  
 1.0   85.7 ± 8.4  
 10.0   87.5 ± 4.0  
 100.0   85.6 ± 8.8  
 1000.0    49.6 ± 3.3  **  
    
Atorvastatin (µmol/L)    
 0.1   91.2 ± 11.8  
 1.0   82.7 ± 8.1  
 10.0   76.6 ± 8.4  
 100.0   78.1 ± 4.3  
    
Simvastatin (µmol/L)    
 0.1   84.1 ± 3.6  
 1.0   89.2 ± 16.4  
 10.0   72.5 ± 9.4  
 100.0   71.9 ± 6.0  
    
Pravastatin (µmol/L)    
 0.1   87.2 ± 6.9  
 1.0   83.0 ± 8.6  
 10.0   90.3 ± 1.5  
 100.0    87.1 ± 5.6  
 1000.0    78.6 ± 4.2  
    
*p < 0.05 vs. control; ** p < 0.01 vs. control 
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9.4.5. Beta-oxidation 
Measurement of β-oxidation in skeletal muscle cells reflects both, acid soluble products and 
formation of CO2 in the tricarboxylic acid cycle. Formation of CO2 represents 1 to 30% of the total 
amount of degradation products of palmitic acid, whereas 60 to 95% are found in the acid soluble 
fraction (38). Since the activity of the respiratory chain can be rate-limiting for mitochondrial fatty acid 
metabolism (39), acetoacetate was added to the incubations. Acetoacetate converts nicotinamide 
adenine dinucleotide (NADH) to NAD- by the action of β-hydroxybutyrate dehydrogenase (an enzyme 
of the mitochondrial matrix) and thereby eliminates the indirect impairment of mitochondrial β-oxidation 
by inhibitors of the electron transport chain (such as fluvastatin, simvastatin and atorvastatin).  
Cerivastatin (100µmol/L), fluvastatin, atorvastatin and simvastatin (each 200µmol/L) inhibited 
mitochondrial β-oxidation between 83 and 97%. Pravastatin revealed to have an inhibitory effect of 
50% at 400µmol/L (see table 4). The corresponding IC50 for the acid soluble fraction were: 14.4µmol/L 
for cerivastatin, 9.0µmol/L for fluvastatin, 29.0µmol/L for atorvastatin, 75.3µmol/L for simvastatin and 
303.6µmol/L for pravastatin. Since there is no ketogenesis taking place in muscle cells, we could 
convincingly show, that mitochondrial β-oxidation was impaired.  
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Table 4: Effects of cerivastatin, fluvastatin, atorvastatin, simvastatin and pravastatin 
on β-oxidation in isolated rat liver mitochondria. 
 Supernatant 
Activity (µUnits/mg) 
CO2 trapping 
Activity (µUnits/mg) 
   
Cerivastatin (µmol/l)   
 control  175.9 ± 72.6   32.0 ± 20 
 2  118.6 ± 29.0   26.0± 9 
 5  80.1 ± 41.7   12.6 ± 4 
 25  24.1 ± 17.9   9.0 ± 0.4 
 50  19.6  ± 16.1   2.2 ± 1.1 
 100  28.2 ± 25.1   0.9 ± 0.4 
   
Fluvastatin (µmol/l)   
 Control  12.7 ± 5.5   15.1 ± 9.9 
 5  9.0 ± 3.5   7.6 ± 3.8 
 25  0.7 ± 0.7 *   1.2 ± 0.2 
 50  0.6 ± 0.3 *   1.0 ± 0.2 
 100  0.1 ± 0.01 *   0.9 ± 0.1 
 200  0.4 ± 0.3 *   0.8 ± 0.2 
   
Atorvastatin (µmol/l)   
 Control  56.4 ± 30.8   20.6 ± 8.2 
 5  62.6 ± 41.8   13.4 ± 10.4 
 25  57.6 ± 28.4   16.0 ± 9.0 
 50  36.0 ± 25.6   11.1 ± 9.1 
 100  5.8 ± 2.3   1.3 ± 0.4 ** 
 200  13.3 ± 7.4   1.0 ± 0.5 ** 
   
Simvastatin (µmol/l)   
 Control  59.0 ± 20.7   35.5 ± 13.3 
 5  68.6 ± 28.8   21.1 ± 8.6 
 25  62.1 ± 33.7   22.8 ± 8.8 
 50  68.1 ± 50.8   11.3 ± 3.8 
 100  4.5 ± 2.4   1.5 ± 0.4 
 200  4.5 ± 3.3   1.5 ± 0.5 
   
Pravastatin (µmol/l)   
 Control  170.9 ± 64.7   24.7 ± 10.7 
 50  148.2 ± 29.5   30.2 ± 9.7 
 100  154.4 ± 39.5   27.2 ± 10.3 
 200  116.0 ± 14.9   17.3 ± 6.3 
 300  91.5 ± 16.5   15.4 ± 6.03 
 400  76.5 ± 51.2   11.8 ± 7.1-3 
*p < 0.05 vs. control; ** p < 0.01 vs. control.  
 
In order to further localize the inhibitory effect of β-oxidation in more detail, three enzymes of 
the β-oxidation were investigated: long-chain acyl-CoA dehydrogenase, ketothiolase and β-hydroxy-
acyl-CoA dehydrogenase. Acyl-CoA dehydrogenase, which is potentially rate-limiting for β-oxidation 
(24, 40), was assessed using palmitoyl-CoA as substrate. In the presence of 100µmol/L cerivastatin, 
or 200µmol/L fluvastatin, atorvastatin or simvastatin, or 400µmol/L pravastatin this enzyme was 
inhibited by 26.4%, 33.4%*, 27.7%*, 37.1%* or 19.9% respectively, reaching statistical significance for 
fluvastatin, atorvastatin and simvastatin.  
The enzyme β-hydroxy-acyl-CoA dehydrogenase was inhibited by 18.5%*, 21.6%*, 9.8%, 
16.3%* or 2.3% in the presence of 100µmol/L cerivastatin, or 200µmol/L fluvastatin, atorvastatin or 
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simvastatin, or 400µmol/L pravastatin, reaching statistical significance for cerivastatin, fluvastatin and 
simvastatin. The third enzyme assessed was β-ketothiolase, the last enzyme in the β-oxidation cycle, 
using acetyl-CoA as a substrate. This enzyme was not significantly inhibited by the statins.  
 
9.4.6. Mitochondrial swelling 
As already demonstrated, statins did cause a loss of the mitochondrial membrane potential. 
This led to the hypothesis that statins, like other drugs, act directly on mitochondria by inducing 
mitochondrial permeability transition (41), which in turn results in mitochondrial depolarization, 
cytochrome c release and swelling (42). In this process, the impermeability of the inner mitochondrial 
membrane is reversed (43), due to the formation of a proteinaceous pore (the mitochondrial 
permeability transition pore) which consists of several mitochondrial proteins (44). Cerivastatin, 
fluvastatin, atorvastatin and simvastatin were inducing mitochondrial swelling in a concentration 
dependent manner, whereas pravastatin did not cause an opening of the mitochondrial permeability 
transition pore (figure 5).  
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Figure 5: Mitochondrial permeability transition was monitored as a decrease in absorbance at 540nm. 
Upon pore opening, osmotically driven influx of water into the mitochondrial matrix leads to swelling of 
mitochondria, which causes a change in light scattering properties of mitochondria. Ca2+ was used as 
positive control. Among the tested statins only pravastatin did not induce mitochondrial permeability 
transition, whereas cerivastatin, fluvastatin, atorvastatin and simvastatin did cause a concentration-
dependent increase in mitochondrial size. * p < 0.05 vs. control; ** p < 0.01 vs. control. 
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9.4.7. Cytochrome c release  
As a consequence of the mitochondrial permeability transition pore opening, cytochrome c 
release from the mitochondrial intermembrane space into the cytoplasma should occur, which in turn 
can trigger the mitochondrial pathway of apoptosis (45-47). To confirm that mitochondria were indeed 
involved in apoptosis induction, cytochrome c release was determined in L6 cells. As shown in figure 
6, only pravastatin did not induce a release of cytochrome c, whereas for cerivastatin, fluvastatin, 
atorvastatin or simvastatin cytochrome c could be detected in the cytoplasm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Cytochrome c release caused by test compounds (each 100µmol/L) after 24 hours of exposure 
detected by immunocytochemistry: With 1% DMSO (panel A) pravastatin (panel G) no leakage into the 
cytoplasma occurred, as indicated by a punctual pattern of immunoreactivity. The nuclei remained 
visible. After treatment with benzbromarone (positive control, panel B), cerivastatin (panel C), fluvastatin 
(panel D), atorvastatin (panel E) or simvastatin (panel F) cytochrome c was released from the 
mitochondrial intermembrane space and shows a widespread immunoreactivity and covered nuclei, 
indicating cytoplasmatic localization.  
 
9.4.8. Determination of apoptosis  
Released cytochrome c can activate caspases and induce apoptosis (45, 48). DNA 
fragmentation occurring during apoptosis can be visualized by fluorescence microscopy upon staining 
with dyes intercalating with DNA. As shown in Figure 7, untreated cells showed an apoptosis rate of 
(A) (B) (C)
(D) (E) (F)
(G) 
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1.1%. At a concentration of 100µmol/L the proportion of apoptotic cells was 10% for cerivastatin, 8% 
for fluvastatin, 9% for atorvastatin, 8% for simvastatin or 1% for pravastatin.  
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Figure 7: Rat myoblasts were treated with test compounds at a concentration of 100µmol/L for 24 hours 
and subsequently stained with Hoechst 33342. The cell nuclei were visualized using fluorescence 
microscopy (panel (A) control, panel (B) atorvastatin, panel (C) pravastatin). Apoptotic cells were 
characterized by DNA condensation (panel B, arrow a) and DNA fragmentation (panel B, arrow b). Panel 
(D) summarizes the percentage of cells undergoing apoptosis. Pravastatin was the only statin not 
inducing apoptosis. * p < 0.05 vs. control; ** p < 0.01 vs. Control. 
 
Another hallmark of the early stages of apoptosis is the translocation of phosphatidylserine 
from the inner leaflet to the outer leaflet of the plasma membrane. Externalized phosphatidylserine can 
be detected using Annexin V, a protein with high affinity for this phospholipid. Cells were co-stained 
with PPI as a marker of cell membrane permeability, which increases during the later stages of 
apoptosis and also in necrosis. In necrotic cells, Annexin-V can enter the cells and bind to the 
phosphatidylserine exposed on the inner leaflet of the cell membrane as well, which might lead to 
false-positive results if Annexin-V was used as the only staining tool. Since PPI only enters cells with 
already disintegrated membranes, early apoptotic cells can be distinguished from late apoptotic and 
necrotic cells. Similar to the stainings with Hoechst 33342, flow cytometric analysis of the cells 
revealed progressive increase of the annexin V signal, thus early apoptotic cells, with increasing 
concentrations of cerivastatin, fluvastatin, atorvastatin and simvastatin. At 100µmol/L between 9 and 
17% of cells exposed to cerivastatin, fluvastatin, atorvastatin or simvastatin underwent early apoptotic 
stages. In contrast, only 3% of cells treated with pravastatin were annexin V positive (Figure 8). Fas 
(A) (B) 
b 
b 
a 
(C) 
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ligand, used as a positive control for apoptosis induction induced early apoptosis in 12% of cells. The 
late apoptotic and necrotic fraction of cells, represented by the population in the upper right quadrant, 
showed also a concentration-dependent increase. Between 20 and 25% of the cells treated with 
100µmol/L of a lipophilic statin were in this stage of cell death (data not shown). If necrosis was a 
major mode of cell death, the proportion of cells in this field should be considerably higher. These 
findings suggest that apoptosis is the major mode of cell death.  
 
(D) 
DM
SO
 1%
FAS
 Lig
and
Cer
ivas
tatin
Flu
vas
tatin
Sim
vas
tatin
Ato
rva
stat
in
Pra
vas
tatin
0
2
4
6
8
10
12
14
16
18
20
22
24 *
**
**
 
ea
rly
 a
po
pt
ot
ic
 c
el
ls
 [i
n 
%
 o
f t
ot
al
]
 Controls
 1µmol/L
 100µmol/L
 
Figure 8: Annexin V binding and PPI uptake by L6 cells. L6 cells were incubated for 24h at concentration 
of 1 and 100µmol/L of each test compound and subsequently stained with Annexin V and PPI. The 
samples were analyzed by flow cytometry (see panel A: control, panel B: fluvastatin 1µmol/L, panel C: 
fluvastatin 100µmol/L).The lower left quadrant represents the unstained, thus viable cells. The cells in 
the lower right quadrant are undergoing early apoptosis and are stained only with Annexin V. The upper 
right quadrant represents the double stained cells undergoing necrosis or later stages of apoptosis. 
Under control conditions, the vast majority of cells were located in the lower left part (panel A), whereas 
fluvastatin was inducing apoptosis in a concentration dependent manner (panel B: fluvastatin 1µmol/L, 
panel C fluvastatin 100µmol/L). Panel D: percentage of cells undergoing early stages of apoptosis 
relative to control values. Fas ligand was used as positive control for apoptosis. Data are given as mean 
± SEM of at least three individual experiments. *p<0.05 vs 1% DMSO, **p<0.01 vs 1% DMSO. 
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9.5. Discussion 
In the present study, we could demonstrate that there is an important difference between 
hydrophobic and hydrophilic statins in their toxic effect on isolated skeletal muscle mitochondria and 
whole skeletal muscle cells. We showed that the effects of hydrophobic statins on cell viability and 
mitochondrial function was entirely different from those for a hydrophilic statin. It was previously shown 
that hydrophilic statins are distributed much more selectively in hepatic cells than hydrophobic ones. 
Extrahepatically, hydrophilic molecules cannot penetrate the lipid bilayer and thus cannot cause 
intracellular events, whereas the hepatic cell membrane contains organic anion transporters, which 
transport hydrophilic statins into the hepatic cytoplasma. In contrast, lipophilic statins can enter hepatic 
and extrahepatic cells and therefore exert their effect in peripheral tissues, such as skeletal muscle (5, 
6). Our findings in skeletal muscle cells are consistent with data in the literature for different cell types, 
such as endothelial cells (49), hepatocytes (50), cardiac myocytes (51) or vascular smooth muscle 
cells (52, 53). However, consistent results were obtained with disrupted mitochondria, indicating that 
the differences in distribution patterns and permeabilities does not entirely account for the differences 
in toxicity between hydrophilic and lipophilic statins. 
It could convincingly be shown that the injury in skeletal muscle induced by lipophilic statins is 
due to apoptosis. It has been demonstrated that hydrophobic statins cause mitochondrial dysfunction, 
which resulted in a dissipation of the electronic potential across the inner mitochondrial membrane and 
mitochondrial permeability transition. The inner mitochondrial membrane potential is generated 
through the activity of proton pumps of the respiratory chain and is the driving force for ATP 
generation by the F1F0-ATPase, thus essential for cell energy supply. The mitochondrial membrane 
permeabilization is considered to be a point-of-no-return of apoptotic cell death (48, 54). Mpt 
culminates in a loss of the barrier function of the outer mitochondrial membrane and the consequent 
release of apoptosis inducing proteins, such as cytochrome c from the mitochondrial intermembrane 
space. The induction of the mitochondrial apoptotic pathway in this case might be further enhanced by 
the fact, that the cell may lack of prenylated (farnesylated or geranylated) small GTP-proteins, such as 
Rho, Ras or Rac, which promote cell maintenance, cell survival and attenuate apoptosis (3, 49, 55, 
56). Apoptosis is a crucial mechanism designed to maintain tissue structure. If inappropriately 
activated, apoptosis can produce pathological conditions. In the case of statin therapy, apoptosis 
induction might be responsible of the slowdown for generation of atherosclerotic plaques by inhibiting 
proliferation of vascular smooth muscle cells, whereas apoptosis in skeletal muscle under statin 
treatment could produce the observed muscle damage (3). These findings further confirm a 
hypothesis mentioned in the literature (10), that myotoxicity is, at least in part, a direct consequence of 
the inhibition of the cholesterol synthesis pathway. So adverse effect and desired effect rely on the 
same mode of action. Therefore, it will be most difficult to distinguish the myotoxic unwanted effect 
from the wanted reduction of cholesterol synthesis.  
Our findings support the results of Kubato et al (50) in hepatocytes. Compatible with our results 
the authors showed that lipophilic statins did cause an apoptotic injury in hepatocytes. Pravastatin did 
neither reduce cell viability nor induce apoptosis. In this case, it is unlikely that the lack of hepatotoxic 
effect of pravastatin results from the limited access of this compound to cell, since a reduction of 
cholesterol synthesis could be shown. Maybe a combination of factors rather than a single reason like 
limited access of pravastatin to the cell interior explains lack of toxicity.  
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As mentioned before, all hydrophobic statins tested did induce apoptosis in skeletal muscle 
cells. They all showed a consistent pattern of effects, only varying, albeit to a minor degree, in their 
toxic potential. For the uncoupling capacity, however, among all the statins measured only cerivastatin 
showed uncoupling of oxidative phosphorylation. Uncoupling seems not to be related to the inhibitory 
concentrations of HMG CoA reductase, since atorvastatin and simvastatin show similar IC50 values to 
those of cerivastatin (5). It has recently become evident that the risk of severe myotoxic events with 
cerivastatin was markedly higher than for other statins (4, 5, 57) and has demonstrated that the safety 
of stains is not a class effect (58). If mitochondrial uncoupling occurs, protons are transported into the 
mitochondrial matrix by bypassing the F1F0-ATPase. As a consequence, the mitochondrial membrane 
potential is decreased, cellular ATP can be depleted and in the long run, cytotoxicity can be induced 
(42). Based on this, it can be assumed, that occurrence of uncoupling for cerivastatin, in addition to 
the other toxic principles, aggravates the toxicity and eventually translates into an increased in vivo 
incidence of cerivastatin induced myotoxicity.  
Having measured the muscle toxicity of statins in vitro, the question arises, to what extent our 
findings translate into the in vivo situation. The data available about plasma concentrations of statins 
after oral administration is not consistent (1, 8) and one might argue that toxicity of hydrophobic statins 
in vitro occurred at concentrations higher than the plasma concentrations achieved under statin 
therapy. In this regard, two points should be considered. Firstly, the volume of distribution of lipophilic 
statins clearly indicates that peripheral tissue binding is extensive (see table 1). Consequently, the 
mass transport of lipophilic transport into tissue is high, which is in accordance with their high 
membrane permeability due to the nonpolar nature of the drugs. So it is highly likely that 
concentrations in skeletal muscle are markedly higher than the concentrations measured in the 
plasma. Secondly, a concept known for other mitochondrial toxins such as salicylate or valproate (59) 
might apply for myotoxicity and statins. Inherited metabolic disorders, e.g. defects in mitochondrial 
functions such as β-oxidation, can be causal in or contribute to toxic processes (60). If a patient 
treated with statins has an underlying mitochondrial defect and is treated with a statin as a 
mitochondrial toxin, this patient might be more susceptible to myotoxicity, which may get apparent at 
lower concentrations. It is interesting to note, that stains not only inhibit β-oxidation, as we could show 
in our study, but they also undergo β-oxidation themselves on the hydroxyheptanoic acid side chain. 
Metabolites shortened by two or in case of pravastatin even four carbon units, resulting in pentanoic 
derivatives or propanoic products, respectively, have been observed in vivo (61-63). Lipophilic statins 
basically autoinhibit this metabolic pathway, whereas with pravastatin, β-oxidation is not affected. 
Certainly, this inhibition itself is not the reason for the observed toxicity of hydrophobic statins, 
however, the question is what happened, if this inhibition coincides with an underlying mitochondrial 
defect in β-oxidation. It is possible, that in this case, the statin induced inhibition and the inherited 
defect raise to apparent toxicity.  
In conclusion, lipophilic statins reduced cell viability and did impair mitochondrial functions, 
such as β-oxidation and respiratory chain, which are essential for cell survival. As a consequence, the 
mitochondrial membrane potential dissipated, the mitochondrial permeability transition pore opened 
and apoptosis inducing factors were released. Mitochondrial dysfunction and the subsequent release 
of mitochondrial proteins are tightly linked to the process of programmed cell death, also called 
apoptosis. Consistently, induction of apoptosis could be convincingly demonstrated, since lipophilic 
statins did cause DNA fragmentation and an increase in annexin V stained cells. Myotoxicity, in 
particular rhabdomyolysis in response to lipophilic statin treatment can be explained by mitochondrial 
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toxicity and the subsequent induction of apoptosis of myocytes. Underlying mitochondrial diseases 
may represent an additional risk factor for statin-induced rhabdomyolysis.  
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10.1. Abstract 
Background: High doses (≥ 500 mg/m2) of cyclophosphamide are known to cause 
venoocclusive disease (VOD). We recently observed a patient treated with immunosuppressive 
cyclophosphamide doses (100 mg/day) and roxithromycin developing VOD. Since roxithromycin 
inhibits cytochrome P450 (CYP) 3A4 and P-glycoprotein, the patient may have been exposed to 
higher cyclophosphamide and/or cyclophosphamide metabolite concentrations. 
Methods: The effect of roxithromycin on the metabolism and toxicity of cyclophosphamide was 
studied using a human endothelial cell line and human hepatic microsomes. 
Results: While cyclophosphamide and roxithromycin were individually almost not toxic on 
endothelial cells, their combination was toxic. While roxithromycin did not favor the generation of toxic 
metabolites from cyclophosphamide, it led to cyclophosphamide accumulation due to inhibition of both 
CYP3A4 and CYP2B6. Although roxithromycin inhibited P-glycoprotein, this was not the mechanism 
for increased cyclophosphamide toxicity, since other P-glycoprotein inhibitors were not toxic. In the 
presence of roxithromycin, cyclophosphamide induced apoptosis in endothelial cells, most probably by 
mitochondrial membrane permeability transition and release of cytochrome c. 
Conclusions: The combination cyclophosphamide and roxithromycin, but not the individual 
compounds, is toxic on endothelial cells. Apoptosis is the principle mechanism of the toxicity of this 
combination, whereas inhibition of P-glycoprotein and formation of toxic metabolites are unlikely.  
 
10.2. Introduction 
Cyclophosphamide is an alkylating drug used widely in the treatment of cancer and 
autoimmune diseases (1, 2). It requires hepatic cytochrome P450 (CYP)-catalyzed transformation to 
generate alkylating metabolites. The current understanding of the metabolism of cyclophosphamide is 
presented in Figure 1 (3). Both activation and deactivation of cyclophosphamide are mediated by 
several CYP isozymes. Roughly, the activation pathway is mainly mediated by CYP 2B6 and to a 
smaller extent by CYP 3A4, whereas the inactivation is mediated almost exclusively by CYP 3A4.  
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Figure 1: Cytochrome P450 (CYP)-catalyzed metabolism of cyclophosphamide via the 4-hydroxylation 
(drug activation) and N-chlorodeethylation (drug inactivation) pathways. CPA = cyclophosphamide, AC = 
acrolein, CA = 2-chloroacetaldehyde. 
 
Hepatic venoocclusive disease (VOD) is characterized by a fibrous obliteration of the central 
and of small sublobular veins. VOD is a well described complication after bone marrow 
transplantation, and can be caused by high doses of cyclophosphamide (≥ 500 mg/m2) (4-6). The 
incidence of VOD following the cyclophosphamide/bulsufan regimen for preparation to bone marrow 
transplantation is between 27 and 36% (5, 6). So far, no data have been published about the induction 
of VOD with low dose cyclophosphamide therapy (1-2 mg/kg) used for the treatment of autoimmune 
diseases. We have recently observed a patient treated with 100 mg cyclophosphamide and with 300 
mg roxithromycin per day who developed VOD (7). Roxithromycin is a semisynthetic macrolide 
antibiotic with in vivo antibacterial activities similar to erythromycin but with a longer duration of action 
and a higher potency (8). Several macrolide antibiotics and its metabolites, including troleandomycin, 
erythromycin, clarithromycin and roxithromycin, have been shown to inhibit CYP3A catalytic activities 
by forming inactive P450-Fe2+ metabolite complexes after activation. Inhibition of CYP 3A4 represents 
the major mechanism of drug-drug interactions between macrolide antibiotics and other drugs (9). To 
the best of our knowledge, no data is available about the inhibitory effects of macrolide antibiotics on 
CYP2B6. 
The aim of the present study was to investigate the mechanisms by which VOD was caused in 
the patient treated with cyclophosphamide and roxithromycin as described above. Considering that 
roxithromycin is an inhibitor of CYP3A4, we speculated that there might be a shift towards CYP2B6-
mediated activation of cyclophosphamide. The patient’s liver and, in particular, hepatic endothelial 
cells may therefore have been exposed to higher levels of toxic metabolites than expected from the 
dose of cyclophosphamide administered. By the use of cultured human umbilical endothelial cells, we 
could confirm the toxicity of the cyclophosphamide/roxithromycin combination and were able to 
investigate the underlying mechanisms of cell death. 
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10.3. Materials and Methods 
10.3.1. Materials 
All chemicals used were of best quality available and purchased from Merck (Darmstadt, 
Germany), Fluka or Sigma (Buchs, Switzerland). Fetal calf serum and all culture media were from 
Gibco (Paisley, UK), 96-well microtiter plates were from Costar (Cambridge, MA), Optiplate-96 were 
from Packard (Zürich, Switzerland) and the Lab-Tek chambered coverglass system from Nunc 
(Napperville, IL, USA).  
 
10.3.2. Cell lines and cell culture conditions 
The murine monocytic leukemia cell line P388/MDR was obtained from Dr. C. Geroni 
(Pharmacia & Upjohn, Centro Ricerche e Sviluppo, Milano, Italy). The cell line was cultured as 
described previously (10). The human umbilical vein endothelial cell line ECV 304 (11) was cultured in 
DMEM (Gibco, Paisly, UK) supplemented with 10% heat-inactivated fetal calf serum, 110µg/mL 
sodium pyruvate, 1mg/mL-glucose, 2µmol/mL L-glutamine, 0.40 µg/mL pyridoxine, 100U/mL penicillin 
and 100 µg/mL streptomycin. The CCRF-MDR cell line was cultured in RPMI glutamax 1640 (Gibco, 
Paisly, UK) supplemented with 10% heat-inactivated fetal calf serum, 50µg/mL gentamycin and 
1µg/mL vincristine. One day prior to the experiments, cells were switched to vincristine-free medium. 
Culture conditions for all lines were 5% CO2/95% air atmosphere at 37°C. 
 
10.3.3. Solutions and incubations 
Cyclophosphamide stock solutions were dissolved in phosphate-buffered saline (PBS, pH 7.4), 
roxithromycin in DMSO. The DMSO concentration did not exceed 1% in any incubation. To all 
incubations, the same amount of DMSO was added as for the incubations containing roxithromycin. 
 
10.3.4. LDH leakage assay 
Cell injury was assessed as the release of lactate dehydrogenase (LDH) into the supernatant 
and compared to cells lysed with Triton X-100 (final concentration 0.8%). LDH activity was analyzed 
as described previously (12) and calculated as described by Huang (13).  
 
10.3.5. P-glycoprotein 
P-glycoprotein expression: P-glycoprotein (P-gp) was visualized by Western blot analysis using 
the monoclonal antibody C219 (Alexis, Lausen, Switzerland). The cells were lysed in a buffer, pH 6.8, 
composed of 5mmol/L EDTA, 20mmol/L Tris HCl, 1% Triton and a protease inhibitor mixture (Roche 
AG, Basel, Switzerland) using a syringe. Proteins were electrophoresed (1 h, 120V) in the presence of 
molecular weight standards (Gibco, Paisly, UK) on a 6% polyacrylamide sodium dodecyl sulfate (SDS) 
gel using a running buffer containing 25mmol/L Tris, 192mmol/L glycine, 0.1% SDS, pH 8.3. 
Electrophoresed proteins were transferred onto a nitrocellulose filter (Hybond ECL, Apbiotech, 
Uppsala, Sweden) for 1 h (120mA) using a wet transfer cell (Biorad, Hercules, CA, USA). After the 
transfer, the membranes were incubated for 2 hours with the primary monoclonal antibody C219 
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(0.5µg/mL). After repeated washing, a peroxidase conjugated sheep anti-mouse antibody (Amersham 
Life Science, Little Chalfont, UK) was added for 45min at room temperature. The immunoreactive 
bands were visualized by enhanced chemiluminescence (ECL, Amersham International, Little 
Chalfont, UK) according to manufacturer’s protocol. 
Efflux assay: The impact of several test compounds on P-gp was measured in P-gp-
overexpressing P388/MDR cells as described previously (10). 
 
10.3.6. In vitro microsomal assay 
Incubations were carried out in open tubes containing 100µL (total volume) of 100mmol/L 
potassium phosphate buffer (pH 7.4), NADPH 1mmol/L, 3mmol/L MgCl2, 100µg human microsomal 
protein, and 25mmol/L cyclophosphamide. Reaction mixtures were incubated at 37°C for 15 minutes 
in a shaking water bath and stopped by the sequential addition of 40µL of ice-cold 5.5% ZnSO4, 40µL 
of saturated barium hydroxide, and 20µL of 10mmol/L HCl. After spinning at 10’000g for 20min, the 
supernatant was split into two 80µL aliquots for the determination of 2-chloroacetaldehyde and 
acrolein, respectively.  
 
10.3.7. Quantification of cyclophosphamide metabolites 
Sample preparation: 2-Chloroacetaldehyde was derivatized with adenosine (14). After the 
derivatization, 1-N6-ethenadenosine-3’,5’-cyclic monophosphate was added as internal standard (final 
concentration 500µmol/L). Acrolein was derivatized with 3-aminophenol as described elsewhere (14).  
Solid phase extraction: Solid phase extraction was performed using disposable reversed-phase 
macropolymer sorbent columns (OASIS HBL 30mg, Waters Corporation, MA, USA). After 
preconditioning with 1mL of 5% methanol in water (v:v) followed by 1mL H2O, samples (400µL) were 
loaded, washed with 1mL 5% methanol and eluted with 1mL acetonitril for 2-chloroacetaldehyde or 
1mL methanol for acrolein, respectively. The eluate was collected in glass tubes and evaporated to 
dryness at 55°C. The residues were dissolved in 400µL H2O, vortexed for 1min and centrifuged at 
100g for 1 minute. 
HPLC analysis: For the determination of 2-chloroacetaldehyde, samples (25µL) were 
chromatographed on a Luna phenyl-hexyl-column, 150 x 4.60mm (5µm particles, Phenomenex, CA, 
USA). Samples were eluted isocratically with 7.5% methanol in potassium phosphate buffer (50mM, 
pH 3.5) with a flow rate of 0.8ml/min. The fluorescent product 1-N6-ethenadenosine was eluted at 
12min, the internal standard at 22min. Detection was achieved using an excitation wavelength of 
270nm and an emission wavelength of 411nm. Analysis of acrolein was performed on a C18 reversed-
phase column, 150 x 4.6mm (5µm particles, LUNA, Phenomenex) as described elsewhere (14). 
 
10.3.8. Determination of apoptosis  
Assays were performed with confluent adherent endothelial cells grown on poly-D-lysine 
coated (0.1mg/ml, 30min) glass slides. Cells were incubated with cyclophosphamide and 
roxithromycin individually and in combination as described in the Result section. Cells were treated for 
24h with different concentrations of test compounds, incubated for 30 minutes at room temperature in 
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Hoechst 33342 dye (50µmol/L in PBS) and visualized by fluorescence microscopy (Olympus IX 50, 
Hamburg, Germany). 
 
10.3.9. Cytochrome c immunocytochemistry 
Cells were grown in an 8 chamber-slide (coated with poly-D-lysine) for 20 hours at 37°C and 
then treated with the test compounds for 24 hours. Afterwards, cytochrome c was visualized using an 
anti-cytochrome c antibody and an anti-sheep IgG antibody-conjugated Cy3TM (Jackson Laboratories, 
West Grove, PA, USA) according to the manufacturer’s protocol. 
 
10.3.10. Mitochondrial membrane potential 
Cells were detached from cell culture flask by adding 10mmol/L EDTA in PBS. After filtration, 
cells were adjusted to a density of 0.5 x 106 cells/ml and incubated for 10 min in the dark in complete 
medium containing 4µg/mL JC-1 (Molecular Probes, Eugene, Oregon, USA). Flow cytometry was 
performed by FACS analysis (Calibur, Becton and Dickinson, San José, CA, USA). Changes in ∆Ψm 
were measured by monitoring JC-1 fluorescence at 590nm. Benzbromarone, a substance that induces 
depolarization of the mitochondrial membrane potential, was used as a positive control. 
 
10.3.11. Statistical analysis 
Data are presented as mean ± SEM. Comparison within groups were performed by one-way 
ANOVA (analysis of variance). If the ANOVA revealed a statistical significance, Dunnett’s procedure 
was performed as a secondary test. P < 0.05 was considered to be statistically significant.  
 
10.4. Results 
10.4.1. In vitro cytotoxicity 
Cellular toxicity of cyclophosphamide and roxithromycin was investigated by treating human 
umbilical vein endothelial cells with various concentrations of test compounds for 24 hours. As shown 
in Figure 2, the incubation with the individual substances cyclophosphamide or roxithromycin did not 
reveal any toxicity up to 500µmol/L. A significant toxicity was observed only in incubations containing 
both cyclophosphamide (variable concentrations) and roxithromycin (constant at 500µmol/L) at 
concentrations above 50µmol/L of cyclophosphamide. In comparison, erythromycin (500µmol/L), 
another macrolide antibiotic used as a control, was neither toxic individually nor in combination with 
cyclophosphamide. 
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Figure 2: Cytotoxicity of the test compounds on the human endothelial cell line ECV 304 as assessed by 
LDH leakage. Units are the percentage from total LDH activity (activity after cytolysis with 0.8% Triton X-
100). Data are given as mean ± SEM of at least three individual experiments. ERY = erythromycin, CPA 
= cyclophosphamide, ROX = roxithromycin. *P<0.05 vs. control, **p<0.01 vs. control. 
 
Cyclophosphamide is a substrate of several CYPs, and it is known that roxithromycin and its 
metabolites are inhibitors of CYP 3A4. Additionally, it is important to note that the CYP system, 
especially the isoform CYP3A, has overlapping substrate specificity with P-gp (15, 16). Following 
these considerations, we decided to study the effect of roxithromycin on P-gp and on CYP-associated 
metabolism of cyclophosphamide, since interactions of roxithromycin with these proteins could 
explain, at least in part, the augmented cytotoxicity of cyclophosphamide. 
 
10.4.2. P-glycoprotein 
The expression of P-gp in endothelial cells was demonstrated by Western blotting. As shown in 
Figure 3, ECV 304 cells show immunoreactivity in the molecular weight range of 150kDa, the 
molecular weight of P-gp. A similar band was observed in P-gp-expressing CCRF-MDR cells, which 
served as a positive control. 
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Figure 3: Western blot analysis of P-glycoprotein expression in ECV 304 cells. CCRF-par and CCRF-
MDR cells are human T-lymphoblastoid cell lines from which lysates were used as negative or positive 
control, respectively. P-glycoprotein was detected by the monoclonal antibody C219. Immunoreactive 
protein was detected in the molecular weight range of 150kD with lysates from CCRF-MDR and ECV 
304 cells, but not from CCRF-par cells, which are devoid of P-glycoprotein. 
 
To investigate the test substances for their P-gp-modulating properties, we measured 
rhodamine 123 (R123) efflux in a P-gp overexpressing cell line using a microtiter-based fluorimetric 
assay. The R123-assay revealed that roxithromycin inhibited P-gp with an IC50 of 194µmol/L (Figure 
4). In contrast, neither cyclophosphamide nor the two metabolites acrolein or 2-chloroacetaldehyde 
showed an inhibitory effect on P-gp (data not shown). Despite cyclophosphamide did not inhibit P-gp, 
it could still be a substrate of this transport protein, since P-gp has a very broad substrate specificity. 
In that case, inhibition of P-gp with roxithromycin should increase the intracellular cyclophosphamide 
concentration and cellular toxicity. However, an increase in the toxicity of cyclophosphamide could not 
be demonstrated by co-incubation with the P-gp inhibitors erythromycin (Figure 2) or verapamil (data 
not shown). 
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Figure 4: P-glycoprotein (P-gp) inhibition by roxithromycin as assessed by a microtiter plate based 
fluorimetric assay. P388/MDR cells were preloaded with the P-gp substrate rhodamine 123. Rhodamine 
123 efflux was monitored in the presence of increasing concentrations of roxithromycin. The 
experiments reveal an inhibition of rhodamine 123 efflux (indicating inhibition of P-gp) with increasing 
roxithromycin concentrations (IC50 194µmol/L). Data are expressed as a percentage of the rhodamine 
123 efflux in absence of inhibitor. Values represent means ± SEM for at least n=3 determinations. 
 
10.4.3. In vitro microsomal metabolism 
Incubations were performed in the presence or absence of roxithromycin at various 
concentrations. As a reference for CYP3A4 inhibition, ketoconazole was used. The CYP3A4 specificity 
of ketoconazole is concentration-dependent. At concentrations >2µmol/L CYP isozymes other than 
CYP3A4 are also inhibited (17). The ketoconazole concentrations used in the experiments therefore 
covered CYP3A4 specific (0.5µmol/L) as well as unspecific concentrations (5 and 50µmol/L). 
Analysis of the 2-chloroacetaldehyde and acrolein pathways of cyclophosphamide revealed 
that the rate of metabolite production was linear between 0 and 20 minutes. The CYP3A4-mediated 2-
chloroacetaldehyde pathway was inhibited by roxithromycin with an IC50 of 24µmol/L, whereas 
ketoconazole inhibited this pathway with an IC50 of 0.09µmol/L (see Table 1). The CYP2B6-mediated 
acrolein pathway was inhibited by roxithromycin with an IC50 of 107µmol/L whereas the corresponding 
IC50 for ketoconazole was 50µmol/L. As shown in Table 1, the ratio of the IC50 for CYP2B6 and 
CYP3A4 is much higher for ketoconazole than roxithromycin, showing a higher selectivity for CYP3A4 
for ketoconazole. In agreement with this observation, at 0.5µmol/L ketoconazole, an increase in 
product formation by the acrolein pathway could be observed, suggesting a shift from the CYP3A4-
driven 2-chloroacetaldehyde to the more CYP2B6-driven acrolein pathway (Figure 5). This 
phenomenon was not observed with roxithromycin, since the inhibition of CYP3A4 by roxithromycin is 
much less specific as compared to ketoconazole (Table 1 and Figure 5). The results of the in vitro 
experiments therefore indicate that selective inhibition of CYP3A4 indeed increases 
cyclophosphamide metabolism by CYP2B6, but that roxithromycin inhibits both pathways 
simultaneously.  
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Table 1: IC50 values for both metabolic pathways of cyclophosphamide (see Figure 1) in 
the presence of roxithromycin or ketoconazole as inhibitors. The assay conditions are 
described in the Method section. Mean ± SEM of at least 3 experiments. 
 Roxithromycin (µmol/L) Ketoconazole (µmol/L) 
CA-pathway 
(CYP3A4) 
24.2 ± 10.4 0.1 ± 0.06 
AC-pathway 
(CYP2B6) 
107 ± 32 13.1 ± 6.4 
CYP2B6/CYP3A4 4.42 131 
 
 
Figure 5: Effect of roxithromycin and ketoconazole on cyclophosphamide metabolism by human liver 
microsomes. N-chlorodeethylation (CA pathway, panel A) and 4-hydroxylation (AC pathway, panel B) 
were determined as described in Materials and Methods at a cyclophosphamide concentration of 
25mmol/L. As a negative control, microsomes were incubated in the absence of NADPH. As shown in 
panel A, ketoconazole inhibits the CYP3A4-mediated CA pathway in all concentrations tested (IC50 
0.1µmol/L). Roxithromycin is an equally effective inhibitor from 50µmol/L upwards with an IC50 of 
24µmol/L. As shown in panel B, ketoconazole is a far less potent inhibitor of the CYP2B6-mediated AC 
pathway, inhibiting acrolein formation with an IC50 of 13µmol/L. At the lowest concentration of 
ketoconazole (0.5µmol/L), the formation of AC appears to be increased as compared to control values 
(not reaching statistical significance). Roxithromycin inhibits this pathway with an IC50 of 102µmol/L, 
which is only slightly higher than for the CA pathway. CPA = cyclophosphamide, Keto = ketoconazole, 
ROX = roxithromycin. *P < 0.05 vs. CPA 500µmol/L, ** p < 0.01 vs. CPA 500µmol/L. Data are given as 
mean ± SEM of at least three individual experiments. 
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10.4.4. Mechanism of cell death 
Since increased toxicity of cyclophosphamide in the presence of roxithromycin could not be 
explained by inhibition of P-gp or CYP3A4 by roxithromycin, we decided to investigate the mechanism 
of cell death in more detail, first looking for markers of apoptosis. As illustrated in Figure 6, staining 
with Hoechst 33342 revealed many endothelial cells with fragmented or condensed nuclei when 
incubated with cyclophosphamide and roxithromycin. In contrast, cells incubated with the individual 
compounds did not show such changes. Cell counts revealed that 27% of the cells incubated with 
500µM cyclophosphamide and roxithromycin underwent apoptosis, while this was the case for only 
0.7% of the cells in the presence of 500µmol/L cyclophosphamide or 0% in the presence of 500µmol/L 
roxithromycin. These findings are consistent with those obtained for LDH leakage, and demonstrate 
that the combination of roxithromycin and cyclophosphamide induces apoptosis of endothelial cells. 
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Figure 6: Induction of apoptosis by cyclophosphamide and roxithromycin. ECV 304 cells were treated 
with test compounds at the concentrations indicated in the Figure. After 20h of exposure, the cells were 
stained with Hoechst 33342 for 15min and analyzed using fluorescence microscopy. Apoptotic cells 
were characterized by DNA condensation. (A) cyclophosphamide, (B) roxithromycin, (C) 
cyclophosphamide + roxithromycin, (D) percentage of cells with DNA condensation relative to the total 
amount of cells. Methotrexate was used as a positive control. ERY = erythromycin, CPA = 
cyclophosphamide, ROX = roxithromycin. * P < 0.05 vs. DMSO 1%; ** p < 0.01 vs. DMSO 1%. Data are 
given as mean ± SEM of at least three individual experiments. 
 
(A) (C) (B) 
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10.4.5. Mechanism of apoptosis 
Since mitochondrial damage has been recognized as an important mechanism of drug-induced 
toxicity (18), we investigated whether mitochondria are involved in the 
cyclophosphamide/roxithromycin-mediated toxicity. If mitochondrial pathways of apoptosis induction 
were initiated, a release of cytochrome c from the mitochondrial intermembrane space into the 
cytoplasm should occur (19-21). As shown in Figure 7, only the combination 
cyclophosphamide/roxithromycin, but not the individual substances, lead to a release of cytochrome c 
from the mitochondrial intermembrane space into the cytoplasm, suggesting a mitochondrial 
contribution to apoptosis. 
 
 
Figure 7: Mitochondrial leakage of cytochrome c in endothelial cells treated for 20 hours with test 
compounds. In the presence of 1% DMSO (panel A), 500µmol/L cyclophosphamide (panel B) or 
500µmol/L roxithromycin (panel C), cytochrome c stays within mitochondria (granular pattern all over the 
cells with the nuclei clearly visible) and no leakage into cytoplasm occurs. After treatment with the 
combination of 500µmol/L cyclophosphamide and roxithromycin (panel D), cytochrome c is leaking out 
of the mitochondrial intermembrane space into the cytoplasm. Cytochrome c immunoreactivity is now 
spread diffusely over the cells, covering the nuclei (30). 
 
To answer the question whether mitochondria are damaged in the presence of 
cyclophosphamide and roxithromycin, we next studied the potential across the inner mitochondrial 
membrane. Functional alterations of mitochondria are usually manifested by the changes in this 
potential, which can therefore be used as an indicator for mitochondrial damage (22). As shown in 
Figure 8, cyclophosphamide or roxithromycin did not affect the mitochondrial membrane potential up 
to a concentration of 500µmol/L. The combination of cyclophosphamide and roxithromycin, however, 
was associated with a partial loss of the mitochondrial membrane potential (Figure 8). At 250µmol/L 
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roxithromycin and 500µmol/L cyclophosphamide, the potential of approximately 20% of the 
mitochondria was dissipated. 
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Figure 8: Effect of cyclophosphamide and roxithromycin on the mitochondrial membrane potential. The 
mitochondrial membrane potential was determined by an ion distribution technique. Endothelial cells 
were loaded with the cationic dye JC-1 that is taken up by mitochondria according to the mitochondrial 
membrane potential, changing the fluorescence emission from red to green. Cells with polarized 
mitochondria are located in the left field (green fluorescence), whereas cells with dissipated potential are 
found in the right field (red fluorescence). Panel A: cyclophosphamide 500µmol/L, B: roxithromycin 
500µmol/L, C: cyclophosphamide and roxithromycin (each 500µmol/L), D: benzbromarone 100µmol/L 
(used as a positive control), E: Results given as the percentage of cells in the right field from total cells 
tested. Results are expressed as mean ± SEM of at least three individual experiments. CPA = 
cyclophosphamide, ROX= roxithromycin. *P < 0.05 vs. control, **p < 0.01 vs. control. 
 
 
10.5. Discussion 
Clinical experience from patients with bone marrow transplantation shows that VOD can occur 
after treatment with high doses of cyclophosphamide. So far, there is no publication about induction of 
VOD with low dose cyclophosphamide as used in patients with autoimmune diseases. Since the 
patient described by us (7) was also treated with roxithromycin, a known inhibitor of CYP 3A4 and P-
gp, it was assumed that the presence of roxithromycin aggravated cyclophosphamide toxicity. Due to 
the vascular origin of VOD (4), we decided to study first the toxicity of cyclophosphamide and 
roxithromycin using a human endothelial cell line. Our investigations showed that neither 
A B C D 
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cyclophosphamide, nor roxithromycin, induced significant cell death up to a concentration of 
500µmol/L. Cell damage occurred only, when cyclophosphamide was combined with roxithromycin. 
Since roxithromycin inhibits P-gp, which is expressed in endothelial cells, inhibition of P-gp 
could be a reason for increased toxicity of cyclophosphamide in the presence of roxithromycin. 
However, other P-gp inhibitors, e.g. erythromycin and verapamil, did not increase the toxicity of 
cyclophosphamide on endothelial cells, showing that inhibition of the export of cyclophosphamide or 
toxic metabolites from endothelial cells could not explain increased toxicity of cyclophosphamide in the 
presence of roxithromycin. Other mechanisms had therefore to account for the toxicification of 
cyclophosphamide by roxithromycin. 
Cyclophosphamide is a prodrug requiring hepatic activation. Roxithromycin and its metabolites 
are known inhibitors of CYP3A4 (9), an enzyme involved in the cyclophosphamide inactivation 
pathway (Figure 1). The activation pathway is primarily driven by CYP2B6, generating the active 
compounds as well as known toxic metabolites (3). We therefore hypothesized that the increase in 
cyclophosphamide toxicity in combination with roxithromycin could be due to shifting of 
cyclophosphamide metabolism from inactivation by CYP3A4 to toxification by CYP2B6. In our 
experiments, we could confirm this concept by using ketoconazole, which is a more specific inhibitor of 
CYP3A4 than roxithromycin (Table 1). In comparison, in the presence of roxithromycin, both pathways 
of cyclophosphamide metabolism were inhibited at all concentrations tested. These results suggest 
that also under in vivo conditions, both CYP3A4 and CYP2B6 are inhibited simultaneously in the 
presence of roxithromycin. By this mechanism, roxithromycin may have increased the exposure of the 
patient’s liver to cyclophosphamide, but at the same time decreased the pharmacological activity of 
the drug and also the exposure to toxic metabolites. The inhibition of CYP isozymes by roxithromycin 
could therefore not explain increased vascular toxicity of cyclophosphamide in the presence of 
roxithromycin. 
Apart from the influence of roxithromycin on cyclophosphamide metabolism, another aspect 
concerning roxithromycin may be taken into consideration. CYP2B6 is one of the less well 
characterized CPY isozymes, probably because it was initially thought to be expressed only at low 
levels (23). Recently, a number of structurally diverse, but frequently used drugs have been 
recognized as CYP2B6 substrates, among them bupropion, ifosphamide, nicotine, lidocaine, 
verapamil, artemisinin and propofol. Since we could show that roxithromycin inhibits CYP2B6, drug-
drug interactions between roxithromycin and drugs metabolized by CYP2B6 have to be expected. 
By investigating the mechanism of cell death induced by the combination of cyclophosphamide 
and roxithromycin, we could show that this drug combination was causing apoptosis in endothelial 
cells at concentrations where the individual drugs were not toxic. The observed decrease of the 
mitochondrial membrane potential in the presence of cyclophosphamide and roxithromycin suggests 
that mitochondria are involved in the induction of apoptosis. In support of this hypothesis, we could 
demonstrate leakage of cytochrome c into the cytoplasm of endothelial cells undergoing apoptosis. 
These findings suggest mitochondrial membrane permeability transition with rupture of the outer 
mitochondrial membrane and leakage of cytochrome c as an initial mechanism of induction of 
apoptosis (19-21). However, our data do not allow to exclude that the cellular pathway of apoptosis 
was also initiated, possibly affecting the mitochondria at a later stage in the cascade. This would be in 
agreement with published data suggesting that cyclophosphamide is an inducer of CD 95-mediated 
apoptosis in T lymphocytes (24-28) and melanocytes (25, 27). However, similar to our observation in 
endothelial cells, in mouse embrionic and in tumor cells, induction of the mitochondrial pathway of 
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apoptosis has been observed (26, 28). In this context, it is interesting to note that low concentrations 
of cyclophosphamide (7.5 µmol/L) can induce apoptosis in primary lung endothelial cells. According to 
these investigations, cancer and/or perivascular cells express thrombospondin-1 in the presence of 
cyclophosphamide, whose activation may mediate apoptosis of endothelial cells (29). While these 
studies show that cyclophosphamide can be toxic on endothelial cells under certain circumstances, 
they do not explain our observation that induction of apoptosis was most effective in the presence of 
the combination cyclophosphamide and roxithromycin. 
In conclusion, we could show that cyclophosphamide is toxic in combination with 500µmol/L 
roxithromycin from 50µmol/L cyclophosphamide upwards. Roxithromycin causes an overall inhibition 
of hepatocyte cyclophosphamide metabolism and inhibition of P-gp, leading to an accumulation of 
cyclophosphamide in hepatocytes and possibly also endothelial cells. Apoptosis is the principle 
mechanism of toxicity of cyclophosphamide in endothelial cells, most probably associated with 
activation of the mitochondrial pathway of initiation of apoptosis. 
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11. Discussion 
11.1. Conclusions and Outlook 
This thesis at large has been covering several aspects of toxicity and toxicology. We were 
dealing with hepatic toxicity, skeletal muscle toxicity, hepatic blood vessel damage, drug interactions, 
animal models, in vitro analysis, investigating single compounds or analyzing classes of drugs. 
Independently of the definite protocol of each individual study, all our investigations served one mutual 
purpose of deciphering some secrets of toxicology.  
The studies put together in this thesis represent an example of how clinical findings related to 
drug therapy can be followed by laboratory investigations in order to help to understand what was 
happening and why something was happening. Ideally, the conclusions from laboratory work go back 
from bench to either bedside or pharmaceutical industry. For instance, we could show in our study 
about hepatic toxicity of benzarone and benzbromarone, that structures containing a benzofuran 
structure coupled to a p-hydroxybenzolring are prone to induce mitochondrial dysfunction. So 
development of hypothetical new chemical entities with structural features mentioned before should be 
carried on cautiously and carefully with regard to mitochondrial toxicity and its consequences. 
Moreover, these data can be of interest in order to develop chemically modified derivatives for 
amiodarone with reduced risk of liver damage but still unimpaired antiarrhythmic activity. Hopefully, lab 
investigations are of use for the clinicians in terms of putting basic science into practice. Basic science 
can provide knowledge on mode of actions along with mechanisms of adverse drug reactions or drug 
interactions to clinicians, which can be of use in order to either prevent complications related to drug 
therapy or optimize therapy models.  
Although all the projects had an accurately defined focus, however, conclusions of general 
interest and use could be drawn from them. In our studies, we could show that mitochondria are 
prominent targets for xenobiotics, in a direct or indirect manner. In the first study the administered 
compound hit mitochondria only indirectly, in contrast to the succeeding two projects. THP was used in 
order to mimic and induce a disease pattern known from the clinics. THP did cause a change in the 
biochemical and molecular environment of a cell, which then was responsible for mitochondrial 
dysfunction and liver steatosis. The study was not explicitly designed to find out the mechanisms 
leading to mitochondrial dysfunction in the first place. Most importantly, the study could help to clarify 
the mechanism leading to liver steatosis. Since liver steatosis, microvesicular steatosis in particular, is 
a well known problem of many drugs; exploration of its mechanism is of broad toxicological and 
pharmacological interest. The second and the third study pointed into the same direction. Both studies 
tried to elucidate in vitro the mechanisms of known ADRs. They were triggered by clinical findings. 
Even though also the fourth study was starting with clinical findings, this project was dealing with 
another aspect of toxicology, with drug-drug interactions. It could be clearly demonstrated that even a 
nontoxic drug may turns into toxic agent by the mere combination with another nontoxic drug and then 
can have dangerous consequences. The precise mechanism of the drug drug interaction studied 
remained to be clarified entirely but also in this case, mitochondrial involvement could be confirmed.  
Taking together data from the literature and our studies, one can say that there are several 
ways to die but it seems that there is no way to bypass mitochondria in process of cell death. 
Mitochondria are the point of converge for extrinsic and intrinsic apoptotic pathways. They can either 
induce or route signals. These organelles seem to sit at the crossroad between life and death, exerting 
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the task of an organellar gatekeeper of cell death. Impairment of these vital organelles is a crucial 
event in a cascade, which may ends up with cell death and subsequent tissue damage. It is this very 
central role in cell survival, which explains the essential need of further investigations in this field. It is 
of pivotal importance to develop and improve screening assays in order to assess a drug’s potential to 
affect mitochondrial function.  
However, up to now drugs continue to be pulled from the market with disturbing regularity 
because of late discovery of toxicity. In many cases hepatic toxicity is responsible for withdrawal 
(benzbromarone, kava-kava, troglitazone) or, less frequently, withdrawal is due to toxicity in other 
tissues, such as skeletal muscle (cerivastatin). Of course, toxicity of a compound is not only 
determined by the nature or dose of the compound itself but also by other factors such as other drugs 
administered at the same time, an individual’s gene expression profile, antioxidant status and capacity 
of regenerations. Many factors take influence on the vulnerability of a specific patient. It turned out that 
also in the question of susceptibility of a patient to ADR, mitochondria play a significant role. It is 
possible that a patient with preexisting mitochondrial diseases (e.g. due to mitochondrial cytopathies 
or drug induced mitochondrial dysfunction) may be at risk for ADR after treatment with a mitochondrial 
toxin. This hypothesis is supported by recent reports in the literature. A patient with decreased activity 
of enzyme complexes of the respiratory chain developed liver failure during treatment with valproate. 
Valproate is a well known toxin for liver mitochondria (1). Moreover a case report was published about 
a physician and his son, developing liver failure after ingestion of rewarmed pasta, which was 
contaminated with bacillus cereus. Cereulide, the toxin of this bacterium, was shown to be a 
mitochondrial toxin. While the father was recovering fully, the son died from liver failure. It is of interest 
to note, that in contrast to the father the son was treated with 1g of aspirin, a mitochondrial toxin. It is 
possible that the son had an additional inhibitory effect on mitochondria, which in combination with 
cereulide had devastating consequences (2). These findings have important clinical implications. 
Before treatment with a drug, known to cause mitochondrial dysfunction, at least a careful family and 
personal history should be obtained, accurate clinical investigations should be performed and the 
therapy plan screened for mitochondrial toxins. Patients with findings compatible with mitochondrial 
disorders (e.g. drug-induced or inherited) should be either excluded from treatment with mitochondrial 
toxins or assessed very profoundly. Since nowadays it is not yet possible to assess mitochondrial 
function with standard laboratory tests, many cases of mitochondrial toxicity undoubtedly go 
undetected. This gap should be addressed in future investigations. Efforts are required in order to 
detect mitochondrial function and thus improve drug safety related to mitochondria.  
So far, we could demonstrate in our studies that mitochondria and their dysfunction could be 
responsible for the induction of tissue damage after treatment with drugs. Mitochondria are also 
associated with diseases. Up to now, several genetic mutations concerning mitochondria are known to 
cause diseases. Moreover, recent results put mitochondria and mitochondrial dysfunction back in the 
centre of neurodegenerative diseases as well. Studies in human postmortem material and in animals 
indicate consistently that decrements in mitochondrial complex I are linked to pathogenesis of 
Parkinson’s disease (PD). 1-Methyl-4-phenyl-1,2,3,6-treadhydropyridine (MPTP) for instance inhibits 
complex I and mimics most features of PD. MPTP selectivity to dopamine neurons is due to its active 
metabolite 1-methyl-4-phenylpyridinium (MPP+), which is then concentrated in dopamine neurons via 
the dopamine transporter, where it kills neurons through inhibition of complex I. Dysfunction of 
complex I leads to increased oxidative stress, ROS generation, reduction of ATP formation and finally 
to cell damage and subsequent cell death (2, 3). Also for Alzheimer’s disease (AD) the stage is now 
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set: mitochondrial abnormalities lie at the heart of AD pathogenesis, whereas the fundamental 
pathological changes of the disease are coordinated responses to control oxidative damage. But 
which factor is responsible for the mitochondrial abnormalities remains to be clarified. Current 
evidence points to changes in the balance of redox transition metals, especially iron and copper. 
However, the key aspect of AD is selective neuronal death. Recent findings show, that damaged 
neurons revealed an oxidative stress response. So far, however, there has not been a mechanism 
linking damage to death (5). Also in this field, further studies will be conducted in the forthcoming 
years.  
Einstein once said, “Everything should be made as simple as possible, but not simpler”. 
Research is constantly evolving and it is to expect that in a few years time, knowledge in this field will 
be expanded dramatically, possibly leading to new conclusions. Whether the conclusions of today will 
be compatible with those in a few years time remains questionable. Most likely it will turn out that our 
today’s hypothesis were not considering all aspects and thus simplifying things. Already today, there 
are firm hints in the literature indicating that there is way more lying beneath than we know today and 
that it won’t take long for these news to come up. This is of course true for many aspects of life but 
also in particular with regard to some aspects touched on in this thesis. Firstly, there seems to be 
more to life and death than mitochondria. Recent publications (6, 7) revealed and highlighted the 
endoplasmic recticulum (ER) as a key upstream signaling organelle for the regulation of apoptosis. 
Despite emerging evidence that the ER is an important location for the regulation of apoptosis, the 
mechanisms have yet to be discovered. One relevant candidate may be the control of the ER Ca2+ 
levels. It seems that members of the Bcl-2 protein family, which are known to play an important either 
pro- or antiapoptotic role within mitochondria are also involved in the ER-related apoptotic processes. 
The ER can act upstream of mitochondria in the initiation of apoptosis and it is hypothesized that they 
can act even independently of mitochondria (6). Clearly, the results so far are interesting and suggest 
that many possibilities remain to be explored. Secondly, the complexity of the multiple, intertwining 
pathways in cell death induction necessitated simplification, provided by the distinction in two clearly 
separated modes of cell death. Although apoptosis and necrosis have long been viewed as opposed 
antinomy, recent data led to the assumption that both forms of cell death constitute two extremes of a 
continuum with uncountable presentations (8), which, are, although difficult, to be investigated and 
differentiated in detail in the future. A third research field which is highly competitive is the 
mitochondrial permeability transition. The mechanism responsible for membrane permeabilization 
remains controversial, even though it is clear that many proteins can inhibit, prevent or affect the 
process by local effects on mitochondrial membranes. So far and in general, two classes of 
mechanisms have been described. In the first class of mechanism a pore opens in the inner 
membrane, allowing water and molecules up to ~ 1.5 kDa to pass through. This model postulates a 
role of the adenine nucleotide transporter in the inner membrane and the voltage- dependent anion 
channel in the outer membrane. Even though there are many publications on this model, it is still 
hypothetical. Newer data postulate that the inner membrane does not necessarily need to be 
permeabilized. The outer membrane permeabilization appears to be mediated by members of the Bcl-
2 family of apoptosis-regulating proteins acting directly on the outer mitochondrial membrane. It 
appears that there is more than one way of mitochondrial membrane permeabilization (9). Considering 
the importance of cell death signaling, much impetus for further research projects in this area is 
around.  
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In conclusion: although many things are still unknown and currently under investigation, 
evidence tightly confirmed that MPT is the central coordinating event of apoptosis as well as necrosis. 
Various damage pathways and proapoptotic signal transduction cascades converge at the level of 
MPT, in line with the fact that MPT can be induced by numerous effects. Once MPT has been 
triggered, a series of common pathways of cell death are initiated, each of which lethal. To sum up, 
based on today’s knowledge, MPT has at least two major consequences: (1) a bioenergetic and redox 
catastrophe disrupting cellular metabolism and (2) liberation of protease and endonuclease activators 
from mitochondria. Depending on which of these processes wins the race, either primary necrosis or 
apoptosis ensues. 
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14.1.1. Summary 
Carnitine is essential for mitochondrial metabolism of long-chain fatty acids and thus for 
myocardial energy production. Accordingly, carnitine deficiency can be associated with 
cardiomyopathy. To better understand this disease, we determined myocardial function and energy 
metabolism in a rat model of carnitine deficiency. Carnitine deficiency was induced by a 3- or 6-week 
diet containing N-trimethyl-hydrazine-3-propionate, reducing cardiac and plasma carnitine by 70–85%. 
Myocardial function was investigated in isolated isovolumic heart preparations. Carnitine-deficient 
hearts showed left ventricular systolic dysfunction, reduced contractile reserve, and a blunted 
frequency-force relationship independently of the substrate used (glucose or palmitate). After glycogen 
depletion, palmitate could not sustain myocardial function. Histology and activities of carnitine 
palmitoyl transferase, citrate synthase, and cytochrome c oxidase were unaltered. Thus, as little as 3–
6 weeks of systemic carnitine deficiency can lead to abnormalities in myocardial function. These 
abnormalities are masked by endogenous glycogen and are not accompanied by structural alterations 
of the myocardium or by altered activities of important mitochondrial enzymes. 
 
14.1.2. Introduction 
Carnitine is essential for mitochondrial transport and metabolism of long-chain fatty acids and, 
thus, for myocardial energy metabolism. Specifically, because the inner mitochondrial membrane is 
impermeable to long-chain fatty acyl-CoAs, carnitine is required to transport these substrates across 
this membrane [1]. Furthermore, carnitine is important for carbohydrate metabolism by stimulating 
glucose oxidation via reversing the inhibition of pyruvate dehydrogenase [2, 3]. Moreover, carnitine 
shifts the ratio of acyl-CoA to CoA-SH in the direction of CoASH and is involved in trapping acyl 
residues from peroxisomes and mitochondria [1, 4, 5].  
As a consequence of these important functions, deficiency of carnitine manifests mainly as a 
dysfunction of skeletal muscles and myocardium, where fatty acids constitute an essential energy 
substrate [4]. Due to decreased metabolism of fatty acids, carnitine deficiency results in accumulation 
of lipids within skeletal muscle, myocardium, and liver. Ultrastructurally, myofibrils are disrupted and 
aggregates of mitochondria and lipid deposits accumulate within the skeletal muscle and myocardium 
[6]. For these reasons, carnitine deficiency can cause hypertrophic or dilated cardiomyopathy in 
children [7], which is associated with a mortality of over 50% [8]. Moreover, myocardial carnitine levels 
are reduced in the hearts of patients with dilated cardiomyopathy, but the significance of this 
observation is currently not known [7]. 
The results of clinical and animal studies suggest that a short period (2 weeks) of moderate 
carnitine deficiency (50% reduction) does not have a major effect on cardiac contractile function [9]. 
However, after longer periods (>20 weeks) of carnitine deficiency, alterations occur in the heart that 
may result in impaired contractile performance, particularly at high workloads [9]. At this point, 
however, the precise mechanisms responsible for this cardiac depression are uncertain. To better 
understand the pathophysiology of carnitine deficiency, some of us have recently developed and 
characterized a rat model of carnitine deficiency [10]. In this model, rats developed systemic carnitine 
deficiency after 3 weeks on a diet containing Ntrimethyl- hydrazine-3-propionate (THP; also known as 
mildronate or MET-88) [11] which inhibits carnitine biosynthesis and increases renal carnitine 
excretion [10].  
In the present study, we sought to investigate in this model whether as little as 3 or 6 weeks of 
severe systemic carnitine deficiency can lead to abnormalities of myocardial function. Additionally, we 
sought to investigate whether this carnitine deficiency would lead to structural alterations of the 
myocardium or to altered activities of important mitochondrial enzymes involved in fatty acid and 
energy metabolism including carnitine palmitoyl transferase, citrate synthase, and cytochrome c 
oxidase. For this purpose, we studied isolated isovolumically contracting hearts of control and THP-
treated rats. Perfusing glucose (carnitine independent) or palmitate (carnitine dependent) as substrate, 
we measured various hemodynamic variables including left ventricular (LV) pressure, indices of 
contractility and relaxation, as well as coronary flow. Additionally, we measured both the contractile 
reserve (assessed as postextrasystolic potentiation) and the frequency- force relationship (staircase), 
as these myocardial characteristics are often altered in cardiomyopathy. Finally, as myocardial 
glycogen may compensate for an insufficient energy supply during perfusion with palmitate in 
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carnitine-deficient hearts, we depleted glycogen in some hearts using substrate-free perfusion before 
LV pressure analysis. 
 
14.1.3. Materials and methods 
14.1.3.1. Animals and induction of carnitine deficiency 
Male Sprague-Dawley rats (Süddeutsche Versuchstierfarm, Tuttlingen, Germany and RCC, 
Füllinsdorf, Switzerland) weighing 290–490 g were used in this study. The animal use protocol was 
approved by the veterinary department of Basel (Switzerland) and was in line with the ‘Ethical 
Principles and Guidelines for Scientific Experiments on Animals’ of the Swiss Academy of Medical 
Sciences. Carnitine deficiency was induced as previously described [10] using vegetarian food poor in 
carnitine (Kliba Futter 2435, Basel, Switzerland) and THP (20 mg/100 g per day) for 3 or 6 weeks (n = 
6 rats each). Control rats were kept for the same periods of time with vegetarian rat chow ad libitum (n 
=7 and 6 rats, respectively). All rats weighed approximately 200 g at the beginning of the diet/THP 
treatment and received tap water ad libitum throughout the study. 
 
14.1.3.2. Perfused heart model 
After anesthesia (50 mg/kg sodium pentobarbital intraperitoneally; Nembutal; Abbott 
Laboratories, Chicago, Ill.), rat hearts were excised rapidly and perfused according to a modified 
Langendorff method as previously described [12]. All hearts were perfused at a perfusion pressure of 
110 cm H2O at 36 °C with a filtered (pore size 0.65 µm) nonrecirculating modified Krebs-Henseleit 
solution containing 117.0 mM NaCl, 4.3 mM KCl, 1.5 mM CaCl2, 1.2 mM Mg Cl2, 25.0 mM NaHCO3, 
1% albumin, and 11.0 mM glucose or 0.4 mM Na palmitate as substrate. The perfusate was saturated 
with a gas mixture of 95% O2 and 5% CO2. Ventricular pacing was carried out using a pair of platinum 
wire electrodes connected to PowerLab/8e using Chart and Scope software (ADInstruments, Castle 
Hill, Australia) on a G3 Macintosh computer (Ingeno, Basel, Switzerland). The pacing electrodes were 
implanted superficially in the right ventricular free wall. To record a bipolar epicardial 
electrocardiogram (ECG), a pair of electrodes was placed on the right atrial appendage and the right 
ventricular base.  
 
14.1.3.3. Experimental protocol 
These experiments were designed to investigate the physiological contractile and energetic 
state of the hearts with a normal myocardial glycogen content. Therefore, rats were studied in the fed 
state, one control and one THPtreated rat per day in randomized order. Twenty minutes after isolation 
and perfusion of the hearts, stable baseline values of LV pressure and coronary flow were recorded 
with one of the substrates at a pacing rate of 200 beats per minute (bpm). The sequence of the 
substrates (glucose or palmitate) was randomized to eliminate confounding effects of varying 
perfusion time or glycogen content. To determine the LV contractile reserve, all hearts underwent the 
postextrasystolic potentiation protocol (see below). Subsequently, to determine the frequency-force 
relationship, we studied the effects of increasing the heart rate on LV pressure in the staircase 
protocol (see below). Then, the substrate was switched and after 20 min, of perfusion with the new 
substrate, baseline recordings and the two protocols (staircase and postextrasystolic potentiation) 
were repeated. At the end of the  experiments, hearts were immediately cut transversely. The base 
was stored in 10% formalin for histological analysis and the apex was frozen in liquid nitrogen for 
measurement of cardiac carnitine concentrations, mitochondrial enzymes (carnitine palmitoyl 
transferase, citrate synthase, and cytochrome c oxidase), and of the high-energy phosphates, 
adenosine triphosphate (ATP) and phosphocreatine. In the fed state, endogenous myocardial 
glycogen may compensate for insufficient energy supply during perfusion with palmitate in carnitine-
deficient hearts. This may mask contractile differences between control and carnitine- deficient 
animals. Therefore, we depleted glycogen in some hearts using substrate-free perfusion (n = 4 hearts 
per group) as described previously [13]. Pilot experiments showed that 60 min of substrate-free 
perfusion was sufficient to deplete the glycogen stores in rat harts (see fig. 1).  
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Figure 1. Effect of substrate-free perfusion (0, 15, 30, or 60 min) on the glycogen concentration in the left 
ventricle of isolated hearts from control rats. Values are mean ± SD; n = 6, 5, 6, or 7 hearts, respectively. 
 
Glycogen was isolated and analyzed by a spectrophotometric method described previously 
[14]. After 60 min of substrate-free perfusion, LV-developed pressure began to decrease. 
Subsequently, the hearts were first perfused with Na palmitate and then with glucose (to prevent 
restoring of glycogen). In these hearts, we analyzed LV pressure but could not perform further 
protocols due to the continuing deterioration of LV pressure particularly during palmitate perfusion of 
hearts from carnitine-deficient rats. For baseline recordings as well as during the protocols for 
staircase and postextrasystolic potentiation, simultaneous measurements of LV pressure, coronary 
flow, and the ECG were performed on PowerLab/8e at a sampling rate of 1000 Hz. Further dependent 
variables included peak positive first-order time derivative of the LV pressure decline (dP/dtmax) as an 
index of contractility as well as two relaxation indices t and b (computed off-line using the differential or 
curve fit extensions of Chart). 
 
14.1.3.4. Measurment of carnitine concentration in the heart and the plasma 
Carnitine content in the heart and plasma (collected after sternotomy) was determined using a 
radioenzymatic method as described previously [15]. Heart and plasma samples were prepared for 
analysis in 3% perchloric acid (v : v). The perchloric acid-soluble fraction was assayed directly for free 
carnitine, and after alkaline hydrolysis for total acid-soluble carnitine (representing the sum of free 
carnitine and short-chain acylcarnitine). The short-chain acylcarnitine content (acyl group chain length 
less than ten carbons) was obtained by subtraction (total acid-soluble minus free carnitine content). 
Long-chain acylcarnitine contents (acyl group chain length ten or more carbons) were determined in 
the perchloric acid pellets. Total carnitine content refers to the sum of long-chain acylcarnitine content 
and total acid-soluble carnitine content.  
 
14.1.3.5. Measurements of LV pressure and coronary flow 
A 60-ml thin latex balloon (size 4; Hugo Sachs Elektronik-Harvard Apparatus, March-
Hugstetten, Germany) was inserted into the left ventricle through the left atrium. LV pressure was 
measured by a plastic tube located inside the balloon, sutured at the proximal end of the balloon, and 
connected to an Isotec pressure transducer (Hugo Sachs Elektronik-Harvard Apparatus) that was at 
the same height as the heart. The volume of the saline-filled balloon was adjusted using a 
microsyringe to establish a constant physiological end-diastolic pressure in the range of 5–10 mm Hg 
[12]. Thus, the left ventricle contracted isovolumically throughout the experiment. LV developed 
pressure was defined as the difference between systolic and diastolic values of LV pressure. Coronary 
flow was measured within the aortic canula using an in-line flowprobe (Transonic 2N) connected to a 
transit time flowmeter (Transonic TTFM-SA type 700; Hugo Sachs Elektronik- Harvard Apparatus). 
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14.1.3.6. Analysis of LV relaxation 
LV relaxation was analyzed on LV pressure recordings using two different relaxation indices. 
These indices were based on mono- and double-exponential function curve fitting to digital LV 
pressure data at baseline and a consistent heart rate of 200 bpm. The first index was the widely used 
time constant tof monoexponential LV pressure decline according to equation 1:  
 
P(t) = (P0 – P•) e– t–t+ P• (Eq. 1)  
 
where P(t) denotes LV pressure as a function of time t, P0 is LV pressure at minimal dP/dt (inflection 
point), and P•relates to lower asymptotic LV pressure [16]. However, τ considers only the final LV 
pressure decline, and contains no information about the initial decline before the inflection point of LV 
pressure. Therefore, a second relaxation index was applied using parameter b of an asymmetric 
double-exponential function according to equation 2:  
 
P(t)= g0 – ge– a· e– b· t (Eq. 2)  
 
where P(t) denotes LV pressure as a function of time t, and g0 and grelate to upper asymptote and 
amplitude of LV pressure. Parameter arelates to the phasic delay of decline onset, whereas 
bprincipally relates to the rate of the entire LV pressure decline [17]. 
 
14.1.3.7. Measurement of contractile reserve and interval-force relationship 
To determine the contractile reserve, three different postextrasystolic potentiation protocols 
were introduced using PowerLab 8/e and Scope software. Specifically, after eight regular beats at 
250-ms intervals (240 bpm), one premature beat was introduced at different intervals (75, 130, and 
145 ms) followed by a pause (215, 335, and 265 ms, respectively). The intervals of the premature 
beats and the pauses were chosen to maximize postextrasystolic potentiation of the following beat 
[12]. The contractile reserve was estimated as the difference of LV developed pressure between the 
potentiated beats and the previous regular beat (averaged from three to five repetitions of each of the 
three potentiation protocols). Because of perturbing effects of arrhythmias on LV pressure, only 
arrhythmia-free sequences were used for this analysis. To determine the interval-force relationship, we 
assessed the effects of increasing heart rates on LV developed pressure. For this purpose, the heart 
rate was increased stepwise over a physiological range in a preprogrammed staircase pacing protocol 
at 240, 300, 360, 420, and 480 bpm generated by PowerLab 8/e using the stimulator function of Chart. 
Each step lasted for 6 s allowing LV pressure to reach a new steady state. Again, only arrhythmia-free 
sequences were used for this analysis. It should be noted that, in contrast to human hearts, rat hearts 
demonstrate a negative staircase at physiological heart rates [18].  
 
14.1.3.8. Histological analysis 
Histological examination of the hearts (carnitine-deficient diet for 3 or 6 weeks and controls, n = 
6 rats each) was performed on 10% formalin-fixed and paraffin-embedded tissue as well as on fresh 
frozen tissue. Paraffin-embedded tissue sections were stained with hematoxylin-eosin (H&E) and 
elastica van Gieson while frozen sections where stained with H&E, periodic acid-Schiff (with and 
without diastase treatment), and modified Gomori trichrome. The histochemical analyses included 
myofibrillar ATPase (preincubated at pH 4.3 and pH 4.6), nicotinamide adenine dinucleotide-
tetrazolium reductase (NADH-TR), succinate dehydrogenase (SDH) and cytochrome oxidase. Oil red 
O was used as a stain for neutral lipids. 
 
14.1.4. Measurement of carnitine palmitoyl transferase, citrate synthase, and cytochrome c 
oxidase 
Activities of the mitochondrial enzymes carnitine palmitoyl transferase, citrate synthase, and 
cytochrome c oxidase were determined using routine methods [19-21]. Briefly, carnitine palmitoyl 
transferase activity was measured after incubation of the heart tissue homogenate with palmitoyl CoA 
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and radioactively labeled carnitine to produce labeled palmitoylcarnitine. Palmitoylcarnitine was 
extracted with butanol and counted in a Packard 1900 TR b-counter (Canberra, Groningen, The 
Netherlands) [20]. Citrate synthase activity was measured spectrophotometrically at 412 nm using 
5,5’-dithio-bis-2-nitrobenzoic acid reacting with CoA-SH that is produced in the reaction from acetyl-
CoA and oxaloacetate to citrate [19]. Finally, cytochrome c oxidase activity was measured 
spectrophotometrically at 550 nm after oxygen-induced oxidation of ferrocytochrome c (produced 
freshly reducing ferricytochrome c with dithionite) [20]. The net activity was obtained by subtracting the 
rate obtained in the presence from the rate in the absence of the specific inhibitor sodium azide [20].  
 
14.1.4.1. Measurement of ATP, phosphocreatine, and lactate 
Concentrations of ATP and phosphocreatine in frozen heart samples were measured 
spectrophotometrically at 340 nm using enzymatic assays as described previously (Sigma-Aldrich 
Diagnostics ATP assay, no. 366 and custom-made assay, respectively) [22, 23]. The plasma lactate 
concentrations were determined fluorimetrically as described by Olsen [24].  
 
14.1.4.2. Data evaluation and statistical analysis 
LV pressure values, dP/dtmax, and the relaxation indices τ and β were averaged from five 
cardiac cycles digitally recorded at a heart rate of 200 bpm. To eliminate confounding effects of 
varying LV developed pressure on the contractility index, dP/dtmax was normalized for LV-developed 
pressure. Furthermore, to compare frequency-force relationships among groups, the sums of the rate-
pressure products were computed over the entire heart rate range for each experiment (240–480 
bpm). Moreover, out of 57 hearts, 3 were excluded from analysis due to unstable perfusion conditions 
(1 from the 3-week control group and 2 before glycogen depletion).  
All results are expressed as mean ± SD except for carnitine data that were not normally 
distributed and were therefore expressed as median with interquartile range (25th–75th percentile). 
Comparisons of normally distributed interval variables among groups (carnitine-deficient vs control rats 
and 3-week vs 6-week treatment) were performed by one-way ANOVA followed by Bonferroni’s test 
for selected multiple comparisons. Comparisons of carnitine data among groups (carnitine-deficient vs 
control rats and 3-week vs 6-week treatment) were performed by corresponding nonparametric tests 
(Kruskal-Wallis test) followed by Dunn’s test for selected multiple comparisons. Comparisons of 
variables within groups (glucose vs palmitate) were performed by repeated-measures ANOVA 
followed by Bonferroni’s test for selected multiple comparisons.  
Statistical computations were done using Prism software (version 3.0a; GraphPad, San Diego, 
Calif.). For all statistical analyses, the null hypothesis was rejected at the 95% level, considering a two-
tailed p < 0.05 significant. In an approximation of sample size determination for this study, six rats in 
each group had 90% power to detect differences of 20% in most variables assuming a SD of 10% and 
a 0.05 two-sided significance level [25]. 
 
14.1.5. Results 
14.1.5.1. Carnitine concentrations in heart and plasma 
After both 3 and 6 weeks of diet and THP treatment, carnitine concentrations in the heart and 
plasma were significantly reduced (table 1). Specifically, hearts and plasma of THP-treated rats had 
15–30% of the total carnitine concentrations of control rats. Furthermore, all THPtreated rats showed 
signs of systemic carnitine deficiency including steatosis and enlargement of the liver. Despite these 
signs, THP-treated rats had similar body and heart weights in comparison to control rats (table 1). 
Additionally, after 6 weeks of diet and THP treatment, total carnitine concentrations in the heart and 
plasma were not significantly lower than after 3 weeks. However, after 6 weeks, control rats had 
higher total carnitine concentrations than after 3 weeks. The plasma lactate concentration was 2.4±0.5 
mmol/l in control rats, and 2.1±0.5 or 1.7±0.1 mmol/l in rats treated with THP for 3 or 6 weeks (each 
group n = 6, p<0.05 for rats treated with THP for 6 weeks vs control rats). 
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14.1.5.2. Hemodynamics, contractility, and relaxation 
After 3 weeks of diet and THP treatment, no significant differences could be detected among 
the groups regarding LV pressure, dP/dtmax, or the relaxation indices τ and β (table 2). Specifically, 
hearts of carnitine-deficient rats did not differ from hearts of control rats in any hemodynamic variable 
independently of the substrate used (11 mM glucose or 0.4 mM Na palmitate).  
However, after 6 weeks, hearts of carnitine-deficient rats showed significantly lower LV systolic 
pressure than control hearts during both glucose and palmitate perfusion (table 2). Consequently, 
hearts of carnitine-deficient rats also showed lower LV developed pressure than hearts of control rats 
(as LV end-diastolic pressure was set at a physiological range of 5–10 mm Hg). However, hearts of 
carnitine-deficient rats showed a similar dP/ dtmax as control hearts indicating unaltered contractility. 
Similarly, hearts of carnitine-deficient rats showed similar relaxation indices τ and β as control hearts. 
Finally, hearts of carnitine-deficient rats had a similar coronary flow as control hearts independently of 
the substrate throughout all experiments (overall mean 16.3 ml/min). 
 
 
 
 
 
14.1.5.3. Contractile reserve and frequency-force relationship 
After 3 and 6 weeks of carnitine deficiency, the contractile reserve was significantly reduced 
independently of the substrate used (fig. 2). Specifically, hearts of carnitinedeficient rats showed a 
reduced postextrasystolic potentiation of LV developed pressure relative to control hearts. This 
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reduction was similar after 3 and 6 weeks of carnitine deficiency and was not affected by the choice of 
substrate.  
 
 
Figure 2. Contractile reserve of isolated hearts from control rats and carnitine-deficient rats during 
glucose or palmitate perfusion after 3 and 6 weeks diet and THP treatment. The contractile reserve was 
assessed as the difference of LV developed pressure between postextrasystolic potentiated beats and 
preceding regular beats. Values are mean ± SD; n = 6 hearts per group. * p < 0.05 vs control at 
corresponding age and perfusion condition. 
 
Similar to the contractile reserve, the frequency-force relationship was blunted in hearts of 
carnitine-deficient rats independently of the substrate used (fig. 3). After 3 weeks of carnitine 
deficiency, the frequency-force relationship was already slightly altered at high heart rates during 
palmitate perfusion. However, the rate-pressure product over the entire heart rate range was not 
significantly different. Nevertheless, after 6 weeks, hearts of carnitinedeficient rats developed 
significantly less LV pressure than control hearts over the entire heart rate range. This difference was 
largely due to differences in LV systolic pressure between carnitine-deficient and control rats. 
LVdiastolic pressure, in contrast, did not differ among the groups.  
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Figure 3. Frequency-force relationship of isolated hearts from control rats and carnitine-deficient rats 
during glucose or palmitate perfusion after 3 and 6 weeks diet and THP treatment. The frequency- force 
relationship was assessed as effect of increasing heart rate from 240 to 480 bpm on LV developed 
pressure. Values are mean ± SD; n = 6 hearts per group. * p < 0.05 vs control evaluated as rate-
pressure product over the entire heart rate range. 
 
 
14.1.5.4. Histological findings 
Histological examination revealed no structural changes of the myocardium in carnitine-
deficient rats. Specifically, we found no vacuolation of muscle fibers and oil red O staining revealed no 
excess of lipid storage in our rats. In addition, we found no disruption of muscle fibers, and glycogen 
storage was normal in both carnitine-deficient and control rats. Finally, we found no fibers with excess 
mitochondria using Gomori trichrome stain, NADH-TR, SDH, or cytochrome oxidase reaction. Thus, 
histologically and histochemically, the myocardium of carnitine-deficient rats did not differ from that of 
control rats. 
 
14.1.5.5. Mitochondrial enzymes, ATP and phosphocreatine 
After 3 and 6 weeks of carnitine deficiency, the activities of all three mitochondrial enzymes 
measured were not significantly different from controls (table 3). Specifically, hearts of carnitine-
deficient rats showed similar activities of carnitine palmitoyl transferase, citrate synthase, and 
cytochrome c oxidase as control hearts, excluding a significant proliferation of mitochondria in hearts 
of carnitine-deficient rats.  
 
Appendix  
  136 
 
 
Concentrations of ATP and phosphocreatine did not significantly differ among hearts of carnitine-
deficient rats and control rats after 3 or 6 weeks diet at the end the experimental protocol (data not 
shown). 
 
 
14.1.5.6. Effect of glycogen depletion 
Pilot studies using hearts of control rats had shown that after 60 min of substrate-free 
perfusion, glycogen was almost completely depleted (fig. 1) and LV pressure started to decrease. The 
effect of glycogen depletion on myocardial function was subsequently investigated using hearts of 
carnitine-deficient and control rats (n = 4 hearts for both groups). When LV pressure began to 
decrease (usually after 60 min of substrate-free perfusion), these hearts were perfused with Na 
palmitate and subsequently with glucose. Compared to values obtained using hearts with normal 
glycogen stores (see table 2), glycogendepleted hearts of control rats produced normal LV systolic 
and diastolic pressures during perfusion with both substrates (fig. 4). In comparison, glycogen-
depleted hearts of carnitine-deficient rats produced LV systolic pressures which were approximately 
10% lower compared to control rats, irrespective of the substrate used. This decrease did not reach 
statistical significance, however, due to high variations in control rats. Diastolic pressure was 
significantly higher in hearts from carnitine-deficient rats perfused with palmitate. Importantly, upon 
subsequent perfusion with glucose, diastolic pressure decreased to values similar to those of control 
rats. It is noteworthy that arrhythmias were frequent findings in glycogen-depleted hearts, in particular 
in hearts from carnitine-deficient rats perfused with palmitate. 
 
 
 
Figure 4. Effect of glycogen depletion on LV systolic and diastolic pressure (upper and lower bar end, 
respectively) of isolated hearts from control and carnitine-deficient rats during glucose or palmitate 
perfusion after 6 weeks diet and THP treatment. Values are mean ± SD; n = 3 hearts per group. * p < 
0.05 vs control at corresponding perfusion condition. 
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14.1.6. Discussion 
In the present study in a rat model of carnitine deficiency, we demonstrated that as little as 3–6 
weeks of severe systemic carnitine deficiency can lead to abnormalities in myocardial function 
including systolic dysfunction, reduced contractile reserve, and a blunted frequency-force relationship. 
These abnormalities may be masked by endogenous glycogen and are not accompanied by structural 
alterations of the myocardium or by altered activities of important mitochondrial enzymes involved in 
fatty acid and energy metabolism.  
Specifically, we found that both 3 and 6 weeks of vegetarian food poor in carnitine plus THP 
treatment (20 mg/100 g per day) led to severe systemic carnitine deficiency in rats (table 1). After 3 
weeks of carnitine deficiency, we found a significant reduction in the contractile reserve assessed as 
postextrasystolic potentiation of isolated isovolumically contracting heart preparations using glucose or 
palmitate as substrate (fig. 2). After 6 weeks of carnitine deficiency, we found further abnormalities in 
myocardial function including LV systolic dysfunction (table 2), reduced contractile reserve, and a 
blunted frequency- force relationship (fig. 3). 
At a mechanistic level, our findings suggest that as long as myocardial workloads are low, ATP 
production may still be sufficient in carnitine-deficient hearts. Accordingly, ATP and phosphocreatine 
concentrations as well as relaxation indices were similar in carnitine-deficient and control hearts. 
However, at high workloads, such as during high heart rates, functional abnormalities occurred, 
suggesting that carnitine deficiency-induced alterations in substrate metabolism result in transiently 
inadequate ATP production as proposed previously [26]. Furthermore, reduced postextrasystolic 
potentiation after 3 and 6 weeks of carnitine deficiency in our experiments suggests that altered 
intracellular calcium handling is an early step in the development of functional abnormalities. 
Specifically, severe carnitine deficiency may reduce the amount of activator calcium and/or interfere 
with sarcoplasmic reticular calcium uptake and/or transport [12, 27]. In our histological analysis, we 
found no disruptions of myofibers that could have explained abnormal myocardial function (in 
particular systolic dysfunction) in carnitine-deficient rats. Systolic dysfunction might arise from 
accumulating long-chain acyl-CoAs due to impaired activity of carnitine palmitoyltransferase I (CPT I) 
in the presence of low intracellular carnitine levels, as demonstrated in the liver of rats treated with 
THP [28]. Long-chain acyl-CoAs can damage biological membranes and impair the function of 
membrane-associated enzymes and/or transport proteins such as the adenine nucleotide translocase 
which is critical for mitochondrial energy metabolism [29]. This mechanism explains why in non-
glycogen-depleted hearts cardiac dysfunction was observed under both conditions, perfusion with 
glucose or with palmitate.  
The Km for M-CPT I, the predominating CPT I isoform in adult rats [30], is in the range of 500 
µmol/l for carnitine [31]. Since the cardiac concentrations of free carnitine in carnitine-deficient rats 
were 190 µmol/kg at 3 and 90 µmol/kg at 6 weeks of THP treatment, an energy deficit with an 
associated impaired cardiac function was expected in hearts perfused with palmitate. However, 
endogenous myocardial glycogen stores may have at least partially compensated for an insufficient 
energy supply during perfusion with palmitate in carnitine-deficient hearts. Our histological 
examination did not reveal differences in my- ocardial glycogen content between carnitine-deficient 
and control hearts. Since this examination was not quantitative and did not control for glycogen 
formation during perfusion, we repeated our studies with hearts after depletion of cardiac glycogen by 
substrate-free perfusion for 60 min. After depletion of glycogen, LV diastolic pressure was higher 
during palmitate perfusion in carnitine-deficient hearts as compared to glucose perfusion, possibly due 
to insufficient energy supply to maintain a normal diastolic intracellular calcium concentration. Based 
on this finding, we propose that in severe disorders of fatty acid metabolism such as systemic carnitine 
deficiency, the myocardial energy supply can depend on endogenous glycogen stores. This is 
particularly the case in the absence of suitable substrates such as glucose, short-chain fatty acids, 
ketone bodies, or amino acids, and also during periods of increased energy consumption, for example, 
during high heart rates. If such periods are prolonged, myocardial glycogen stores may be depleted 
and glycogenolysis may be insufficient to meet the metabolic needs of the carnitine-deficient 
myocardium.  
In patients suffering from mitochondrial diseases, proliferation of mitochondria in the affected 
organ (e. g., skeletal muscle and/or heart) is a frequent finding [32, 33]. In contrast, in our carnitine-
deficient rats, the observed alterations of myocardial function were not accompanied by increased 
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activities of mitochondrial enzymes or histological abnormalities, excluding mitochondrial proliferation. 
However, after a longer duration of severe systemic carnitine deficiency, mitochondrial proliferation 
may occur. Interestingly, juvenile visceral steatosis mice, an animal model of inherited severe systemic 
carnitine deficiency, develop cardiac hypertrophy and mitochondrial proliferation [34]. Importantly, the 
present study provides the first description of carnitine deficiency-induced abnormalities of myocardial 
function in rats after as little as 3–6 weeks of systemic carnitine deficiency. In previous studies, 20 
weeks of carnitine deficiency (induced by sodium pivalate in drinking water) was considered the 
minimal duration to induce functional abnormalities in rats [26]. This difference may be due to the 
lower degree of carnitine deficiency in previous studies (50–60% reduction) than in the present study 
(70–85% reduction). As carnitine concentrations did not differ between the third to the sixth week in 
our experiments, one may reasonably speculate that both the severity and duration of carnitine 
deficiency determine the development of functional abnormalities and ultimately cardiomyopathy.  
In conclusion, our study in rats shows that as little as 3–6 weeks of severe systemic carnitine 
deficiency can lead to abnormalities in myocardial function including systolic dysfunction, reduced 
contractile reserve, and a blunted frequency-force relationship. These abnormalities are partially 
masked by endogenous glycogen and are not accompanied by structural alterations of the 
myocardium or altered activities of important mitochondrial enzymes involved in fatty acid and energy 
metabolism. The functional abnormalities in carnitine-deficient hearts may represent early signs of a 
metabolic cardiomyopathy.  
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14.2.1. Summary 
The consequences of carnitine depletion upon the metabolic and contractile characteristics of 
otherwise healthy skeletal muscle remains largely unexplored. The present study wishes to investigate 
the integration of fat & carbohydrate metabolism and contractile function in predominantly slow- 
(soleus) and fast-twitch (extensor digitorum longus) rodent skeletal muscles following treatment with 
N-trimethyl-hydrazine-3-propionate (THP); a competitive inhibitor of both renal carnitine reuptake and 
the final enzyme within carnitine biosynthesis. Male Sprague Dawley rats were fed a standard rat 
chow in the absence (CON; n=8) and presence of THP (22.2±0.2 mg THP·100g-1 body mass day-1; 
n=8) for 3 weeks. Following treatment, rats were fasted for 24h prior to the tendon-to-tendon excision 
of their soleus and EDL muscles for biochemical characterisation at rest and following 5min of 
contraction in vitro. THP treatment reduced the total-carnitine pool to the same extent in both soleus 
and EDL muscles from CON (~80%; P<0.01). Carnitine depletion was associated with atrophy (-30%; 
P<0.05) and a reduced magnitude of pyruvate dehydrogenase complex (PDC) activation during 
contraction (-63%; P<0.05) in soleus muscle whilst contractile function, total-coenzyme-A and water 
content remained unaltered from CON. In EDL muscle, carnitine depletion was associated with 
impaired peak tension development (-48%, P<0.05), ATP homeostasis (-40%, P<0.05), reduced free-
coenzyme-A availability (-25%, P<0.05) and increased glycogen hydrolysis (55%, P<0.05) during 
contraction, whilst PDC activation, muscle weight and water content remained unaltered from CON. In 
conclusion, whilst the biochemical and functional properties of soleus muscle fibres is largely normal, it 
appears that carnitine-deficiency results in a selective loss of slow-twitch fibres. Conversely, despite 
the preservation of EDL mass, the biochemical and functional properties of this predominantly fast-
twitch muscle were impaired, with an increased reliance upon energy production from non-oxygen 
dependent routes when compared to CON. Based on this evidence, the muscle myopathy often 
associated with carnitine deficiency is most likely attributable to impaired mitochondrial energy 
production in fast-twitch muscle fibres. 
 
14.2.2. Introduction 
Carnitine is a naturally occurring compound that is found in all mammalian tissues, which 
marks the 100th anniversary of its original discovery in skeletal muscle extracts this year (Gulewitsch & 
Krimberg, 1905). L-Carnitine, the biologically effective isomer of carnitine, plays a key role within 
several cellular energy producing pathways (Bremer, 1983). By way of example, carnitine is essential 
towards the transport of long-chain fatty acids across the inner-mitochondrial membrane towards their 
oxidative fate inside the mitochondrial matrix (Fritz, 1955), is important towards the removal of 
potentially toxic acyl-CoAs from the mitochondria by forming acylcarnitines (Brass & Hoppel, 1980; 
Bieber et al. 1982), serves as a temporal acetyl group buffer in the oxidation of carbohydrates during 
periods of augmented pathway flux (Childress et al. 1966; Roberts et al. 2002) and is an 
osmoprotectant (Hofmeister, 1888); thus can impact upon cell volume and osmotic stress responses 
(Peluso et al. 2000). There is also expanding evidence indicating that L-carnitine has more complex 
functions within the cell, towards the regulation of gene expression (Giovenali et al. 1994, Horiuchi et 
al. 1999) and the blockage of apoptosis at multiple levels (Andrieu-Abadie et al. 1999, Mutomba et al. 
2000, Vescovo et al. 2002). 
In humans, a typical 70 kg healthy omnivore male contains ~21 grams of carnitine, in both free 
and acetylated forms (Brass, 1995), with ~95% of the carnitine pool located in skeletal muscle and 
heart, where ~90% of this cellular reserve exists outside of the mitochondria. There is limited synthesis 
of carnitine within the body, with ~30% of the daily requirement being met by de novo production in the 
kidneys (humans; Rebouche & Engel, 1980) or liver (rats; Rebouche, 1982) and to a lesser extent 
brain and testes from the amino acid precursors of L-methionine and L-lysine (Fig. 1A). The remaining 
70% of the requirement is received in our diet from the consumption of carnitine-rich foods; such as 
red & white meats, fish and to a lesser extent dairy produce and vegetables (Mitchell, 1978). The 
dietary absorption of carnitine, which occurs in the small intestine, and cellular uptake, which often 
occurs against a concentration gradient, is facilitated by a high-affinity (sodium-dependent) active 
transport system termed organic cation transporter new two (OCTN2; Sekine et al. 1998, Tamai et al. 
1998). The final component of carnitine homeostasis is the slow net-turnover and excretion of carnitine 
in the urine (5µmol/kg/day; Lombard et al. 1989), which is aided by the marked efficiency (90-95%) of 
Appendix  
  143 
the kidney to reabsorb carnitine from the urine, due to the high activity of the OCTN2 transporter in 
proximal tubules (Wu et al. 1999; Fig. 1B) 
 
 
Figure 1:N-trimethyl–hydrazine-3-propionate (THP) induced alterations in rodent carnitine biosynthesis 
(A) & nephron carnitine reabsorption in the kidney (B) upon whole-body carnitine homeostasis. 
Abbreviations; Organic Cation Transporter New Two (OCTN2).  
 
Fundamental to our understanding of the role of carnitine within the body is the ability to 
manipulate the size of the cellular carnitine pool and to investigate the consequences of such upon 
cellular, tissue and whole-body function, at rest and in response to external stresses; such as 
muscular contraction. This desire is complicated by the fact that it is difficult to markedly elevate 
carnitine reserves (especially within muscle) through prolonged carnitine supplementation in healthy 
(omnivore) individuals (for review see Karlic & Lohninger, 2004). This makes investigating the 
consequences of carnitine depletion (hypocarnitinemia) within clinical patients and animal models of 
disorders in carnitine uptake and homeostasis often the only research-avenue open. 
The first case of carnitine deficiency was reported by Engel & Angelini in human skeletal 
muscle in 1973 (Engel & Angelini, 1973). Since this discovery, hypocarnitinemia has been shown to 
occur via several inborn defects or deficiencies in the cellular uptake and handling of carnitine, 
frequently termed systemic or primary carnitine deficiencies, with mutations in the genes encoding the 
OCTN2 transporter often causative (Brooks & Krähenbühl, 2001). A multitude of secondary, indirectly-
induced, carnitine deficiencies have also been reported in response to several disease states (AIDS, 
Reye’s syndrome, endocrine disorders), during clinical treatments (renal dialysis, valproic acid, 
zidovudine, quinidine) and as a consequence of pregnancy and carnitine malnourishment (Lombard et 
al. 1989). The side effects associated with these secondary carnitine deficiencies can often be 
overcome with oral or intravenous L-carnitine supplementation. 
Advancements in our understanding of carnitine deficiencies have been made with the 
discovery of juvenile visceral steatosis (JVS) mice (Koizumi et al. 1988), which have a point mutation 
defect in the gene encoding OCTN2, and thereby display a greatly impaired reuptake of carnitine by 
the kidney resulting in net carnitine loss (Kuwajima et al. 1991, Horiuchi et al. 1994). Given the locus 
of their carnitine abnormality, the likelihood of compensatory changes within intermediary metabolism 
during neonatal development and the chronic nature of this deficiency (even when dietary carnitine is 
provided; Kuwajima et al. 1999) the JVS mouse is not an ideal model to compare towards humans, 
especially those who develop secondary carnitine deficiencies. Clearly, this need would best be 
served by an animal model whereby a systemic carnitine deficiency could be induced acutely in 
otherwise healthy tissue. 
Recent work by our group has developed a rodent model of systemic carnitine deficiency, which 
can be induced in response to acute feeding with the carnitine and butyrobetaine analogue N-
trimethyl-hydrazine-3-propionate, in otherwise healthy Sprague Dawley rats (Spaniol et al 2001). N-
trimethyl-hydrazine-3-propionate (THP); also known as mildronate (Eremeev et al. 1984) or MET-88 
(Simkhovich et al. 1988) within the literature, effectively leaches carnitine from the body by 
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competitively inhibiting the final, γ-butyrobetaine hydroxylase reaction within carnitine biosynthesis, 
with respect to its natural substrate butyrobetaine (Fig. 1A; Heinonen & Takala, 1994, Tsoko et al. 
1995, Spaniol et al. 2001) and by competing against carnitine for OCTN2 mediated re-absorption by 
the kidney (Fig. 1B; Spaniol et al. 2001). Three weeks of THP treatment has been shown to reduce the 
tissue carnitine content of heart, liver, plasma and skeletal muscle (quadriceps femoris) by 72-83%, to 
cause liver steatosis, peroxisomal proliferation, impaired palmitate metabolism and result in 
abnormalities in lipid storage and myocardial function (Spaniol et al. 2001, Spaniol et al. 2003, Zaugg 
et al. 2003). To date, the characterisation of this novel model of carnitine-deficiency has focussed 
predominantly upon THP’s effect upon liver and kidney (main sites of production), plasma and heart 
carnitine stores, whereby its role within skeletal muscle, the major storage site (consumer) of carnitine 
within the body, has received relatively little attention thus far (Spaniol et al. 2001). 
The present study wishes to address this point, by examining the consequences of THP pre-
treatment upon the composition of coenzyme-A and carnitine pools, tissue water content and the 
integration of fat and carbohydrate metabolism at rest and in response to contraction in rodent skeletal 
muscle. To further our understanding, we examined the above in two functionally / biochemically 
distinct muscle groups, namely; soleus (84% slow-twitch fibres; Ariano et al. 1973) & extensor 
digitorum longus (EDL; 98% fast-twitch fibres; Armstrong & Phelps, 1984), where the role of the 
carnitine pool varies from predominantly facilitating fat translocation to preserving the free coenzyme-A 
content for sustained carbohydrate oxidation.  
 
14.2.3. Methods 
14.2.3.1. Animal handling 
All in vivo procedures were performed in full accordance with the ‘Ethical Principles and 
Guidelines for Scientific Experiments on Animals’ of the Swiss Academy of Medical Sciences and 
following Cantonal approval from the Veterinary Department of Basel, Switzerland. Sixteen male 
Sprague Dawley rats, weighing ~200g, were obtained from the Süddeutsche Versuchstierfarm 
(Tuttlingen, Germany) and were acclimatised to the laboratory one week prior to the start of the study. 
The animals were housed in a temperature (20-22oC) and light (12h light – 12h dark cycle) controlled 
animal facility. 
 
14.2.3.2. Treatment groups 
Following a week of habituation, animals were randomly assigned to one of two treatments 
groups and received either a standard powdered rat chow (Kliba Futter 3433, Basel, Switzerland) in 
the absence (CON; n=8) or presence of 20mg THP 100g-1 body mass day-1 for 21 days (THP, n=8) 
with water provided ad libitum throughout the study. The THP was commercially prepared by 
ReseaChem GmbH (Burgdorf, Switzerland), and the amount of THP to be added to the animal’s 
individual chow feed each day was based upon the previous day’s food consumption for each animal; 
which typically did not vary from ~35g of chow per day. Notwithstanding, food consumption, actual 
THP dosing and changes in body weight were examined daily (Fig. 2). Based upon the findings of our 
previous study, rats were fed a standard rat chow (carnitine content 16.9 nmol g-1; Kliba Futter, Basel, 
Switzerland), as the effect of carnitine-deficient food upon carnitine homeostasis is minor in the rat 
(Spaniol et al. 2001). This can be expected based upon the mechanisms by which THP induces 
systemic carnitine deficiency; i.e. via inhibition of carnitine biosynthesis (Fig. 1A) and by inhibiting 
carnitine reabsorption by the kidney (Fig. 1B). 
 
14.2.3.3. Anaesthesia & muscle excision 
To investigate the consequences of muscular carnitine depletion upon contractile function, in 
isolation of the systemic (central) THP-induced carnitine deficiencies, muscle groups (soleus and EDL) 
were excised and stimulated to contract ex vivo under physiological conditions.  
Following 21 days of CON or THP treatment, animals were starved for 24 h, in an attempt to 
stress intermediary metabolism towards the oxidation of lipid reserves, prior to the induction of 
anaesthesia with 160 mg kg-1 i.p. ketamine (Ketalar, Park-Davis, Zurich, Switzerland). Once adequate 
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anaesthesia was established, the animal’s soleus and EDL muscles were quickly and carefully 
isolated (total time <5 mins), tendon-to-tendon, from both the left and right hind-limbs. Immediately 
following their excision, one soleus and one EDL muscle were snap-frozen in liquid nitrogen for future 
biochemical analysis of basal metabolite values in response to treatment. The distal and proximal 
tendons of the remaining soleus and EDL muscles were tied with braided nylon (non-absorbable) 
suture (Surgilon, grade 3-0) prior to their removal from the animal and were immediately placed in 
continually gassed (95% oxygen – 5% carbon dioxide) Krebs buffer (135mM NaCl, 5mM KCl, 1mM 
Na2H2PO4, 15mM NaHCO3, 11mM glucose, 1mM MgSO4, 2.5mM CaCl2; pH 7.4; 25oC). In an attempt 
to maintain the in vivo appearance, fibre alignment and 3D architecture of the muscles, the Krebs 
incubated soleus and EDL muscles were loaded with ~1.2g upon the distal tendon whilst in Krebs 
suspension prior to the assessment of their in vitro contractile properties. Following the excision of the 
two soleus and two EDL muscles, the animal was killed by decapitation whilst still under anaesthesia. 
 
14.2.3.4. Contractile function of isolated muscles 
Muscles were mounted within the electrical stimulatory apparatus following their excision from 
the animal (<10min). The contractile properties of the isolated muscles were individually assessed, 
with the EDL muscle always the first to be studied followed by the soleus muscle. No differences in 
tissue handling existed between the CON and THP groups. Muscles were vertically mounted in the 
water-tight chamber of the electrical stimulatory apparatus (manufactured in-house), by the anchoring 
of the distal tendon to a fixed hook at the base of the bath and the attachment of the proximal tendon, 
by thread, to the isometric force transducer (Grass FT03, Quincy, Medfield, MA, USA). The force 
transducer, was mounted upon the micropositioner and was calibrated over the range of 0.25-1.00g 
prior to each electrical stimulation protocol. Following muscle connection, the chamber of the 
apparatus was filled with Krebs buffer and continually gassed with a mixture of 96% O2 and 5% CO2 
and maintained at 37.5oC (Julabo 5B, JD Instruments, Houston, TX, USA) for the duration of the 
muscle stimulation protocol. Optimal muscle length (length producing maximal twitch tension) was 
determined by varying the muscle length in increments of 1mm with the micropositioner and by 
performing a single ‘twitch’ stimulus. Once optimal muscle length was determined, all subsequent 
measurements were made at this setting and the muscle was allowed to equilibrate for 5 min prior to 
the commencement of the contractile, electrical stimulation protocol. Muscular contraction was 
electrically induced through the bathing (Krebs) solution by two platinum-plate electrodes located at 
the proximal and distal origins of the muscle. Muscles were stimulated for 5 mins (1 s train interval, 
333 ms train duration, 25 ms pulse interval, 1 ms pulse duration, 130 V), in accordance with the work 
of Brass et al. (1993). Contractile function was recorded using a 1-channel chart recorder (LKB 
Bromma 2210, Bromma, Sweden). Following the assessment of the EDL muscle, the stimulatory 
protocol was repeated for the soleus muscle. Immediately following the contraction protocol (<1 s), 
muscles were snap frozen in liquid nitrogen for subsequent biochemical determinations. 
 
14.2.3.5. Muscle sample handling & analysis 
All muscle samples, basal and post-contraction, were divided into two equal portions under 
liquid nitrogen. Subsequently, one portion was freeze-dried, dissected free from visible blood and 
connective tissue and powdered. Freeze-drying and powdering of muscle samples not only ensures a 
more homogenous muscle sample but allows the correct determination of metabolite contents 
independent of fluctuations in tissue water content. Total muscle water content of samples was 
determined by weighing the samples before and after freeze-drying. Freeze-dryed samples were then 
extracted in 0.5 M perchloric acid containing 1 mmol EDTA, with the resulting supernatant neutralised 
with 2.2 M KHCO3 and used for the spectrophotometric determination of ATP, phosphocreatine (PCr), 
creatine and muscle lactate (Harris et al. 1974). The extract was also used for the radio-isotopic 
determination of free-carnitine, acetylcarnitine, total-CoASH and acetyl-CoA (Cederblad et al. 1990). 
Finally, the extract was analysed fluorometrically for the determination of the tricarboxylic acid cycle 
intermediate citrate (Moellering & Gruber, 1966, Passoneau & Lowry, 1993). Freeze-dried muscle 
powder was also used for the spectrophotometric determination of muscle glycogen (Harris et al. 
1974). The remaining portion of frozen, wet muscle was used to assess the activation status of the 
pyruvate dehydrogenase complex (Constantin-Teodosiu et al. 1991). 
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14.2.3.6. Calculations & statistics 
All data are reported as means ± S.E.M. Comparisons between treatments were carried out 
using two-way analysis of variance (ANOVA) with repeated-measures. When a significant F-value was 
obtained (P<0.05) an LSD post-hoc test was used to locate any differences (SPSS Base 12.0).  
 
 
14.2.4. Results 
14.2.4.1. Animal Data 
No differences in body mass existed between treatment groups during the 21 days of 
powdered chow feeding in the presence and absence of THP; with each group linearly gaining ~90g 
during the course of the study (Fig. 2). Daily food consumption was no different between treatment 
groups during the 21 days of CON and THP treatment (CON = 38.7 ± 0.2 vs. THP = 38.3 ± 0.3 g per 
day, Fig. 2); equating to a THP dosage of 22.2 ± 0.2 mg THP 100g-1 body mass per day. 
 
 
 
Figure 2: Daily alterations in rodent body mass (g; circles) and food consumption (g; triangles) during 21 
days of powdered-chow feeding in the absence (CON, open symbols, n=8) and presence of N-trimethyl–
hydrazine-3-propionate treatment (THP, closed symbols, n=8). Results are expressed as means ± 
S.E.M. * Different from corresponding CON value (P<0.05). 
 
 
 
14.2.4.2. Muscle mass & water content 
No differences in muscle water content existed between CON and THP groups following 21 
weeks of treatment in either the EDL (CON = 76.9 ± 0.3 vs. THP = 76.5 ± 0.2 % water) or soleus 
muscles (CON = 75.4 ± 0.2 vs. THP = 75.3 ± 0.1 % water), with water accounting for ~75% of the wet 
mass within each muscle. 
The absolute muscle weight of tendon-to-tendon excised soleus muscle was reduced by 30 % 
in THP pre-treated animals when compared to CON (CON = 186.7 ± 18.9 vs. THP = 132.1 ± 14.7 mg 
wet muscle, P<0.05). This muscle atrophy was maintained when soleus weight was expressed relative 
to the animals body weight (CON = 0.47 ± 0.05 vs. THP = 0.34 ± 0.03 mg wet muscle g-1 body mass, 
P<0.05). No reduction in absolute weight (CON = 140.7 ± 3.7 vs. THP = 124.4 ± 15.3 mg wet muscle) 
or muscle weight relative to body weight (CON = 0.35 ± 0.01 vs. THP = 0.32 ± 0.03 mg wet muscle g-1 
body mass) was observed from CON following THP pre-treatment in EDL muscle. 
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14.2.4.3. Composition of muscular carnitine pool 
Pre-treatment of rodent skeletal muscle with THP markedly reduced muscular acetylcarnitine 
concentration by ~75% from that observed in CON in both soleus and EDL muscles, whilst at rest and 
following 5 min of electrically-induced contraction (P<0.01, Fig. 3A). No differences in acetylcarnitine 
content existed between EDL and soleus muscle in both the CON and THP pre-treated animals at rest 
and in response to contraction (Fig. 3A). No increase in acetylcarnitine concentration from basal 
values was observed in response to contraction in both CON and THP pre-treated EDL and soleus 
muscles (Fig. 3A).  
Pre-treatment of rodent skeletal muscle with THP markedly reduced muscular free-carnitine 
concentration by ~85% from that observed in CON in both EDL and soleus muscles whilst at rest and 
following contraction (P<0.01, Fig. 3B), with no differences in free-carnitine existing from their 
respective basal values in response to contraction (Fig. 3B). No reduction in free-carnitine 
concentration from basal was observed in response to contraction in both CON and THP pre-treated 
EDL and soleus muscles (Fig. 3B).  
In accordance with the changes in acetylcarnitine and free-carnitine, muscular total-carnitine 
was reduced by 75-82 % in EDL and soleus muscle at rest and following contraction in THP vs. CON 
pre-treated muscle (P<0.01, Fig. 3C). 
Despite the marked reductions in both muscular acetylcarnitine and free-carnitine content in response 
to THP feeding, the acetylcarnitine to free-carnitine ratio was increased by ~95% in EDL muscle 
(P<0.05, Fig. 3D) and by ~125% in soleus muscle (P<0.01, Fig. 3D) following THP treatment when 
compared to CON at rest and also following isometric contraction in EDL muscle (P<0.05, Fig. 3D) 
and soleus muscle (P<0.01, Fig. 3D). No differences in the acetylcarnitine to free-carnitine ratio were 
observed between muscle groups at rest or following contraction in the CON group (Fig. 3D). 
However, the acetylcarnitine to free-carnitine ratio was higher in the soleus vs. EDL muscle at rest 
following THP treatment (P<0.05, Fig. 3D). 
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Figure 3: Acetylcarnitine (A), free-carnitine (B) & total-carnitine (C) concentrations & the acetylcarnitine to 
free-carnitine ratio (D) in rodent extensor digitorum longus (EDL) and soleus (SOL) muscles at rest and 
following 5 min of electrically induced contraction (Cont) in control (CON) and N-trimethyl –hydrazine-3-
propionate (THP) pre-treated muscles. Results are expressed as means ± S.E.M. with units of mmol kg-1 
dry muscle * Different from CON (P<0.05); † different from corresponding EDL muscle within the same 
treatment group (P<0.05). 
 
 
 
14.2.4.4. Composition of muscular coenzyme-A pool 
No differences in muscular acetyl-CoA concentration existed between CON and THP treatment 
groups at rest or in response to contraction in either EDL or soleus muscles (Fig. 4A). No alteration in 
muscle acetyl-CoA content from rest was observed in either EDL or soleus muscle following 5 min of 
electrical stimulation (Fig. 4A). However, the concentration of acetyl-CoA was significantly higher in 
CON and THP pre-treated EDL muscle when compared to the corresponding soleus muscle (P<0.01, 
Fig. 4A).  
No differences in muscular free-CoASH concentration existed between control and THP 
treatment groups at rest and following contraction in soleus muscle (Fig. 4B). However, THP pre-
treatment markedly reduced free-CoASH content in EDL muscle from CON at rest and following 
contraction (P<0.01, Fig. 4B). No alteration in muscle free-CoASH content from rest was observed in 
either EDL or soleus muscle in response to the 5 min of electrical stimulation (Fig. 4B). 
In accordance with the alterations in tissue acetyl-CoA and free-CoASH concentrations, THP 
pre-treatment markedly reduced EDL total-CoASH content from CON at rest and following contraction 
(P<0.05, Fig. 4C). However, muscle total-CoASH content was unaltered from CON at rest and 
following contraction in soleus muscle following THP treatment (Fig. 4C). No alteration in muscle total-
CoASH content from rest was observed in either EDL or soleus muscle in response to the 5 min of 
electrical stimulation (Fig. 4C). 
No differences in the acetyl-CoA to free-CoASH ratio was observed following THP treatment when 
compared to CON at rest and also following isometric contraction in soleus muscle (Fig. 4D). 
However, the acetyl-CoA to free-CoASH ratio was markedly elevated following THP treatment when 
compared to CON at rest and also following isometric contraction in EDL muscle (P<0.05, Fig. 4D). 
Electrical stimulation markedly elevated the acetyl-CoA to free-CoASH ratio from its basal value in 
THP pre-treated EDL muscle (P<0.05, Fig. 4D). The ratio of acetyl-CoA to free-CoASH was higher in 
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CON and THP treated EDL muscle when compared to their corresponding soleus muscle (P<0.01, 
Fig. 4D). 
 
 
Figure 4: Acetyl-CoA (A), free-CoASH (B) & total-CoASH (C) concentrations & the acetyl-CoA to free-
CoASH ratio (D) in rodent extensor digitorum longus (EDL) and soleus (SOL) muscles at rest and 
following 5 min of electrically induced contraction (Cont) in control (CON) and N-trimethyl–hydrazine-3-
propionate (THP) pre-treated muscles. Results are expressed as means ± S.E.M. with units of µmol kg-1 
dry muscle * Different from CON (P<0.05). 
 
 
14.2.4.5. Muscle metabolites at rest & during contraction (ex vivo) 
No differences in ATP concentrations existed between groups at rest or following contraction in 
either EDL or soleus muscle (Table 1). The concentration of ATP was maintained at basal levels 
following contraction in CON treated EDL and CON and THP pre-treated soleus muscle groups (Table 
1). However, after 5 min of contraction ATP concentration in the THP pre-treated EDL muscle was 
significantly lower than its basal value (P<0.05, Table 1). 
No differences in PCr concentration existed between groups at rest or following contraction in 
either EDL or soleus muscle (Table 1). Following 5 min of electrically-induced contraction, PCr 
concentrations were significantly lower than rest in both CON and THP pre-treated EDL and soleus 
(P<0.05, Table 1). 
Similarly, no differences in creatine concentration existed between groups at rest or following 
contraction in either EDL or soleus muscle (Table 1). No alteration in cellular creatine content was 
observed from basal following contraction in any treatment group or specific muscle. (Table 1).  
In accordance with the alterations in tissue PCr and creatine content, muscle total creatine (the 
sum of creatine + phosphocreatine) was no different between CON and THP treatment groups at rest 
and following contraction in either EDL or soleus muscle (Table 1). Paradoxically, there was a 
significant reduction in total-creatine concentration in CON and THP pre-treated soleus muscle in 
response to contraction when compared to their resting (basal) value (P<0.05, Table 1). 
Resting muscle glycogen concentration was no different between treatment groups at rest in EDL 
and soleus muscles and following contraction with the sole exception of THP pre-treated soleus 
muscle, where the rate of glycogenolysis was doubled from that observed in CON (P<0.05, Table 1). 
Muscle glycogen content was maintained at its basal value in response to 5 min of muscular 
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contraction with the sole exception of THP pre-treated soleus muscle, where the glycogen content was 
halved (P<0.05, Table 1). 
Resting muscle lactate concentration was no different between treatment groups at rest in EDL 
and soleus muscles and in response to contraction (Table 1). Muscle lactate content was maintained 
at its basal value in response to 5 min of muscular contraction with the sole exception of CON pre-
treated EDL muscle, where lactate was significantly elevated. (P<0.05, Table 1). 
Resting muscle citrate concentration was unaltered at rest in soleus muscle, yet was higher 
than the CON group at rest following THP pre-treatment in EDL skeletal muscle (P<0.05; Table 1). 
 
Table 1: Muscle metabolite concentrations in rodent extensor digitorum longus (EDL) and soleus (SOL) 
muscles at rest and following 5 min of electrically-induced contraction (Cont) in control (CON) and N-
trimethyl–hydrazine-3-propionate (THP) pre-treated muscles 
   EDL (Rest) EDL (Cont)  SOL (Rest) SOL (Cont) 
        
CON  29.0 ± 3.8 21.8 ± 3.6  24.8 ± 4.2 21.7 ± 1.9 
[ATP] 
THP  31.5 ± 4.2 18.7 ± 4.0†  25.1 ± 2.8 21.3 ± 1.6 
CON  33.3 ± 5.5 11.6 ± 2.5†  19.3 ± 5.1 4.2 ± 3.3† 
[PCr] 
THP  39.5 ± 9.0 9.0 ± 1.9†  16.7 ± 3.7 5.6 ± 0.8† 
CON  151 ± 6 157 ± 10  142 ± 7 131 ± 4 
[Creatine] 
THP  144 ± 11 157 ± 11  139 ± 5 129 ± 5 
CON  184 ± 6 169 ± 10  161 ± 9 135 ± 6† [Total- 
Creatine] THP  183 ± 7 166 ± 10  155 ± 4 134 ± 5† 
CON  41 ± 7 63 ± 6†  46 ± 9 50 ± 5 
[Lactate] 
THP  49 ± 15 70 ± 7  46 ± 10 48 ± 3 
CON  47 ± 5 50 ± 4  51 ± 6 50 ± 5 
[Glycogen] 
THP  46 ± 10 22 ± 8*†  39 ± 10 44 ± 8 
CON  0.25 ± 0.04 n/a  0.29 ± 0.07 n/a 
[Citrate] 
THP  0.52 ± 0.06* n/a  0.35 ± 0.06 n/a 
        
All values are expressed as means ± S.E.M. ATP, PCr, creatine, total-creatine, lactate and citrate are 
expressed as mmol kg-1 dry muscle, (each n = 8). Glycogen expressed as mmol glycosyl units kg-1 dry 
muscle. * Different from CON (P<0.05); † different from rest within the same group (P<0.05). 
 
 
14.2.4.6. Pyruvate dehydrogenase complex activation 
No differences in PDC activation status existed between CON and THP treatment groups at 
rest or in response to electrical stimulation in either the soleus or EDL muscle groups (Fig. 5). PDC 
activation increased from basal following 5 min of contraction in THP and CON pre-treated EDL 
muscles and in CON treated soleus muscle (P<0.05, Fig. 5), however, no contraction-induced 
increase in PDC activation was observed in THP pre-treated soleus muscle (Fig. 5). Indeed, the 
magnitude of PDC activation, from basal to the cessation of contraction, was reduced by 63% in THP 
treated soleus muscle when compared to the corresponding CON value (CON 0-5 min = 0.72 ± 0.20 
vs. THP 0-5 min = 0.26 ± 0.15 mmol acetyl-CoA min-1 kg-1 wet muscle @ 37OC; P<0.05). No difference 
in the magnitude of PDC activation in response to contraction was observed between treatment 
groups in the EDL muscles (Fig. 5). 
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Figure 5: Pyruvate Dehydrogenase Complex activation (PDCa) in rodent extensor digitorum longus 
(EDL) and soleus (SOL) muscles at rest and following 5 min of electrically induced contraction (Cont) in 
control (CON) and N-trimethyl–hydrazine-3-propionate (THP) pre-treated muscles. Results are 
expressed as means ± S.E.M. with units of mmol acetyl-CoA min-1 kg-1 wet muscle @ 37OC * Different 
from CON (P<0.05); † different from rest within the same group (P<0.05). 
 
14.2.4.7. Muscular contractile properties 
No differences in resting tension existed between CON and THP treatment groups in either 
EDL (CON = 736 ± 108 vs. THP = 723 ± 98 g tension 100g-1 wet muscle) or soleus muscles (CON = 
824 ± 98 vs. THP = 830 ± 100 g tension 100g-1 wet muscle). 
Peak isometric tension was reduced by 48% in the EDL muscle following THP pre-treatment 
when compared to CON and remained significantly lower throughout contraction (P<0.01, Fig. 6A). 
Despite this difference in peak tension, no difference in the rate of fatigue development existed 
between treatment groups, which fell from peak tension by 29% and 39% in the CON and THP groups 
respectively following 5 min of contraction (Fig. 6A). 
No difference in soleus peak isometric tension development existed between CON and THP pre-
treated muscles (Fig. 6B). Similarly, no difference in the rate of fatigue development existed between 
treatment groups, which fell from peak tension by 33% and 38% in the CON and THP groups 
respectively following 5 min of contraction (Fig. 6B). 
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Figure 6: Isometric tension production & fatigue development in tendon-to-tendon excised rodent 
extensor digitorum longus (EDL; A) & soleus muscles (B) during 5 min of electrically induced contraction 
in the presence (CON) and absence of 3 weeks of N-trimethyl–hydrazine-3-propionate (THP) treatment. 
Results are expressed as means ± S.E.M. with units of g of tension per 100g of wet muscle @ 37OC. * 
Different from CON (P<0.05). 
 
 
14.2.5. Discussion 
This is the first study to examine the consequences of carnitine depletion upon the metabolic and 
contractile characteristics of predominantly slow- and fast-twitch skeletal muscles from otherwise 
healthy rats. Twenty-one days of THP treatment, a competitive inhibitor of carnitine biosynthesis and 
re-uptake by the kidney, reduced the total-carnitine pool to the same extent in both soleus and EDL 
muscles from that measured in control animals (~80%; P<0.01) and to a level comparable to that 
reported in JVS mice (Higashi et al. 2001) and in human sufferers of carnitine-deficiencies (Shapira et 
al. 1993). The THP-induced leaching of carnitine was associated with a marked atrophy (-30%; 
P<0.05) and a reduced magnitude of pyruvate dehydrogenase complex (PDC) activation during 
subsequent contraction (-63%; P<0.05) in soleus muscle whilst contractile function, total-coenzyme A 
and water content remained unaltered from control treated soleus muscle. In contrast, carnitine 
depletion was associated with impaired peak tension development (-48%, P<0.05), ATP homeostasis 
(-40%, P<0.05), a reduction in free-coenzyme A availability (-25%, P<0.05) and increased glycogen 
hydrolysis (55%, P<0.05) during contraction in EDL muscle whilst PDC activation, muscle weight and 
water content remained unaltered from control treated muscle.  
 
14.2.5.1. Contractile function 
 At present very little is known in the literature regarding carnitine’s effect upon the contractile 
properties of skeletal muscle; especially with regard to peak tension development and towards the 
maintenance of contractile function. Work by Brass et al. (1993) examining the contractile properties of 
soleus and EDL muscle strips in vitro documented an improved maintenance of contractile function 
throughout 5 mins of electrical stimulation when soleus was incubated in a media rich in carnitine, 
when compared to control muscles (Brass et al. 1993). However, no carnitine-mediated improvements 
in contractile function were observed from control in EDL muscle. Based on these findings, carnitine 
depletion could be expected to increase the fatigue index of the musculature (soleus in particular) by 
virtue of the reduced ability to transport lipids across the mitochondrial membrane and buffer excess 
acetyl-CoA generated through carbohydrate oxidation. However, peak tension and the decline in 
contractile function during 5 min of electrical stimulation of soleus muscle in vitro was unaffected by 21 
days of THP pre-treatment when compared to CON in the present study (Fig. 6B). The absence of any 
THP-induced impairment in function could be due to the intensity and duration of stimulation. Given 
that no elevation in acetylcarnitine content was observed in THP & CON soleus from rest in response 
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to contraction, it appears that acetyl-CoA delivery through the carbohydrate oxidising pathways closely 
matched the demands of the TCA cycle for this oxidative substrate. Therefore, carnitine’s ability to 
buffer excess acetyl-CoA was not sufficiently tested using the current intensity of contraction, which 
was likely too low (<65% maximal oxygen uptake; Roberts et al. 2002) to test the functional role of the 
carnitine pool in this regard. Furthermore, given the slow onset of lipid derived energy production upon 
the initiation of contraction, it is likely that the duration of stimulation was too brief to view differences 
in ATP generation via this route and its effect upon contractile function. Interestingly, peak isometric 
tension production was reduced in EDL muscle in response to THP pre-treatment, although the 
maintenance of peak tension was identical to that observed in the CON treatment (Fig. 6A). As 
discussed later in this discussion, this was most likely due to the reduced availability of free-CoASH to 
stimulate oxidative ATP synthesis and due to a reduced total-CoASH content in response to THP pre-
treatment.  
 
14.2.5.2. Integration of fat & carbohydrate metabolism 
Based upon their findings in alloxan diabetic rats, Philip Randle and co-workers first described 
a mechanism for the integration and regulation of carbohydrate and lipid metabolism; which they 
termed the glucose-fatty acid cycle (GFC; Randle et al. 1963; Randle, 1986). Central to the operation 
of this cycle is the activation status of the pyruvate dehydrogenase complex (PDC), which catalyses 
the irreversible reaction that commits the glycolytic product pyruvate to its oxidative fate inside the 
mitochondrion and hence controls the overall rate of carbohydrate oxidation (Randle, 1986). When the 
availability and utilisation of fat is increased a restriction upon the oxidation of the limited intramuscular 
stores of carbohydrates is put in place. Rising acetyl / acyl-CoA to free-CoASH and NADH to NAD+ 
ratios, resulting from the β-oxidation of lipid reserves, feeds back to inhibit the transformation of the 
PDC to its active (dephosphorylated) form, leading to the accumulation of the tricarboxylic acid cycle 
intermediate citrate; a known inhibitor of the glycolytic flux controlling enzyme phosphofructokinase 
(Cooper et al. 1975, Hansford & Cohen, 1978, Hansford et al. 1990). Decreased flux through 
phosphofructokinase leads to an upstream accumulation of glucose-6-phosphate in the glycolytic 
pathway, which in turn inhibits hexokinase activity restricting further glucose uptake by the cell and 
thereby glycogen hydrolysis. Essential to the operation of this metabolic cycle is that the reverse 
should also be possible. Therefore, a THP-induced reduction in carnitine and thereby, lipid derived 
acetyl-CoA generation, should shift intermediary metabolism towards the more favourable oxidation of 
carbohydrates (i.e. greatest amount of ATP per unit of oxygen). 
THP pre-treatment markedly reduced carnitine content in the soleus muscle (Fig. 3A-C) and 
achieved this independent of any alteration in composition of the coenzyme A pool at rest (Fig. 4A-D). 
In accordance with the operation of the GFC, the similar acetyl-CoA to free-CoASH ratio resulted in no 
alteration in PDC activation (Fig. 5), the concentration of citrate and glycogen content from CON 
muscle at rest (Table 1). Therefore, it would appear that carnitine deficiency did not impinge upon the 
integration of fat and carbohydrate metabolism in the predominantly slow-twitch soleus muscle. 
Despite these similarities, there was a marked reduction in the magnitude of PDC activation in 
response to contraction in THP pre-treated soleus muscle when compared to CON (Fig. 5). Although 
activation is a pre-requisite for an increase in flux through the PDC, flux is further controlled by the 
availability of various reaction substrates and products as well as numerous co-factors (Wieland, 
1983).  
Similarly to soleus muscle, THP pre-treatment reduced the carnitine content in EDL muscle (Fig. 
3A-D). However, in contrast to soleus, the acetyl-CoA to free-CoASH ratio was increased (Fig. 4D) 
and the concentration of free-CoASH, a key substrate for the PDC reaction, was lowered when 
compared to CON muscle (Fig. 4C). Despite these differences in free-CoASH availability in EDL 
muscle, no difference in PDC activation existed between groups at rest, yet the concentration of citrate 
was elevated in THP muscle when compared to CON (Table 1). This finding indicates that despite a 
similar degree of PDC activation, acetyl-CoA delivery via this enzyme complex (i.e. flux) was reduced 
in THP vs. CON muscle. This is most likely due to the availability of free-CoASH being limited in THP 
treated EDL muscle, thus reducing PDC flux (Fig. 4B). The selective decline in free-CoASH 
concentration in EDL vs. soleus muscle following 21 days of THP is a surprising observation that 
warrants further investigation. This is most likely attributable to an increased acetyl-CoA to free-
CoASH ratio (Fig. 4D) in response to the decline in tissue carnitine content and a concomitant reduced 
ability of carnitine acyltransferase to buffer excess acetyl groups to maintain free-CoASH for sustained 
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PDC flux. An additional complication of an elevated acetyl-CoA to free-CoASH ratio is its effect upon 
pantothenate kinase, the master regulator of coenzyme A biosynthesis in mammalian cells (Robishaw 
& Neely, 1985). Evidence is emerging that acetyl-CoA and free-CoASH differentially regulate 
pantothenate kinase; with acetyl-CoA potently inhibiting activity, leading to a reduction in total-CoASH 
content (Fig. 4C), with free-CoASH stimulating coenzyme A biosynthesis (Rock et al. 2000). In 
conclusion, the integration of fat and carbohydrate metabolism is largely unaffected by THP pre-
treatment in soleus muscle, however, this integration is lost in EDL muscle due to inhibitory pressures 
upon both fat and carbohydrate oxidation and coenzyme A synthesis.  
Based upon the resting and post-contraction concentrations of ATP, PCr and muscle lactate 
(Table 1), and using the calculation of Spriet et al. (1987), we estimated the contribution of oxygen-
independent ATP resynthesis towards the energy demands of contraction in THP vs. CON pre-treated 
soleus and EDL muscle (Oxygen-independent ATP provision = [∆ PCr + (1.5 x ∆ lactate) + (2 x ∆ 
ATP)]). No difference in oxygen-independent ATP resynthesis was observed between treatment 
groups in soleus muscle (CON = 27.8 ± 4.1 vs. THP = 22.2 ± 3.9 mmol ATP min-1 kg-1 dry muscle). 
Given that no difference in peak tension and the maintenance of contractile output existed between 
THP and CON groups in soleus muscle (i.e. similar ATP demand for contraction; Fig. 6B), it appears 
that the THP-induced carnitine deficiency did not affect oxidative metabolism within this muscle group, 
using the present stimulatory parameters. In contrast, there was a marked elevation in oxygen-
independent ATP production in EDL muscle following THP pre-treatment when compared to CON 
(CON = 68.7 ± 5.2 vs. THP = 87.6 ± 6.0 mmol ATP min-1 kg-1 dry muscle, P<0.05). This increase is 
surprising, as peak tension development, area under the tension curve and therefore the ATP demand 
for contraction was markedly reduced in EDL muscle in response to THP treatment (Fig. 6A), implying 
that carnitine-deficiency interferes with oxidative (mitochondrial) ATP production in EDL muscle. This 
must be accountable to a THP-induced decline in flux through carbohydrate metabolism, most likely 
due to the reduced availability of free-coenzyme A for PDC flux (Fig. 4B). 
 
14.2.5.3. Atrophy of the soleus muscle 
Muscle atrophy refers to the wasting or loss of muscular tissue that occurs as a result of disuse 
or, in rare occasions, as a consequence of damage to the nerves that supply the muscle or from a 
disease of the muscle itself (Kandarian & Stevenson, 2002). In the present study, we observed a 30% 
reduction in the mass of the soleus muscle in response to THP treatment that was not observed in the 
corresponding EDL muscle. As the soleus muscle is predominantly composed of 84% slow-twitch 
fibres (Ariano et al. 1973) compared to the largely fast-twitch EDL muscle (Armstrong & Phelps, 1984), 
this finding would imply a selective type I fibre loss in response to carnitine-depletion. Given that THP 
treatment results in no alteration in rodent overnight activity (P. Kauffmann, unpublished observation), 
it would appear that the atrophy reported herein was not the result of disuse but resulted from an 
abnormality within the muscle itself. It is noteworthy that a type I atrophy has been reported in an 18 
year old female with a secondary carnitine deficiency (Fukusako et al. 1995).  
Programmed cell death, better termed apoptosis, is one of the major determinants of skeletal 
muscle atrophy (Dalla-Libera et al. 1999, Vescovo et al. 2000) and in vitro studies have demonstrated 
that L-carnitine can inhibit apoptosis at several levels and thus protect against cell death (Di Marzio, et 
al. 1997, Mutomba et al. 2000, Vescovo et al. 2002). By way of example, L-carnitine can interfere with 
Fas-ligand mediated apoptotic signalling, thereby reducing acid sphingomyelinase activity and the 
ability of ceremide to stimulate the pro-apoptotic Bax / Bad complexes (Di Marzio et al. 1997, Moretti 
et al. 1998). L-carnitine can inhibit caspases 3, 7 & 8 and the opening of the mitochondrial membrane 
permeability transition pore; which normally leads to apoptosis (Pastorino et al. 1993, Mutomba et al. 
2000,). Finally, L-carnitine, through interaction with carnitine palmitoyltransferase 1 (CPT1), can 
stimulate the activity of the anti-apoptotic BCL2 / BCLX complex and dampen down pro-apoptotic 
signals (Pugazhenthi et al. 1999). Clearly hypocarnitinemia is likely to promote rather than suppress 
apoptosis. Further studies are required to understand the selective nature of apoptosis in type I vs. 
type II muscle fibres; which could be attributable to the higher mitochondrial content in the former and 
reduced carnitine-CPT1 interactions following THP treatment leading to reduced anti-apoptopic 
signalling (Pugazhenthi et al. 1999). It is worth noting that 24 weeks of L-carnitine administration has 
been shown to have a selective trophic effect upon type I muscle fibres in man (Giovenali et al. 1994). 
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Taken together, the findings of the present manuscript and of Giovenali et al. (1994) support a role for 
L-carnitine supplementation towards the reduction of aged-related muscle atrophy in man. 
Recent evidence has shown that THP pre-treatment not only inhibits liver carnitine 
biosynthesis and reabsorption by the kidney but also leads to a increase in gamma-butyrobetaine 
concentration in the rat (Dambrova et al. 2002, Dambrova et al. 2004); which is logical given that THP 
competes against butyrobetaine as a substrate for the final reaction within carnitine biosynthesis (Fig. 
1A). One consequence of butyrobetaine elevation is a transient increase in nitric oxide content in rat 
tissues (Dzintare et al. 2002), which akin to repeated exposure to an ischaemic / hypoxic environment, 
could lead to muscular adaptation in vivo (Dambrova et al. 2002). Another interesting finding is that 
the methylester of butyrobetaine, a major breakdown product of butyrobeatine, possesses dose-
dependent acetylcholine like effects through muscarinic receptor binding (Dzintare et al. 2002). It is 
unknown if THP pre-treatment elevated gamma-butyrobetaine in the present study and whether the 
consequences of carnitine depletion reported herein are directly related to the leaching of carnitine per 
se or result from increased muscarinic receptor or nitric oxide synthase activity. 
In conclusion, we have presented novel data demonstrating that a THP-induced carnitine-
deficiency, in otherwise healthy skeletal muscle, results in a selective loss of soleus (type I) muscle 
fibres, whilst the biochemical and functional properties of the soleus muscle remained largely normal. 
Conversely, despite the preservation of EDL muscle mass, the biochemical and functional properties 
of this predominantly type II fibred muscle were impaired, with an increased reliance upon energy 
production from non-oxygen dependent routes when compared to control muscle. Based on this 
evidence, the muscle myopathy often associated with carnitine deficiency is most likely attributable to 
impaired mitochondrial energy production in type II muscle fibres. 
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14.3.1. Summary 
Cyclophosphamide is a well known cause of hepatic veno-occlusive disease when used at high 
doses (>500 mg/m2) for bone marrow eradication before transplantation. At immunosuppressive 
doses (≤2 mg/kg) this adverse effect has so far not been reported. 
We observed a patient with autoimmune haemolytic anemia who developed hepatic veno-
occlusive disease while being treated with immunosuppressive cyclophosphamide in combination with 
roxithromycin. After stopping all drugs, the patient recovered within 2 weeks. 
Since roxithromycin inhibits cytochrome P450 3A4, which is involved cyclophosphamide 
metabolism, a drug-drug interaction could have been responsible. In addition, roxithromycin is an 
inhibitor of the drug transporter P-glycoprotein, possibly leading to accumulation of cyclophosphamide 
in endothelial cells. Since cyclophosphamide has been described to induce apoptosis, roxithromycin 
could have rendered endothelial cells more vulnerable for apoptosis. 
 
14.3.2. Introduction 
Cyclophosphamide can cause hepatic veno-occlusive disease in patients treated with high 
doses (≥500 mg/m2) for bone marrow eradication before transplantation (1). In contrast, at 
immunosuppressive doses (1-2 mg/kg), this adverse reaction has not been described. We describe a 
patient with autoimmune hemolytic anemia, who developed veno-occlusive disease while being 
treated with immunosuppressive doses of cyclophosphamide combined with roxithromycin. 
 
14.3.3. Case report 
This 66 years-old lady had a history of diabetes mellitus type 2, arterial hypertension and 
pulmonary embolism, and was treated with insulin, enalapril and oral anticoagulation with 
phenprocoumon for more than two years. Two years before the actual presentation, she had been 
diagnosed for idiopathic autoimmune hemolytic anemia. She was treated successfully with 
prednisone, until she developed another hemolytic episode after one year. After splenectomy, she 
recovered rapidly and could again be treated successfully with 20 mg prednisone per day. One year 
later (two months before the actual illness), she presented with cholestasis, and endoscopic 
retrograde pancreatico-cholangiography (ERCP) revealed sludge in the extrahepatic bile duct. After 
papillotomy, she recovered completely within the following 2 weeks. Two months later, she developed 
fever and cough and consulted a general practitioner. Despite negative chest radiographs, he started 
a treatment with oral roxithromycin (2 x 300 mg per day). Two days later, she got jaundiced without 
having symptoms or signs of cholestasis. The local hematologist interpreted this episode as a flair-up 
of autoimmune hemolytic anemia. Prednisone was stopped and oral cyclophosphamide (100 mg per 
day) was started, while roxythromycin was continued. Four days later, jaundice was progressive and 
she complained of breathlessness and pain in the right upper quadrant of the abdomen, leading to 
admission to the University Hospital of Basel. 
On admission, she was deeply jaundiced, had a normal blood pressure and a heart rate of 100 
per minute. Lungs and heart were clear and the abdomen was soft with normal bowel sounds, but the 
right upper quadrant was painful upon palpation. Clinically, there was no ascites and there were no 
edema. Her hemoglobin level was 41 g/L and the leukocyte count slightly elevated due to the 
presence of erythroblasts. The serum bilirubin concentration was 198 µmol/L, ASAT 2253 U/L (normal 
range 11 - 37 U/L), ALAT 847 U/L (16 - 37 U/L), GGT 120 U/L (8 – 49 U/L ) and alkaline phosphatase 
168 U/L (31 – 108 U/L). Her factor V concentration was 78% of normal (70 – 120%). Viral serologies 
(HAV, HBV, HCV, EBV, CMV, herpes simplex) and auto-antibodies (anti-nuclear, anti-smooth muscle, 
anti-microsomal) were negative. Upper gastrointestinal endoscopy did not show intestinal bleeding 
and an ultrasound of the liver did not reveal any signs of extrahepatic cholestasis but showed impaired 
portal blood flow and some ascites around the liver. The diagnosis of an acute hemolytic crisis was 
confirmed. The administration of roxithromycin, enalapril and phenprocoumon was stopped and a 
treatment with 100 mg prednisone per day was started in addition to cyclophosphamide. After the 
transfusion of packed erythrocytes, her hemoglobin level remained stable at 90 g/L. In order to clarify 
the reason for the hepatopathy, a transjugular liver biopsy was performed the next day. As shown in 
the Figure, the histology revealed veno-occlusive disease with some necrosis of hepatocytes in the 
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centroacinar region, explaining elevated transaminases. After stopping cyclophosphamide, the patient 
started to recover. When she left the hospital 11 days after entry, transaminases and bilirubin levels 
were only slightly elevated, and ultrasound and Doppler examinations of the liver were normal. Three 
weeks later, all liver values had completely normalized and the patient was well. 
 
 
Figure: The central vein in the center of the figure (arrow) shows proliferation of the intima. In the 
centroacinar region, liver sinusoids are dilated and contain deposits of fibrin. There is necrosis of 
hepatocytes in the centroacinar region. 
 
 
 
14.3.4. Discussion 
While high doses of cyclophosphamide, in particular in combination with busulfan for bone 
marrow eradication, are well known to be associated with hepatic veno-occlusive disease (1), this has 
so far not been described for immunosuppressive doses of cyclophosphamide. For the other drugs the 
patient was treated with (enalapril, prednisone, roxithromycin, phenprocoumon and insulin), hepatic 
veno-occlusive disease has not been described so far. Cyclophosphamide is therefore the most likely 
offender of veno-occlusive disease in this patient, although it was used at an immunosuppressive 
dosage. The toxicity of cyclophosphamide may have been enhanced by another drug, most probably 
by roxithromycin. Roxithromycin is a macrolide antibiotic and is an inhibitor of cytochrome P450 
(CYP)3A4 (2), which is partially responsible for the metabolism of cyclophosphamide. By CYP3A4, 
cyclophosphamide can be N-dealkylated and thereby degraded to N-dechloroethyl- cyclophosphamide 
and chloroacetaldehyde (3). On the other hand, CYP3A4 and CYP2B6 catalyze the oxidation of 
cyclophosphamide to phosphoramine mustard and acrolein, which are the active metabolites, but are 
also toxic (4). Selective inhibition of CYP3A4 may therefore be associated with increased formation of 
phosphoramine mustard and acrolein in hepatocytes, possibly leading to damage also in the adjacent 
endothelial cells.  
Since inhibitors of CYP3A4 are usually also inhibitors of P-glycoprotein, a transporter of many 
substances including antineoplastic drugs (5), inhibition of P-glycoprotein might also be involved in the 
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toxicity of cyclophosphamide observed in our patient. P-glycoprotein is expressed in the canalicular 
membrane of hepatocytes (5) and may also be expressed in endothelial cells. Inhibition of P-
glycoprotein may therefore be associated with decreased biliary excretion of toxic metabolites of 
cyclophosphamide and/or with trapping of cyclophosphamide and toxic metabolites in endothelial 
cells. 
Finally, the toxicity of cyclophosphamide in the presence of roxithromycin may be unrelated to 
its inhibitory action on CYP3A4/P-glycoprotein and may involve so far unknown properties of 
roxithromycin, which are specific for this drug or may be shared by other macrolide antibiotics. Since 
cyclophosphamide can induce apoptosis, it is possible that roxithromycin sensitized endothelial cells to 
apoptotic effects of cyclophosphamide. 
The differentiation between these mechanisms is clinically relevant, since macrolides and other 
CYP3A4-inhibitors are drugs used widely. In the accompanying paper, we have therefore investigated 
the proposed mechanisms in vitro (6). We could show that the combination of cyclophosphamide with 
roxithromycin induces apoptosis of endothelial cells via a mitochondrial mechanism. This mechanism 
is specific for roxithromycin, other macrolides or CPP3A4/P-glycoprotein inhibitors did not increase 
cytotoxicity of cyclophosphamide. 
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